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ABSTRACT 
The Apocynaceae family is well known for its potential anticancer activity. Pleiocarpamine 
isolated from the Apocynaceae family and a constituent of Pleiocarpa pycnantha has been 
reported for anti-cancer activity. Prompted by a general growing interest in the pharmacology of 
Apocynaceae species, most importantly their anticancer potential together with the fact that there 
is scanty literature on the pharmacology of P. pycnantha, we explored the anticancer potential of 
the ethanolic extract of P. pycnantha leaves and constituents. Three known triterpenoids, ursolic 
acid C1, 27-E and 27-Z p-coumaric esters of ursolic acid C2, C3 together with a new triterpene  
2,3-seco-taraxer-14-en-2,3-lactone (pycanocarpine C5) were isolated from an ethanolic extract 
of P. pycnantha leaves. The structure of C5 was unambiguously assigned using NMR, HREIMS 
and X-ray crystallography. The cytotoxic activities of the compounds were evaluated against 
HeLa, MCF-7, KMST-6 and HT-29 cells using the WST-1 assay. Ursolic acid C1 displayed 
potent cytotoxic activity against HeLa, HT-29 and MCF-7 cells with IC50 values of 5.06, 5.12 
and 9.51 µg/ml respectively. The new compound C5 and its hydrolysed open-chain derivative 
C6 were selectively cytotoxic to the breast cancer cell line, MCF-7 with IC50 values 10.99 and 
5.46 µg/ml respectively. We further investigated the mechanism of action of the isolated 
compounds using specific markers of apoptosis. Exposure of C1-C6 (12.5 µg/ml) to HeLa cells 
showed a significant increase in reactive oxygen species (ROS) production with the exception of 
C5. On HT-29, C1, C4, C5 and C6 at 25 µg/ml increased ROS production while on MCF-7 
using the same dose, only C5 and C6 caused a significant increase in ROS production compared 
with a control at P< 0.05. The result on caspase 3/7 activation showed that C1 and C2 (50 µg/ml) 
caused a marked increase in caspase 3/7 activity between 6-24 h on HeLa cells while only C1 
(50 µg/ml) showed a significant increased caspase 3/7 activity on both HT-29 and MCF-7 cell 
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lines when compared with the control, P< 0.05. Some selected compounds were further 
investigated for their dose-response on caspase 3/7 activity on HeLa and MCF-7 cells. 
Compounds C2 and C3 activated caspase 3/7 at 12.5 and 25 µg/ml respectively, while on  
MCF-7only C6 significantly increased caspase 3/7 activity within 24 h of treatment when 
compared with an untreated control. The result of time -dependent caspase 9 activity showed that 
C1, C2 and C3 caused an increased activity on HeLa cells between 6-12 h, while only C1 
activated caspase 9 on HT-29 cells (3-24 h) and MCF-7 (6-24 h). The dose-response caspase 9 
activity showed a significant increase in activation for C6 (12 and 25 µg/ml) on HeLa and C5 
(25 µg/ml) on HT-29 cells. All isolated compounds inhibited Topoisomerase I when compared 
with Camptothecin. Compounds C1-C6 could induce apoptosis on cancer cell lines through an 
intrinsic pathway and topoisomerase 1 inhibition. This is the first report on the isolation of a  
2,3-seco-taraxerene derivative from Apocynaceae family and the anticancer activity of 
Pleiocarpa pycnantha constituents. 
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CHAPTER 1 
1.0 INTRODUCTION 
1.1. General overview of the use of plants 
Plants have been serving the animal kingdom as its main source of energy (food, fuel) as well as 
its means of shelter and sustenance since the very beginning of life on earth. Over 250,000 
species of flowering plants have so far been recognized. In addition to provision of food, fuel and 
shelter, each of these plants have also been great sources of medicinal agents since they possess 
chemical constituents such as phenolic compounds, alkaloids, terpenes, glycosides, steroids and 
a host of others commonly referred to as secondary metabolites. The secondary metabolites are 
present in low concentrations and are sometimes species specific in terms of their production, in 
some cases, specific metabolites may be found in only one part of a plant (Trease and Evans, 
1996). 
In early times and in the present day traditional medicine as practised in many countries, 
medicinal plants are taken in as their crude forms and prepared in the form of decoctions, 
infusions or powders. The isolation of defined chemical substances from plants started in the 
nineteenth century. At the beginning, structural elucidation of isolated compounds were limited 
by the technology available at that time in which case, it was done by classical and exhaustive 
degradative methods and the structures that were proposed were confirmed through synthesis and 
in most cases followed by biological activity determinations. One of the most common activities 
tested with isolated compounds was antibacterial activity since this can easily be detected even 
from an unpurified crude extract while scientists avoided other biological activities. The in vivo 
experiments conducted were cumbersome, requiring large numbers of animals and crude 
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extracts. In more recent times developments of in vitro and biochemical screening methods have 
renewed interest in the screening of plants for biological activity since the methodologies do not 
require pure material and very small quantities can be evaluated quite easily and rapidly. 
 Currently, the isolation of chemical compounds from plant sources in drug discovery is bioassay 
guided involving selective and sensitive screening procedures with low concentrations 
(nanomole/litre) of compounds which are sufficient for the detection of a specific response.  
The structure of an isolated compound is elucidated with only a few milligrams of pure material 
using sophisticated instrumentation such as HPLC, NMR (1D and 2D), COSY, HMQC, HMBC 
and HREMS. Many new compounds (flavonoids, alkaloids, terpenoids, peptides and phytosterols 
to name a few) are generated each year through the combination of sensitive screens and modern 
structural elucidation methods. Some of these compounds are antimicrobial, anti-inflammatory, 
anthelmintics, anticancer, antimalarial, enzyme inhibitor and some are known to bind to specific 
receptors of pharmacological interest. However, there are some compounds isolated through 
chemically guided isolation that have proved to be biologically active.  
After the isolation and identification of a compound, larger quantities are normally required for 
further and more comprehensive evaluation and this is achieved through either chemical 
synthesis or cultivation and collection of large quantities of plant material for extraction and 
purification by large scale chromatographic means. Nigeria and South Africa have abundant 
flora and fauna which are yet to be fully explored for potential drugs. Traditional medicines from 
plants are cheap and are the main sources for herbal drugs for citizens to be used against diseases 
endemic to the tropical and non tropical countries. 
 
 
 
 
 3 
 
Cancer is one of the classes of disease that is a major public burden and a threat to both 
developed and the developing nation. It is characterized by uncontrolled growth and the 
consequent spread of abnormal cells and if the spread is not controlled, it usually results in death. 
It is caused by both external factors (tobacco, chemicals, radiation, and infectious organisms) and 
internal factors (inherited mutations, hormones, immune conditions and mutations that occur 
from metabolism). These causal factors may act together or in sequence to initiate or promote 
carcinogenesis. Worldwide, one in eight deaths is due to cancer which additionally causes more 
deaths than AIDS, tuberculosis and malaria combined. When countries are grouped according to 
economic development, it is the leading cause of death in developed countries and the second 
leading cause of death in developing countries (following heart diseases) (ACS, 2011). 
According to the World Health Organization (WHO) projections in 2007, cancer will have 
replaced ischemic heart disease as the overall leading cause of death worldwide in 2010 (WHO, 
2007). 
The estimates from the International Agency for Research on Cancer (IARC) proposed 12.7 
million new cancer cases in 2008 worldwide, of which 5.6 million occurred in economically 
developed countries and 7.1 million in economically developing countries. The corresponding 
estimates for total cancer deaths in 2008 were 7.6 million (about 21,000 cancer deaths per day), 
2.8 million in economically developed countries and 4.8 million in economically developing 
countries. By 2030, the global burden is expected to grow to 21.4 million new cancer cases and 
13.2 million cancer deaths simply due to the growth and aging of the population, as well as 
reductions in childhood mortality and deaths from infectious diseases in developing countries 
(Ferlay et al., 2010; Jemal et al., 2011).  
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The global cancer statistics released by the American Cancer Society reads “The total number of 
deaths in 2007 was 7.6 million, or about 20,000 deaths per day, with 38% in developed countries 
and 62% in developing countries. By 2050, 27 million new cancer cases and 17.5 million cancer 
deaths are projected to occur in the world” (Dunham, 2007; ACS, 2007). 
Cancer is an emerging public health problem in Africa, about 681,000 new cancer cases and 
512,400 cancer deaths occurred in 2008. These numbers are projected to nearly double  
(1.28 million new cancer cases and 970,000 cancer deaths) by 2030 simply due to the aging and 
growth of the population with the potential to be even higher because of the adoption of 
behaviors associated with western lifestyles, such as smoking, unhealthy diet and physical 
inactivity (Ferlay et al., 2008; WHO, 2007; 2008). Cancers related to these factors, such as lung, 
breast, and colorectal cancers are increasing in economically transitioning countries. Rates of 
cancers common in western countries will continue to rise in developing countries if preventive 
measures are not widely applied. In economically developed countries, the three most commonly 
diagnosed cancers were prostate, lung / bronchus and colorectal among men and in women; 
breast, colorectal and lung / bronchus. In economically developing countries, the three most 
commonly diagnosed cancers were lung / bronchus, stomach and liver in men while in women 
were breast, cervix uteri and stomach. In both economically developed and developing countries, 
the three most common cancer sites were also the three leading causes of cancer deaths (ACS, 
2007).  
According to the new cancer statistics released by GLOBOCAN (2012), an estimated  
14.1 million new cancer cases and 8.2 million cancer-related deaths occurred in 2012, compared 
with 12.7 million and 7.6 million, respectively in 2008. The most commonly diagnosed cancers 
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worldwide were those of the lung (1.8 million, 13.0% of the total), breast (1.7 million, 11.9%), 
and colorectum (1.4 million, 9.7%). The projections based on the GLOBOCAN (2012) estimates 
has also predicted a substantive increase to 19.3 million new cancer cases per year by 2025 due 
to growth and ageing of the global population. More than half of all cancers (56.8%) and cancer 
deaths (64.9%) in 2012 occurred in less developed regions of the world, and these proportions 
will increase further by 2025 (Ferlay et al., 2013).  
Breast cancer is the most common cause of cancer death among women (522 000 deaths in 
2012), the most frequently diagnosed cancer among women in 140 of 184 countries worldwide, 
it now represents one in four of all cancers in women and also a leading cause of cancer death in 
the less developed countries of the world. In 2012, 1.7 million women were diagnosed with 
breast cancer, since the 2008 estimates, breast cancer incidence has increased by more than 20%, 
while mortality has increased by 14% (Ferlay et al., 2013). Based on the recent cancer statistics, 
cervical cancer has been reported to be the fourth most common cancer affecting women 
worldwide after breast, colorectal and lung cancers; it is most notable in the lower-resource 
countries of sub-Saharan Africa. It is also the fourth most common cause of cancer death  
(266 000 deaths in 2012) in women worldwide. Almost 70% of the global burden falls in areas 
with lower levels of development and more than one fifth of all new cases are diagnosed in India.  
Cervical cancer was estimated to have about 528 000 new cases every year. In sub-Saharan 
Africa, 34.8 new cases of cervical cancer are diagnosed per 100 000 women annually and 22.5 
per 100 000 women die from the disease. These figures compare with 6.6 and 2.5 per 100 000 
women, respectively in North America. The drastic differences might be the lack of access to 
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effective screening and to services that facilitate early detection and treatment in the developing 
countries (Ferlay et al., 2013). 
Despite this growing burden, cancer unfortunately continues to receive low public health priority 
in Africa, largely because of limited resources and other pressing public health problems, 
including communicable diseases such as acquired immune deficiency syndrome (AIDS)/human 
immunodeficiency virus (HIV) infection, malaria and tuberculosis. It may also be partly due to a 
lack of awareness about the magnitude of the current and future cancer burden among policy-
makers, the general public and international private or public health agencies interested in global 
health. Although the knowledge of cancer in this region is now improving, better surveillance of 
cancer incidence, mortality, and prevalence of risk factors is urgently needed to monitor the 
development of the cancer epidemic, formulate appropriate cancer-control strategies, and assess 
the outcomes of these strategies (Jemal et al., 2012).  
Since cancer is one of the most common devastating diseases affecting millions of people per 
year and also the second leading cause of death in humans, there has been an intense search on 
various biological sources to develop a novel anti-cancer drug to combat this disease. The use of 
natural products as anticancer agents has a long history that began with folk medicine and 
through the years has been incorporated into traditional and allopathic medicine. To date, more 
than 3000 plant species have been described as displaying evidence of previous use for treating 
cancer (Hartwell, 1982). Several drugs currently used in chemotherapy were isolated from plant 
species or derived from a natural prototype. They include the Vinca alkaloids, vinblastine and 
vincristine, isolated from Catharanthus roseus, etoposide and teniposide, the semisynthetic 
derivatives of epipodophyllotoxin, isolated from species of the genus Podophyllum, the naturally 
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derived taxanes isolated from species of the genus Taxus, the semisynthetic derivatives of 
camptothecin, irinotecan and topotecan, isolated from Camptotheca acuminata and several 
others (Cragg and Newmann, 2000; Chabner et al., 2005; DeVita et al., 2008). 
A recent analysis of the anticancer drug market in North America, Europe and Japan during the 
period 1981-2006 showed that 47.1% of a total of 155 clinically approved anticancer drugs was 
either unmodified natural products or their semi-synthetic derivatives, or synthesized molecules 
based on natural product pharmacophores (Newman and Crag, 2007). Medicinal plants would 
assist in the fight against cancer by reducing or minimizing the associated toxic side effects of 
chemotherapy and radiation treatment regimes. 
1.2. Recent progress in drug discovery from medicinal plants 
Plants, either as the whole plant or its leaves, stem bark and even the roots, have been utilized as 
medicines for thousands of years (Samuelsson, 2004) and natural products have been the single 
most productive source of lead compounds for the development of drugs (Harvey, 2008). 
Current research in drug discovery from medicinal plants involves an all round approach 
combining botanical, phytochemical, biological, and molecular techniques. Medicinal plant drug 
discovery continues to provide new and important leads against various diseases including 
cancer, HIV/AIDS, Alzheimer’s, malaria and pain. Several natural product drugs of plant origin 
have either recently been introduced to the United States market, including arteether, 
galantamine, nitisinone, tiotropium, elliptinium and huperzine or are currently involved in late-
phase clinical trials (Newman and Cragg, 2007; Butler, 2008; Chin et al., 2006). Although drug 
discovery from medicinal plants continues to provide an important source of new drug leads, 
numerous challenges are encountered including the procurement of plant materials, the selection 
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and implementation of appropriate high-throughput screening bioassays, and the scale-up of 
either synthesizing or isolating active compounds (Balunas and Kinghorn, 2005). 
The use of plants as a source for medicines involved the isolation of active compounds, 
beginning with the isolation of morphine from opium in the early 19th century (Kinghorn, 2001; 
Samuelsson, 2004). Others are cocaine, codeine, digitoxin and quinine, of which some are 
currently still in use (Newman et al., 2000; Butler, 2004; Samuelsson, 2004). Isolation and 
characterization of pharmacologically active compounds from medicinal plants still is an on-
going exercise and continues to date. More recently, drug discovery techniques have been 
applied to the standardization of herbal medicines and to elucidate analytical marker compounds. 
Numerous methods have been utilized to acquire compounds for drug discovery including 
isolation from plants and other natural sources, synthetic chemistry, combinatorial chemistry and 
molecular modeling (Ley and Baxendale, 2002; Geysen et al., 2003; Lombardino and Lowe, 
2004). Despite the recent interest in the above stated methods; natural products, particularly 
medicinal plants, remain an important source of new drugs, new drug leads, and new chemical 
entities (NCEs) (Newman et al., 2000, 2003; Butler, 2004). Between 2001 and 2002, 
approximately one quarter of the best selling drugs worldwide were natural products or derived 
from natural products (Butler, 2004).  
Some new medicinal plant-derived drugs that have been recently introduced to the U.S. market 
include; Arteether (1, trade name Artemotil) which is a potent antimalarial drug derived from 
artemisinin, a sesquiterpene lactone isolated from Artemisia annua L. (Asteraceae) and a plant 
used in traditional Chinese medicine (TCM) (van Agtmael et al., 1999; Graul, 2001) (See Fig 1.1 
 
 
 
 
 9 
 
for the chemical structures of some of these new drugs.). Other derivatives of artemisinin are in 
various stages of use or clinical trials as anti-malarial drugs in Europe (van Agtmael et al., 1999). 
Galantamine (2, also known as galanthamine, trade name Reminyl) is a natural product 
discovered through an ethno botanical lead and first isolated from Galanthus woronowii Losinsk 
(Amaryllidaceae) in Russia in the early 1950s. It is used for the treatment of Alzheimer’s disease 
(Heinrich and Teoh, 2004; Pirttila et al., 2004). 
Nitisinone (3, trade name Orfadin) is a newly released medicinal plant-derived drug that works 
on the rare inherited disease, tyrosinaemia, demonstrating the usefulness of natural products as 
lead structures (Frantz and Smith, 2003). It is a modification of mesotrione, an herbicide based 
on the natural product leptospermone, a constituent of Callistemon citrinus Stapf. (Myrtaceae) 
(Hall et al., 2001; Mitchell et al., 2001). It inhibits HPPD enzyme in humans preventing tyrosine 
catabolism and the accumulation of toxic bioproducts in the liver and kidneys (Hall et al., 2001). 
Tiotropium (4, trade name Spiriva) is employed for treating chronic obstructive pulmonary 
disease (COPD) (Mundy and Kirkpatrick, 2004; Frantz, 2005). It is an inhaled anticholinergic 
bronchodilator, based on ipratropium, a derivative of atropine that has been isolated from Atropa 
belladonna L. (Solanaceae) and other members of the Solanaceae family (Barnes et al., 1995; 
Dewick, 2002; Mundy and Kirkpatrick, 2004). Tiotropium has shown increased efficacy and 
longer lasting effects when compared with other available COPD medications (Barnes, 2002; 
Mundy and Kirkpatrick, 2004). 
Morphine-6-glucuronide or M6G (5) is a metabolite of morphine isolated from Papaver 
somniferum L. (Papaveraceae) and is used as an alternate pain medication with fewer side effects 
to that of morphine (Lotsch and Geisslinger, 2001). 
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Vinflunine (6) is a modification of vinblastine isolated from Catharanthus roseus (L.) G. Don 
(Apocynaceae) for use as an anticancer agent with improved efficacy (Bonfil et al., 2002; 
Okouneva et al., 2003).  
Exatecan (7) is an analog of camptothecin isolated from Camptotheca acuminata Decne. 
(Nyssaceae) and is being developed as an anticancer agent (Butler, 2004; Cragg and Newman, 
2004). Modifications of existing natural products exemplify the importance of drug discovery 
from medicinal plants as new chemical entities and as possible new drug leads.  
Calanolide A (8) is a dipyranocoumarin natural product isolated from Calophyllum lanigerum 
var. austrocoriaceum (Whitmore) P.F. Stevens (Clusiaceae), a Malaysian rainforest tree 
(Kashman et al., 1992; Yang et al., 2001; Yu et al., 2003). Calanolide A (8) is an anti-HIV drug 
with a unique and specific mechanism of action behaving as a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) of type-1 HIV and is effective against AZT-resistant strains of 
HIV (Currens et al., 1996; Buckheit et al., 1999; Yu et al., 2003). It is currently undergoing 
Phase II clinical trials (Creagh et al., 2001).  
Huperzine A (9) is a naturally occurring sesquiterpene alkaloid found in the firmoss Huperzia 
serrata (Kozikowski et al., 1999) and also found in varying quantities in other Huperzia species 
including H.elmeri, H. carinat and H. aqualupian (Lim et al., 2010). It is an acetyl cholinesterase 
inhibitor which has a mechanism of action similar to donepezil, rivastigmine and galantamine. 
Its pro drug form huperzine A (ZT-1) is under development as a treatment for Alzheimer's 
disease (Scalfaro, 2003). Huperzine A (9) is sold as a dietary supplement for memory support in 
the US, while it is used in China for the treatment of swelling, fever and blood disorders.  
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Clinical trials in China have shown it to be effective in improving cognitive performance in 
patients with Alzheimer's disease
 
and enhancing memory in students (Wang et al., 2009; Sun et 
al., 1999). 
The search for phytochemicals effective against the human immunodeficiency virus (HIV), the 
causative agent of Acquired Immune Deficiency Syndrome (AIDS) has resulted in the isolation 
of several promising compounds, including the tetrahydroxyindolizidine alkaloid 
castanospermine (10) from Castanospermum australe (Leguminosae) and the phorbol ester 
prostratin (11) from Homalanthus nutans (Euphorbiaceae) (Cox and Balick, 1994). 
Natural products have played an important role as new chemical entities (NCEs) - approximately 
28% of NCEs discovered between 1981 and 2002 were natural products or natural product-
derived (Newman et al., 2003). Another 20% of NCEs discovered during this period were 
considered natural product mimics, meaning that the synthetic compound was derived from the 
study of natural products (Newman et al., 2003). Combining these categories, research on natural 
products accounts for approximately 48% of the NCEs reported from 1981–2002. 
Newman and Cragg (2007) have also reported that inspection of NCE approvals demonstrated 
that the natural product field is still producing or its involved in ~ 50% of all small molecules in 
the year 2000-2006. Many structural features common to natural products (e.g., chiral centers, 
aromatic rings, complex ring systems, degree of molecule saturation, and number / ratio of 
heteroatoms) have been shown to be highly relevant to drug discovery efforts (Clardy and 
Walsh, 2004; Piggott and Karuso, 2004; Koehn and Carter, 2005). Drugs derived from medicinal 
plants can serve not only as new drugs themselves but also as drug leads suitable for 
optimization by medicinal and synthetic chemists (Balunas and Kinghorn, 2005). Even when 
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new chemical structures are not found during drug discovery from medicinal plants, known 
compounds with new biological activity can provide further important drug leads.  
 
 10  
Figure1. 1. Examples of medicinal plant drugs newly introduced to the market/those in late 
phase clinical trials. 
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1.3. Plants as a source of anti-cancer agents 
Worldwide, over ten million new cancer cases (all parts of the body and sites excluding non-
melanoma skin), with over six million deaths were estimated in the year 2000. There has been 
about 22% increases in cancer incidence and mortality since 1990 (Parkin et al., 2001). Although 
these figures are disconcerting, it is noteworthy that some progress has been made in cancer 
diagnosis and treatment as is evident through the high incidence of breast, prostate, testicular and 
uterine cancer and their relatively lower mortality (Parkin 2001; Jemal et al., 2005; Jatoi and 
Miller, 2003). 
Drug discovery from medicinal plants have played an important role in treatment of cancer and 
most new clinical applications of plant secondary metabolites and their derivatives over the last 
half century have been applied towards combating cancer (Newman et al., 2003; Butler, 2004). 
Of all the anticancer drugs produced between 1940 and 2002, 40% were natural products or 
natural product - derived while 8% are considered to be natural product mimics (Newman et al., 
2003). Anticancer drugs in clinical use include vinblastine, vincristine, camptothecin derivatives, 
topotecan and irinotecan, etoposide, derived from epipodophyllotoxin, and paclitaxel (taxol®). 
There are some promising new agents in clinical development based on selective activity against 
cancer-related molecular targets, including flavopiridol and combretastin A4 phosphate, while 
some agents which failed in earlier clinical studies are in more recent times stimulating renewed 
interest (Cragg and Newman, 2005). Other anticancer drugs for future developments include: 
roscovitine, betulinic acid, pervilleine A and silvestrol (Balunas and Kinghorn, 2005). 
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1.4. Plant-derived anti-cancer agents in clinical use 
Vinca alkaloids vinblastine (12) and vincristine (13) were the first agents to advance into clinical 
use for the treatment of cancer (Cragg and Newman, 2005). They were isolated from 
Catharanthus roseus (L.) G. Don (Apocynaceae) (formerly Vinca rosea L.) and have been used 
clinically for over 40 years (van Der Heijden et al., 2004). Vinblastine and vincristine have been 
used in combination with other cancer drugs to treat breast, lung, leukemia, advanced testicular 
cancer and Kaposi’s sarcoma. Some of these plant derived anti-cancer agents are shown in 
(Fig.1.2A & B). The discovery of paclitaxel (Taxol®, 14 from the bark of the Pacific Yew, 
Taxus brevifolia Nutt. (Taxaceae) is further evidence of the success achieved in natural product 
drug discovery. Various parts of Taxus brevifolia and other Taxus species (e.g., Taxus 
Canadensis Marshall, Taxus baccata L.) have been used by several native American tribes for 
the treatment of some non-cancerous cases (Cragg and Newman, 2005) while Taxus baccata was 
reported to be used in the Indian Ayurvedic medicine for the treatment of cancer (Hartwell, 
1982). The structure of paclitaxel was elucidated in 1971 and was clinically introduced to the US 
market in the early 1990s. Paclitaxel is active against ovarian cancer, advanced breast cancer and 
small and non-small cell lung cancer (Wani et al., 1971; Oberlies and Kroll, 2004). 
Another important anti-cancer drug is Camptothecin (15), isolated from Camptotheca acuminata 
Decne (Nyssaceae) which was later not used due to its severe toxicity to the bladder. However, 
extensive research has led to the development of more effective derivatives of Topotecan and 
Irinotecan which were used for the treatment of ovarian and colorectal cancer respectively 
(Creemers et al., 1996). The taxanes and the camptothecin accounted for approximately one-third 
of the global anticancer market (over 2.75 billion dollars) in 2002 (Oberlies and Kroll, 2004).  
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Podophyllotoxin (16) isolated from the resin of Podophyllum peltatum L. (Berberidaceae).was 
found to be too toxic in mice and this led to its derivatization to produce Etoposide (17) and 
Teniposide (18) which are semi-synthetic derivative of epipodophyllotoxin, an isomer of 
Podophyllotoxin. They are used in the treatment of lymphomas and bronchial and testicular 
cancers (Cragg and Newman, 2005). 
Other anticancer drugs in clinical use include Elliptinium (19), a derivative of ellipticine, isolated 
from a Fijian medicinal plant Bleekeria vitensis A.C. Sm., and is being sold in France for the 
treatment of breast cancer (Cragg and Newman, 2005). Homoharringtonine (20) was isolated 
from the Chinese tree Cephalotaxus harringtonia var. drupacea (Sieb and Zucc.) 
(Cephalotaxaceae) (Itokawa et al., 2005). Racemic mixtures of harringtonine and 
homoharringtonine have been used in the treatment of acute myeloid leukemia and chronic 
myeloid leukemia in China (Cragg and Newman, 2005), while homoharringtonine was used for 
similar treatment in United States and Europe (Quintasa Cardama et al., 2007). 
Indirubin(21) a bis-indole alkaloid which has been reported to show a broad spectrum of 
antitumor activity (Eisenbrand et al., 2004) and is one of the components of Chinese traditional 
medicine called “Qingdai” used mainly for the treatment of hematemesis, eczema and other 
diseases (Zhongyaoshijia, 2009). Other components of “Qingdai” include Indigo and other plants 
comprising leaves and / or stems of Baphicacanthus cusia (Nees) Bremek (Acanthaceae), 
Indigofera tinctoria L. (Fabaceae), Indigofera suffruticosa Mill. (Fabaceae), Isatis tinctoria L. 
(Brassicaceae) and Polygonum tinctorium Ait. (Polygonaceae) (Deng, 1986). 
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Mesoindigo (22) is a derivative of indirubin with improved water solubility and reduced side 
effects. It has been reported to inhibit tumor growth in HT-29 colon cancer xenografts, cyclin-
dependent kinases, promote apoptosis, and arrest cells in the G0/G1 phase of the cell cycle  
(Zuo et al., 2008). It is currently undergoing Phase III clinical trials in China for the treatment of 
chronic myelogenous leukemia (CML) (Cooperative Study Group of Phase III Clinical Trial on 
Meisoindigo, 1997). Perillyl alcohol, a limonene-type monoterpenoid, found in the essential oils 
of some aromatic herbs, such as lavender (Lavandula  intermedia, Lamiaceae), peppermint 
(Mentha  piperita L., Lamiaceae), spearmint (Mentha spicata L., Lamiaceae) and celery seeds 
(Apium graveolens L. Apiaceae) (Belanger, 1998) has been reported to induce apoptosis and 
arrest cell cycle in the G1 phase (Peffley et al., 2007; Yeruva et al., 2007). A Phase II clinical 
trial was sponsored by the U.S. National Cancer Institute (NCI) to study its effectiveness in 
treating patients with metastatic breast cancer (Bailey et al., 2008). 
Phenoxodiol (23), derived from genistein, a natural isoflavone constituent of soybean [Glycine 
max (L.) Merr. Fabaceae] has been promoted as a new promising drug for its broad anticancer 
spectrum and minimal toxicity Butler (2008) and is currently under advanced clinical trials for 
development as a ‘‘chemosensitizer’’ when combined with platinum drugs for the treatment of 
ovarian cancer. It has additionally been identified as a monotherapy for cervical and prostate 
cancers (Silasi et al., 2009). Protopanaxadiol (24) a dammarane-type triterpene aglycone traded 
under the trade name PandimexTM, is derived by hydrolysis of certain saponins from ginseng 
[Panax ginseng C.A. Mey.; Araliaceae] and has been reported to induce apoptosis in cancer cells 
and cell cycle arrest through various signaling pathways including caspases. It also displays 
cytotoxic activity against multidrug-resistant tumors (Li et al., 2006; Liu et al., 2007). 
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Protopanaxadiol (24) is now in Phase I clinical trial launched by PanaGin in the US for the 
treatment of lung cancer and other solid tumors (Saklani and Kutty, 2008; PanaGin 
Pharmaceuticals Inc., 2009). Additionally, it has also been approved in China for the treatment of 
advanced cancers of the breast, colon-rectum, lung and pancreas (PanaGin Pharmaceuticals Inc., 
2009).  
Among other active agents are Triptolide (25), a diterpenoid triepoxide isolated from 
Tripterygium wilfordii Hook.f. (Celastraceae) and its sodium salt (14-succinyl triptolide sodium 
salt), a water-soluble prodrug of PG490, which is metabolized into triptolide in vivo after 
intravenous administration, has entered Phase I clinical trials for patients with solid tumors 
(Kiviharju et al., 2002; Fidler et al., 2003; Saklani and Kutty, 2008). Salvicine (26), a semi-
synthetic analog of Saprorthoquinone diterpenoid quinone isolated from Salvia prionitis Hance 
(Lamiaceae), was found to exhibit significant growth inhibitory activity against a wide spectrum 
of human cancer cells in vitro, and showed effects in in vivo xenograft models bearing S-180 
sarcoma, Lewis lung, A-549 lung, and LAX- 83 lung adenocarcinoma cells (Zhang et al., 1999). 
Salvicine (26) also demonstrated a potent cytotoxic effect on multidrug- resistant (MDR) tumor 
cells (Miao et al., 2003). It has entered Phase II clinical trials for the treatment of solid tumors in 
mainland China (Cai et al., 2008). 
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Figure 1.2A. Examples of anticancer agents in clinical use. 
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Figure 1.2B. Examples of anticancer agents in clinical use. 
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1.5 Rationale for the study 
Pleiocarpa pycnantha is generally known as a worm expeller but it is surprising to discover that 
there is no scientific data to support this claim nor any other type of biological activity reported 
for this plant either as a whole or any of its isolated compounds. An investigation of the anti-
cancer potential of the plant extract has thus been chosen because of the increased cancer threat 
in Africa and the rising international interest in cancer chemotherapy, especially from medicinal 
plants that have not been investigated before. 
Some anticancer agents have been reported from the Apocynaceae family, for example, 
Vinflunine is a modification of Vinblastine isolated from Catharanthus roseus (L.) G. Don 
(Apocynaceae) for use as an anticancer agent with improved efficacy (Bonfil et al., 2002; 
Okouneva et al., 2003). Alstonia macrophylla, Alstonia glaucescens, and Alstonia scholaris have 
been reported to be cytotoxic (Keawpradub et al., 1997). Pleiocarpamine from Alstonia specie 
(Apocynaceae), which is also a constituent of P. pleiocarpa was reported to demonstrate 
anticancer potential (Keawpradub et al., 1997). Therapeutic effects of anticancer herbs is 
identified by their inhibition of the cancer activating enzymes, stimulating a DNA repair 
mechanism, thus promoting production of protective enzymes, including antioxidant action and 
by enhancing activity of the immune cells. Certain biological response modifiers derived from 
herbs are known to inhibit growth of cancer by modulating the activity of specific hormones and 
enzymes. Some herbs reduce toxic side effects of chemotherapy and radiotherapy (Sabtu, 2007).  
Prompted by the general anticancer potential of Apocynaceae and in the light of our ongoing 
research activity to identify anticancer agents from medicinal plants from Africa, we explored 
the anticancer potential of P.pleiocarpa, its extracts and isolated compounds. 
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P.pycnantha is an indigenous plant from Nigeria and from some statistics already discussed 
indicated that many Africans are dying of cancer. Our preliminary investigation of cytotoxicity 
of total extracts from the leaves and some fractions demonstrated that the leaf extract and one of 
the fractions selectively killed the cancer cells investigated without touching the normal cells. 
This finding underpins the necessity to design selective anti-cancer drugs with minimal toxic 
side effects from the plant. On the one hand this will help cancer patients to have access to 
anticancer drugs from a relatively cheap origin i.e. natural sources to be able to fight the disease 
in Africa and Worldwide .This research will also assist to bridge the scientific gap that has long 
been created by the lack of useful informations about the plant and thus it is anticipated to add 
new knowledge to the scientific world. 
1.6. Aim/Objectives 
The purpose of this study is to investigate the anticancer potential of the ethanolic extract of 
Pleiocarpa pycnantha leaves, isolate and purify the bioactive constituents. 
1.6.1. Specific Objectives 
 To collect, authenticate and extract the leaves of Pleiocarpa pycnantha into ethanol by 
cold maceration for 72 h. 
 To phytochemically screen the ethanolic extracts of P. pycnantha leaves to ascertain their 
secondary metabolites. 
 To investigate the anticancer potential of the crude extracts extract using HeLa, HT-29, 
MCF-7 and KMST-6 cell lines.  
 To do a bioassay-guided fractionation and isolation of crude extract using the WST-1 
assay on the cancer and normal cell lines. 
 
 
 
 
 22 
 
 To isolate in pure form all bioactive compounds using a combination of chromatographic 
techniques. 
 To determine the structures of bioactive compounds using physical methods, especially 
spectroscopy: including, IR, UV, NMR and MS. 
 To investigate the mechanism of action of the bioactive compounds to establish a lead 
compound. 
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CHAPTER 2 
2.0 LITERATURE REVIEW 
This chapter gives a vivid review of the literature on Pleiocarpa family known as Apocynaceae 
and the genera. It also presents a general overview, their ethnomedicinal uses, phytochemistry 
and pharmacology.  
The chapter as well summarises the subject “apoptosis” which is one of the main focus of the 
thesis, various apoptosis biomarkers like ROS, caspases, cell cycle and Topoisomerase I were 
also discussed. These biomarkers were furthermore linked with the focal topic – cancer. 
2.1 Apocynaceae family 
The family Apocynaceae consists of about 250 genera and 2000 species of tropical trees, shrubs 
and vines (Wiart, 2006). They are woody climbers, and herbs distributed primarily in tropical 
and subtropical areas of the world. Many species may appear as tall trees found in tropical 
rainforests, while some grow in tropical dry (xeric) environments while yet others are perennial 
herbs from temperate zones. Many of these plants have milky, often poisonous juice; smooth-
margined leaves; and flowers in clusters (rarely solitary). The fruit may be berry like or fleshy 
but usually is a dry pod (follicle) that splits open at maturity, releasing numerous winged or 
tufted seeds. Members of the family are native to European, Asian, African, Australian and the 
American tropics and subtropics, with some temperate members (Endress and Bruyns, 2000). 
The most numerous genera are Asclepias L. (230), Tabernaemontana L. (230), Cynanchum L. 
(200), Ceropegia L. (150), Hoya R. Braun (150), Matelea Aubl. (130) and Rauwolfia L. (110). 
One of the most remarkable characteristics of Apocynaceae is that they are rich in various types 
of biologically active alkaloids. For instance, vincristine, vinblastine, pleiocarpine, 
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strophanthilin, thevetin, peruvoiside, neriifolin, neriocorin, neriin, oleanderin, reserpine, 
serpentine, catharanthine are known to be present. Incidentally, alkaloids are one of the most 
fascinating classes of natural products, thus providing many drugs for human use  
(Philipson et al., 1993; Kayser et al., 2003). 
2.2 Economic uses of some Apocynaceae plants 
2.2.1 As drugs 
Members of this family are sources of useful drugs, such as cardiac glycosides, which affect 
heart function. These have traditionally been used in folk medicines but are also now important 
in treating mental illness and cancer. They include the Acokanthera, Apocynum, Cerbera, 
Nerium, Thevetia and Strophantus. Rauwolfia serpentina, or Indian Snakeroot, yields the 
alkaloids Reserpine and Rescinnamine, which are useful in the treatment of high blood pressure 
and even some forms of psychosis (Wikipedia, accessed online on 2013-03-12). Catharanthus 
roseus is the source of the so-called vinca alkaloids, Vincristine and Vinblastine, used in cancer 
chemotherapy (Cragg and Newman, 2005). Holarrhena antidysenterca is used to treat dysentery, 
Thevetia peruviana is used to treat rheumatism and dropsy while Alstonia scholaris is also used 
to treat cancer. Pleiocarpa pycnantha is used as anthelmintic and to treat stomach problems 
(Burkill, 1985). In this research, we have demonstrated its usefulness as a potential anticancer 
plant. A comprehensive list of Apocynaceae plants and their uses is documented in Table 2.1. 
2.2.2 As rubber plants 
The genera Carpodinus, Landolphia, Hancornia, Funtumia and Mascarenhasia were used as a 
commercial source of inferior rubber. Valuable India rubber is extracted from these species 
(Burkill, 1985). 
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2.2.3. As ornamentals 
Many members of this family are also cultivated as ornamentals, such as Vinca (periwinkle), 
Thevetia peruviana, Nerium  (oleander), Amsonia (bluestar), Carissa (Natal plum, an edible 
fruit), Allamanda (golden trumpet), Plumeria (frangipani), Thevetia (lucky nut), Mandevilla 
(Savannah flower), Tabernaemontana (Crape jasmine), Rauwolfia and Adenium (desert-rose) 
( Joselin et al., 2012) 
2.2.4 As dye plants and wood 
Wrightia tinctoria leaves are the source of a blue dye Indigo. Carissa edulis is another source of 
dye. Alstonia scholaris is an evergreen tree with a dense crown, which is often planted in gardens 
and as avenue tree. The treated wood is used in packing and the bark has medicinal value. 
Funtumia africana is used as wood while Strophanthus mirabilis is used as a fodder plant. 
2.2.5. As fish poison 
The juice of Acokanthera species such as A. venenata and the milky juice of the Namibian 
Pachypodium have been used as venom for arrow tips by the Bushmen (Rapanarivo and 
Leeuwenberg, 1999).  
2.2.6. As food plants 
Many genus of the plants are used as food, for example the genus Apocynum is used as a source 
of fiber by Native Americans and Carissa edulis also possesses edible roots. The edible flower of 
Fernaldia pandurata (common name: loroco) is a popular part of El Salvadorian and 
Guatemalan cooking while the aromatic juice of Saba comorensis (syn. Landolphia comorensis 
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(Bojer ex A. DC.) K. Schum.), also known as the Bungo or Mbungo fruit is popular and highly 
appreciated in Pemba Island and other parts of coastal Tanzania (Orwa et al., 2012).
 
2. 3. Mode of administration 
According to published ethno-botanical data, Apocynaceae plant parts used for medicinal 
preparations are leaves, bark, roots, root barks stem, latex, seeds, aerial parts, fruits, flowers and 
the whole plant. In some cases the whole plant is used together with the roots. The most 
frequently used plant parts are the roots, leaves, stem bark, and root bark (Omino and Kokwaro, 
1993). Generally, in herbal preparations; single plants may be used alone or in association with 
other plants or with other material of animal or mineral origin. Remedies are mainly prepared in 
the form of powder, concoction and decoction. The methods of administration of herbal 
medicines are internal, particularly by oral absorption and external poultice/topical application or 
bathing (Karou et al., 2011). 
2.4 Traditional uses of Apocynaceae family 
The study of Apocynaceae species used in traditional medicine reveals that 25 species in 16 
genera are of ethnobotanical interest. Nineteen species are medicinal, sixteen of which fall under 
the subfamily Plumerioideae which usually contains indole alkaloids (Omino and Kokwaro, 
1993). The most common category of diseases treated is skin and ectoparasitic diseases followed 
by abdominal diseases, diseases of the head, female conditions and venereal diseases. The root is 
the most commonly used part of the plant and it is possible that the alkaloids play an important 
role in the medicinal value of the plants (Omino and Kokwaro, 1993). Apocynaceae species are 
also used to treat gastrointestinal ailments, fever, malaria, pain and diabetes Wiart (2006) while 
some are used in the treatment of cancer (Atta-ur-Rahman et al., 1986; Wang et al., 2012). 
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2.5 Chemistry of Apocynaceae 
Plants are invaluable sources of pharmaceutical products and are recognized for their ability to 
produce a wealth of secondary metabolites. Mankind has used many species for centuries to treat 
a variety of diseases (Sadqui et al., 2006). Various natural products occur in Apocynaceae plants; 
an extensive phytochemical investigation has been conducted demonstrating the natural 
occurrence of alkaloids, terpenoids, flavonoids/phenolic acids, glycosides and iridoids . 
The occurrence of indole alkaloids seemed to be a rule in this family. They occur as tetracyclic, 
pentacyclic or polycyclic rings. The occurrence of alkaloids in some apocynaceae family has 
been documented (Liu et al., 2012; Raffauf and Flagler, 1960). Some biologically active 
alkaloids found in Apocynaceae include: pleiocarpamine, alstoumerine, alstonerine, 
alstophylline, macralstonine, villalstonine, vinblastine, vincristine, pleiocarmine, strophanthilin, 
thevetin, peruvoiside, neriifolin, neriocorin, neriin, oleanderin, reserpine, serpentine and 
catharanthine.  
2.5.1 Occurrence of Alkaloids 
Alstonia species are rich in important alkaloids like alstonidine, alstonine, alstovenine, 
chlorogenic acid, chlorogenine, ditain, ditaine, ditamine, echicaoutchin, echicerin, echiretin, 
echitamine, echitein, echitenin, echitin, porphyrine, porphyrosine, reserpine, venenatine, 
villalstonine, pleiocarpamine, O-methylmacralstonine, macralstonine, O-acetylmacralstonine, 
villalstonine, macrocarpamine, corialstonine, corialstonidine, nareline, scholaricine, methyl 
burnamine, and vallesamine (Arulmozhi et al., 2007; Rastogi et al., 1990; Cai et al., 2007).  
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The chemical investigation of an alkaloidal extract of Alstonia macrophylla bark led to the 
isolation and identification of two new nitrogenous derivatives, alstoniaphyllines A and B, a new 
indole alkaloid, alstoniaphylline C and eight known alkaloids (Cheenpracha et al., 2013).  
Nine bisindole alkaloids, four from the macroline-sarpagine group, and the remaining five from 
the macroline-pleiocarpamine group, were isolated from the stem-bark of Alstonia angustifolia, 
(Tan et al., 2013). Nineteen monoterpenoid indole alkaloids including seven new ones, 
melodinines A−G were isolated from Melodinus henryi (Feng et al., 2010). 
A new bisindole alkaloid, 19, 20-dihydroervahanine A was isolated from the stems of Ervatamia 
coronaria grown in Brazil, together with the five known alkaloids: coronaridine, heyneanine, 
voacristine, voacamine, descarbomethoxyvoacamine (Henriques et al., 1996). Four bisindole 
alkaloids, viz., 190(S)-hydroxyconodurine, conodurinine, 190(S)-hydroxyconoduramine and 
190(S)-hydroxyervahanine A, in addition to conodurine and ervahanine A, were obtained from 
the leaf and stem-bark extracts of Tabernaemontana corymbosa (Kam and Sim, 2003).  
The stem bark of Muntafara sessilifolia has been reported to contain vobasinyl-iboga bisindole 
and 2-acylmonomeric indole alkaloids. Examples include 30-oxotabernaelegantine B, 
30- oxotabernaelegantine A, 30(R/S)-hydroxytabernaelegantine A, oxotabernaelegantine and  
30(S) hydroxytabernaelegantine C (Girardot et al., 2012). Bisindole alkaloids from the 
macroline–sarpagine group and macroline–pleiocarpamine group were isolated from the stem-
bark extracts of Alstonia angustifolia which includes: perhentisine A-C, lumutinine E and 
villalstonidine A-E. Additional bisindole alkaloids isolated from the bark extract includes; 
bipleiophylline, perhentinine, perhentidines A and C, anhydromacralstonine, villalstonine, 
villalstonine-N-oxide, and macrocarpamine (Tan et al., 2013). Indole alkaloids condylocarpine, 
coronaridine, 14,15-dehydro-16-epi-vincamine, heyneanine, 10-hydroxycoronaridine,  
 
 
 
 
 29 
 
3-oxotabersonine, 3-oxovoacangine, stemmadenine, stemmadenine-N-oxide, tabersonine and 
tabersonine-N- oxide. Tetrahydroalstonine, voacangine, and voacristine have been isolated from 
the seeds of Tabernaemontana cymosa (Achenbac et al., 1997).  
Catharanthus roseus is a source of pharmaceutically important alkaloids with more than 130 
being described to date. It is the sole source of vincristine and vinblastine used against a variety 
of cancers. Three new terpenoid indole alkaloids, vidolicine, normacusine B N-oxide, and 
lochnerine N-oxide, together with seven known ones were isolated from the whole plants of 
Catharanthus roseus (Wang et al., 2011). Globospiramine, a new spirobisindole alkaloid 
possessing an Aspidospermae, Aspidosperma skeleton, together with deoxyvobtusine, 
deoxyvobtusine lactone and vobtusine lactone were isolated from Voacanga globosa 
(Macabeo et al., 2011). Three indole alkaloids (Aspidocarpine, 11-methoxytubotaiwine and 
picraline) were isolated from the aqueous extract from the bark of Aspidosperma cuspa (Kunth) 
Blake, (Pérez et al., 2012).  
Zocoler et al., (2005) identified the indole alkaloids: ibogamine, coronaridine, ibogaine 
pseudoindoxyl, voacangine hydroxyindolenine, voacangine pseudoindoxyl, tabernanthine, 
catharanthine, voacangine, 19-oxovoacangine, 10-hydroxycoronaridine, affinisine, 16-epi-
affinine, voachalotine, ibogaline, and conopharyngine from Tabernaemontana fuchsiaefolia. 
Four new aspidosperm aspidosperma-type bisindole alkaloids; 3-oxovoafrine B, voacandimine  
A –C were isolated from the seeds and root bark of Voacanga Africana (Kitajima et al., 2013). 
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2.5.2 Occurrence of Flavonoid/flavanone/phenolic acids 
Five phenolic acids: vanillic, gentisic, syringic, 4-hydroxybenzoic and salicylic acid have been 
reported to be isolated from Ervatamia coronary (Henriques et al., 1996). Bioactive davidigenin, 
a dihydrochalcone was also reported from Mascarenhasia arborescens (Desire et al., 2010).  
Paris and Duret (1974) documented the occurrence of flavonoids in the leaves of fifteen 
Apocynaceae collected from different geographical sources; kaempferol and quercetol were 
uniformly present irrespective of their geographical origin and isorhamnetol was found to be 
occasionally present in the plants. Other flavonoid glycosides present are isoquercitroside, 
rutoside, nicotifloroside and robinoside. The flavonoid content of Apocynaceae leaves were said 
to be low with some exceptions, depending on collection time. 
2.5.3 Occurrence of Terpenoids 
Iridoids are monoterpernes derived from isoprene units  ¸ which are considered the universal 
building blocks of all terpenoids (Dewick, 2002). They have shown a broad range of biological 
activities like antibacterial, antifungal, anti-inflammatory, antitumoral, hepatoprotective, 
cardioprotective, antioxidative, and antiprotozoal activity. They have also been reported to 
inhibit the growth of the hepatitis C virus. Apocynaceae has been described as the most 
important plant order that produces Iridoids with ca 5000 species distributed worldwide and they 
are concentrated in a few genera like Plumeria, Himatanthus, Allamanda and Cerbera 
(Amaral et al., 2013). 
The isolation of four new iridoids in Apocynaceae has been reported to give; plumeridoids A-C 
and epiplumeridoid C which were isolated from the stem bark of Plumeria rubra Linn. together 
with fulvoplumerin, dihydroplumericin, plumieride, isoplumericin, plumericin, allamcin, and 
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allamandin. Triterpenes, viz., ajunolic acid, ursolic acid, oleanolic acid, β-amyrin acetate, 
betulinic acid, lupeol and its acetate, 2,3-dihydroxypropyl octacosanoate, glucoside of  
β-sitosterol, and a mixture of common sterols (stigmasterol and β-sitosterol) have also been 
reported (Kuigoua et al., 2010). 
Loganic acid, loganin, boonein, isoboonein were isolated from the bark of Rauwolfia grandiflora 
(Bianco et al.,1994). The isolation of lupeol, a pentacyclic triterpenoid was reported by 
(Macabeo et al., 2011). The triterpenoids lupeol linoleate, lupeol palmitate and α-amyrin 
linoleate are present in the stem bark of Alstonia species (Satyavati et al., 1987; Cai et al., 2007). 
Triterpenes: α-amyrin, β-amyrin, lupeol, betulinic acid, ursolic acid, oleanoic acid and the acetyl 
derivate of the cyclitol methoxy-myo-inositol were isolated from Mucoa duckei (Markgraf) 
Zarucchi (Koolen et al., 2012). 
2.5.4 Occurrence of Lignans and Lignan glucosides 
(+)-Lyoniresinol, (+)-5,5'-Dimethoxy-9-O- (β-D-glucopyranosyl)lariciresinol,Glucopyranosyl+)-
(+)-3α-O-(β-D-glucopyranosyl)lariciresinol, (-)-3α-O-(β-D-glucopyranosyl)lariciresinol, (-)-2α-
O-(β-D-glucopyranosyl)lariciresinol, (-)-3α-O-(β-D-glucopyranosyl) -5'-methoxyisolariciresinol 
and  (+) -8,8'-Dimethoxy- 1-O-( β -D-glucopyranosyl) secoisolariciresinol were isolated from the 
seeds of Tabernaemontana cymosa (Achenbac et al., 1997). 
2.5.5 Occurrence of Glycosides 
Fanie et al., (2007) reported the isolation of two pregnane glycosides from the dried stems of  
Hoodia gordonii and Hoodia pilifera. Cardiac glycosides such as oleander, oleandrin, 
cardenolide N-1, cardenolide N-4,3 β –O-( β -D-sarmentosyl)- 16b-acetoxy-14-hydroxy-5 β,14 β 
-card-20-(22)-enolide and16 β -acetoxy,14-dihydroxy-5 β,14 β -card-20-(22)-enolide has been 
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isolated from Nerium oleander (Zhao et al., 2007). Hoodigoside L was reported as the major 
appetite-suppressant principle isolated from Hoodia gordonii (van Heerden, 2008).  
2.5.6 Other compounds from Apocynaceae family  
Sweroside and 3-O-(β-D-Glucopyranosyl) 5-O-methylgallic acids were isolated from the seeds 
of Tabernaemontana cymosa (Inouye et al., 1966; KÖnig et al., 1973). The isolation of 
coumarins and coumarino lignan as well as chlorinated coumarinolignan from the genus Mondia 
was reported by (Patnam et al., 2005). (−)-Loliolide which showed affinity to SERT in a binding 
assay has recently been reported (Neergaard et al., 2010). 
2.6 Chemical structure of some isolated compounds from selected medicinal plants from 
Apocynaceae species 
Some isolated compounds from selected Apocynaceae species from recent published articles are 
presented below in Figures 2.1-2.6. 
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Figure 2.1. Isolated compounds from Catharanthus roseus (Alkaloids). 
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Figure 2.2. Isolated compounds from Melondinus henryi (Alkaloids). 
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 Angustimaline     R= α-OH                
                                                Alstoniaphylline A R= =O    
 
                                                             
Alstoniaphylline C 
                                                                                       
                                                   
                                                           Alstoniaphylline B 
 
Figure 2.3. Isolated compounds from Alstonia macrophylla (Alkaloids). 
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Glycoside 3β [-β-D-thevetopyranosyl-(1→4)-β-D-cymaropyranosyl- 
(1→4)-β-D-cymaropyranosyloxy]-12-β-tigloyloxy-14 -β -hydroxypregn-5-en-20-One (also 
known as P57A53) 
 
         Hoodigogenin A    R=H 
         Gordonoside A       R=H 
         Hoodigoside A       the-cym 
         Hoodigoside B       the-the-cym 
         P57A53       the-cym-cym 
         Hoodigoside C       the-cym-cym-cum 
        Hoodigoside D        the-the-cym-cym 
              
     
 
Hoodigoside L  
Figure 2.4. Glycosides derived from 12-hydroxypregnane glycoside isolated from Hoodia 
gordonii. 
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α-Amyrin                                                                                 β-Amyrin 
Figure 2.5. Triterpenes from Mucoa duckei. 
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Figure 2.6. Terpenes from Rauwolfia grandiflora. 
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2.7 Biological activities of representative members of Apocynaceae family  
Apocynaceae species have been screened for various biological activities both in vitro and in 
vivo using animal models. The main biological activities were antiplasmodial, anticancer, 
antibacterial, anti-inflammatory and antidiabetic activities. 
2.7.1 Anthelmintic activity 
A number of plants from Apocynaceae have shown anthelmintic activity against different 
organisms viz; Thevetia peruviana (Pers.) K. Schum, Mondia whitei (Hook. f.), Acokanthera 
oppositifolia, Acokanthera oblongifolia, Asclepias fruticosa L. and Secamone filiformis  
(Aremu et al., 2012). 
2.7.2 Anti-inflammatory activity 
The aqueous and alcoholic extracts of Ervatamia coronaria, when administered p.o. or i.p. to 
rats 1 h before a subplantar injection of carrageenin had a significant anti-inflammatory effect. 
The alcoholic extract also had an analgesic effect and increased the pentobarbital induced 
sleeping time, (Henriques et al., 1996). In vitro anti-inflammatory activity of Mondia whitei 
leave extracts indicated that methanol and water extracts had moderate (above 65%) COX-1 
inhibition while the extract from the roots showed over 80% inhibitions (Matu and Van Staden, 
2003).  
Statistical analysis revealed that Trachelospermum jasminoides WET (0.5, 1.0 and 2.0 g/kg) 
significantly inhibited the development of carr-induced paw edema after 3 h of treatment when 
compared with control (Sheu et al., 2009). The DCM fraction of ethanolic extract of Alstonia 
scholaris has demonstrated anti-inflammatory activity (Arulmozhi et al., 2012). 
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2.7.3 Antiplasmodial activity 
The isolated compounds from Muntafara sessilifolia were evaluated in vitro for antiplasmodial 
activity against the chloroquine-resistant strain FcB1 of Plasmodium falciparum, and  
30-oxo-tabernaelegantine A exhibited antiplasmodial activity (4.4 µM IC50) associated with a 
non-significant cytotoxicity selectivity index of 48 (Girardot et al., 2012). Nicalaterine, 
bisnicalaterine B and bisnicalaterine C were isolated from the bark of H. zeylanica.  
Nicalaterine (IC50, 0.05 µM) displayed a higher antimalarial activity against P. falciparum than 
bisnicalaterine B (IC50 0.11 µM) while bisnicalaterine C showed a weak cytotoxic activity  
(IC50 value of 1.13 µM) (Nugroho et al., 2011).  
The aqueous extract of a partitioned ethanolic leaf extract of Alafia barteri (Hook F. Icon) 
displayed antiplasmodial activity with an IC50 value of 1.5 ±0.7 µg/mL while the root aqueous 
extract gave 3.0 ±0.4 µg/mL comparable to the reference antimalarial drug Quinine with an IC50 
value of 0.95 ±0.25µg/mL against Plasmodium falciparum strain (Lasisi et al., 2012). 
Alstonisine, isolated from Alstonia macrophylla exhibited antiplasmodial activity against 
Plasmodium falciparum with an IC50 of 7.6 μM (Cheenpracha, 2012). Four vobasinyl-iboga 
bisindole and one 2-acyl monomeric indole alkaloids were isolated from the stem bark of 
Muntafara sessilifolia along with eleven known compounds. Tabernaelegantine B and D 
displayed the highest cytotoxicity with IC50 values of 0.47 and 1.89 μM on MRC-5 cells and 
0.42 and 2.7 μM on L-6 cells, respectively (Girardot et al., 2012). Four indole alkaloids, 
geissolosimine , geissospermine B , geissoschizoline and geissospermine D, were isolated from 
the stem bark of Geissospermum vellosii, with geissolosimine showing the highest cytotoxicity 
against the chloroquine- sensitive strain of P. falciparum (IC50 0.96 µM)  
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(Mbeunkui et al., 2012).  
Indole alkaloids: geissospermine D, leucoridine A N-Oxide and anhydropereirine isolated from 
the leaves of L. griffithii and evaluated for antimalarial activities against P. falciparum 3D7 
showed potent activity at IC50 values of 0.09, 0.007 and 0.06 μM, respectively  
(Nugroho et al., 2012).  
2.7.4 Anticancer/Antineoplastic activity 
Vincristine and vinblastine used against a variety of cancers such as acute leukemia, Hodgkin’s 
disease, rhabdomyosarcomas, neuroblastoma and other lymphomas are from C.roseus 
(Mukherjee et al., 2001; Van der Heijden et al., 2004; Aslam et al., 2009). Eight indole alkaloids, 
14’,15’-didehydrocyclovinblastine,17-deacetoxycyclovinblastine,17-deacetoxyvinamidine, 
vinamidine, leurosine, catharine, cycloleurosine and leurosidine were also isolated from the 
whole plants of C. roseus. All the isolated alkaloids showed cytotoxic effects against the human 
breast cancer cell line MDA-MB-231, while Leurosine exhibited the most potent inhibitory 
activity (IC50 value of 0.73 µM) (Wang et al., 2012).  
Lochnericine an indole alkaloid was isolated from the whole plants of C. roseus and it showed 
cytotoxic activities against HL-60, SMMC-7721 and A549 with IC50 values of 11.0, 22.8 and 
29.5 µM, respectively (Wang et al., 2011). Eight indole alkaloids were isolated from the whole 
plants of C. roseus among which leurosine had the most cytotoxic effects against MDA-MB-231 
with an IC50 value of 0.73 µM (Wang et al., 2012).  
The ethanolic extract, subsequent hexane fractions and fraction F-4 from W. tomentosa inhibited 
the proliferation of human breast cancer cell lines, MCF-7 and MDA-MB-231 in vivo.  
The fraction F-4 obtained from the hexane fraction inhibited proliferation of MCF-7 and  
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MDA-MB-231cells in a concentration and time dependent manner with an IC50 of 50 µg/ml and 
30 µg/ml for 24 h, 28 µg/ml and 22 µg/ml for 48 h and 25 µg/ml and 20 µg/ml for 72 h 
respectively. The fraction F-4 induced G1cellcycle arrest, reactive oxygen species (ROS) 
generation, loss of mitochondrial membrane potential and subsequent apoptosis.  
Apoptosisis indicated in terms of increased Bax/Bcl-2 ratio, enhanced Annexin-V positivity, 
caspase 8 activation and DNA fragmentation. The active molecules isolated from fraction F-4 
viz., oleanolic acid and ursolic acid inhibited cell proliferation of MCF-7 and MDA-MB-231cells 
at IC50 value of 7.5 µM and 7.0 µM respectively, whereas there is no significant cell inhibiting 
activity in the non-cancer originated cells, HEK-293. In both MCF-7 and MDA-MB-231, 
oleanolic acid and ursolic acid induced cell cycle arrest and apoptosis as indicated by a 
significant increase in Annexin-V positive apoptotic cell counts (Chakravarti et al., 2012). 
Tumor resistance to platinum-based drugs has been an obstacle to the treatment of ovarian 
cancer, in order to enhance the effectiveness of platinum-based drugs, the anticancer effects of 
Rauwolfia vomitoria extract (Rau), both alone and in combination with carboplatin (Cp),  
a platinum based drug was studied. Rauwolfia vomitoria extract was found to decrease cell 
growth in tested ovarian cancer cell lines in a dose dependent manner. Apoptosis was the 
predominant form of Rau-induced cell death and it occurred in a time- and dose-dependent 
manner.  
Synergy of Rau with Cp was detected with combination index values of <1 and dose reduction 
index values for Cp ranging from 1.7- to 7- fold. Tumor growth in mice was significantly 
suppressed by 36% or 66% with Rau treatment alone at a low (20 mg/kg) or a high dose  
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(50 mg/kg) respectively, an effect comparable to that of Cp alone. It was concluded that the 
combination of Rau with Cp remarkably enhanced the effect of Cp and reduced tumor burden by 
between 87% to 90% and ascites volume from 89% to 97% (Yu et al., 2013).  
Bisleuconothine A, a bisindole alkaloid was isolated from the bark of Leuconotis griffithii.  
It showed cell growth inhibitory activity against four human cancer cell lines HL60, HCT116, 
MCF-7 and A549 with IC50 values of 11.0, 5.7, 9.2 and 7.0 µM, respectively.  
 It also induced G1 phase arrest in HCT116 in a dose-dependent manner (68.3%, 0µM; 72.0%,  
5 µM; 75.1%, 10 µM; 79.5%, 20 µM) after treatment for 24 h (Hirasawa et al., 2010).  
The in vitro cytotoxic activity of the Himatanthus drasticus latex proteins (HdLP) was 
determined on cultured HL-60, MDA-MB-435, SF-295 and HCT-8 cell lines but did not give 
any significant in vitro cytotoxic effect at experimental exposure levels.  
The in vivo antitumor activity was assessed in two experimental models, Sarcoma 180 and 
Walker 256 carcino-sarcoma. It was found that intraperitoneally administered HdLP was active 
against in vivo experimental tumors but inactive by oral administration. Intraperitoneal HdLP 
reduced tumor weight to 1.60 ± 0.18 and 1.66 ± 0.18 g on sarcoma cell lines at doses of 10 and  
20 mg/kg/day, respectively. These reductions gave inhibition rates of 36.46% and 34.22% when 
compared with the control (2.52 ± 0.14 g). On Walker 256 carcino sarcoma, the average tumor 
weight of the control was 8.36 ± 0.55 g and intraperitoneal HdLP reduced tumor weight to  
3.52 ± 0.94 and 3.74 ± 0.95 g at doses of 10 and 20 mg/kg/day, respectively with % inhibition 
rates of 57.91 and 55.23. It was concluded that HdLP had some interesting anticancer activity 
that could be associated with its immune stimulating properties (Mousinho et al., 2011).  
The ethanolic extract of leaves of Himatanthus obovatus showed strong cytotoxic activity in 
cancer cell lines (Mesquita et al., 2009). 14-Dihydroxy-5b, 14b-card-20-(22)-enolide has shown 
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in vitro cytotoxicity against T-cell, HL-60, HeLa, MCF-7, LNCap, DU145, PC3, VA-13) and 
HepG2 (Raghavendra et al., 2007; Zhao et al., 2007). The purified alkaloid fraction of  
E. coronaria was cytotoxic to the HT-29, A-549 and MCF-7 cell lines with IC50 values of 32.5, 
47.5 and 72.5 μg/mL respectively. It also induced DNA fragmentation in the HT-29 cell line at a 
concentration of 65 μg/mL (Hullatti et al., 2013). 
2.7.5 Antituberculosis activity 
Globospiramine showed potent antituberculosis activity against Mycobacterium tuberculosis 
H37Rv as evidenced in microplate Alamar blue assay (MIC = 4 µg/ml) and low-oxygen recovery 
assay (LORA MIC 5.2 µg/ml) (Macabeo et al., 2011). 
2.7.6 Anticholinesterase activity 
The bisindole alkaloids isolated from Voacanga globosa, exhibited promising anticholinesterase 
activity with butyrylcholinesterase, the most potent being deoxyvobtusine (IC50 = 6.2 µM) 
(Macabeo et al., 2011). Pleiocarpine had also demonstrated promising anticholinestrase activity 
(Naaz et al., 2013). 
2.7.7 Neurobiological activity 
The ability of reserpine from Rauwolfia serpentina to induce depression and deplete brain 
amines became one of the pillars of the monoamine theory of affective disorders. The alkaloid 
reserpine was introduced into Western psychiatry as an antipsychotic drug in the 1950s, despite 
its effectiveness as an antipsychotic agent, reports of secondary depression side effects has 
lessened its popularity (Healy and Savage 1998; Walter and Rey 1999). 
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2.7.8 Aphrodisiac activity 
Mondia whitei has been reported to possess aphrodisiac activity. The combined extract used as 
formulation: Mondia whitei + Ekerbegia capensis, showed a dose-dependent direct effect in 
increasing sexual arousability, better sexual stimulation and increase in copulatory efficiency in 
rats (Gundidza et al., 2009). 
2.7.9 Antibacterial /Antifungal activity 
Alkaloids isolated from Tabernaemontana divaricata (L.) R. Br were investigated for 
antibacterial and antifungal activities where it was found that 5-oxocoronaridine showed strong 
antibacterial activity against Klebsiella pneumonia at 50 µg/ml  while tabernaelegantine D 
displayed maximum antifungal activity against Penicillium chrysogenum at 60 µg/ml 
(Singh et al, 2011). 
2.7.10 Anti-appetite activity 
One of the two pregnane glycosides from the dried stems of H. gordonii and H. pilifera  
was tested for its appetite suppressant properties in rats by oral gavage at 6.25–50 mg/kg and the 
results showed that all doses resulted in a decrease of food consumption over an eight day period 
and a body mass decrease when compared to the control sample receiving only the vehicle 
(van Heerden et al., 2007).  
2.7.11 Anticonvulsant activity 
Carissa edulis exhibited dose-dependent inhibition of the convulsion induced by MEST with 20 
mg/kg providing 90% protection while phenytoin (20 mg/kg) produced 100% protection. 
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The median lethal dose (LD50) of Carissa edulis was 282.8 mg/kg and over 5000 mg/kg 
following intraperitoneal and oral administration, respectively. It also produced 40% and 20% 
protection against convulsion at 5 and 20 mg/kg, respectively, compared with 100% protection 
with benzodiazepine.The mean onset and percentage protection against convulsion in  
Carissa edulis extract-treated mice were reduced by flumazenil and naloxone. The result was 
said to support the ethnomedicinal claims of the use of the plant in the management of epilepsy  
(Ya’u et al., 2008). C. procera latex proteins were evaluated with respect to anticonvulsant and 
sedative activity in mouse models of pentylene tetrazol (PTZ)-, pilocarpine- and strychnine-
induced convulsions or turning behavior and pentobarbital induced sleep. In the strychnine- and 
pilocarpine-induced seizure models, C. procera latex proteins caused no significant alterations in 
latencies to convulsions and death when compared with controls. In the PTZ induced seizure 
model, administration of C. procera latex proteins in high doses (50 or 100 mg/kg) and diazepam 
caused significant increases in latencies to convulsions and death (Lima et al., 2012). 
2.7.12 Antihyperglycaemic activity 
Evaluation of antihyperglycaemic activity of the seed extracts of Hunteria umbellate (HU) by  
Oral administration with 1 mg/kg of glibenclamide, 50 mg/kg, 100 mg/kg, and 200 mg/kg of HU 
extract significantly and dose dependently (p < 0.05, <0.01 and <0.001) attenuated development 
of hyperglycaemia, decreased levels of plasma HbA1c, free insulin, and serum triglyceride and 
cholesterol, in the Groups III, IV, V and VI rats, respectively, when compared to  
fructose-induced hyperglycaemic (Group II) rats. Similar effects were also recorded in the 
dexamethasone-induced hyperglycaemic rats. The results from the study suggested that the 
hypoglycaemic and antihyperlipidaemic effects of HU were mediated via enhanced peripheral 
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glucose uptake and improvements in hyperinsulinaemia. The findings supported the folkloric use 
of HU to manage diabetes mellitus (Adeneye and Adeyemi, 2009). 
The aqueous extract of T. iboga potentially stimulated glucose-induced insulin secretion in dose- 
and glucose-dependent manners (5.6–16.7 mM). T. iboga may represent a source of anti-
hyperglycaemic natural products that could serve as type II diabetes mellitus therapeutics  
(Souza et al., 2011). Investigation of the anti-diabetic activity of unripe Carissa carandas Linn. 
fruit extract indicated that the methanol extract and its ethyl acetate soluble fraction significantly 
lowered the elevated blood glucose levels by 48% (p < 0.001) and 64.5% (p < 0.001) 
respectively at a dose level of 400 mg/kg per oral administration after 24 h as compared to 
diabetic control (Itankar et al., 2011). 
2.7.13 Antidiarrhoeal activity 
A. congensis extracts showed significant and dose-dependent antidiarrhoeal activity in treated 
wistar rats at oral doses of 100 and 200 mg/kg body weight. At the highest dose of 200 mg/kg 
body weight, the 80% hot methanol extract produced 79.87 ± 2.1% and 78.67± 0.5%,  
75.0 7± 2.1% and 71.47± 2.1% inhibition of defecation and diarrhea respectively against castor 
oil- induced diarrhea. 75.07± 1.2% and 73.37± 1.2% inhibition were recorded against 
magnesium sulphate-induced diarrhea (Nsaka Lumpu et al., 2012). 
2.7.14 Antiprotozoal activity 
The aqueous and 80% MeOH extracts from the leaves stem bark, root bark and series of sub 
fractions from Alstonia congensis has been reported to show significant antiprotozoal activity 
against the KI strain of Plasmodium falciparum with IC50 values ranging from 2 to 5 µg/ml.  
The total alkaloid extract was active against Leishmania infantum with IC50 < 10 µg/ml 
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(Lumpu et al., 2013). 
2.7.15 Analgesic activity 
The DCM (30 mg/kg
-1
) fraction of ethanolic extract of A. scholaris demonstrated an analgesic 
effect on mice with % inhibition of 45.06 ± 4.62 as compared with the control  
(Arulmozhi et al., 2012). 
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Table 2.1. Ethno medicinal usage of some Apocynaceae species 
Scientific names          Ethno medicinal uses                                          Region                     References                                         
Adenium oleifolium      Root concoction is used as a tonic    Namibia Aiyambo, 2010 
Alstonia angustiloba   Stems, leaves and latex for gynecological   Indonesia              Mulyoutami et al., 2009 
         and  skin sores                   
        Leaves applied externally for headache         Malaysia             Lin, 2003 
       especially for gastric disturbances, and as a  
                                       remedy for fever. Ointment made from this 
                                       plant can be applied to snake and scorpion bites 
 
Alstonia boonei               Used for the treatment of malarial disease,        Nigeria                  Ajibesin et al., 2008, 
as astringent, antifebrile, antihelmintic,  
antispasmodic among other indications                                           Iwu  and Klayman, 1992   
   
Alstonia congensis         Aqueous decoction from leaves  
                                       used to treat diarrhea                                          Congo                   Lumpu et al., 2012 
 
 
Alstonia  oblongifolia     Roots applied topically to relieve itching                                        McGraw et al. 2000 
Benth.& Hook.f., 
 
Ceropegia  
purpurascens                 The tubers are baked in the ashes before they are                 
                                     eaten                                                                     Namibia               Aiyambo, 2010 
                                    
Ceropegia stenoloba 
                                     Tubers are eaten raw or roasted in hot ash.         Namibia               Aiyambo, 2010 
Calotropis                      Used to treat skin and liver diseases, leprosy                                   Rajakaruna et al., 2002 
gigantea (L.)                  dysentery, worms, ulcers, tumours and  
                                       ear aches. 
                                        Latex used for wound healing                                                          Nalwaya et al., 2009 
  
Carissa edulis              Headache, chest pain, gonorrhea, syphilis,  
                                     rheumatism, rabies and as well as a diuretic                                     Nedi et al., 2004  
                                
                                     Also for fever, cell anaemia and hernia                                            Ibrahim, 1997 
                                     rooots are used for venereal diseases,                   Kenya                  Jeruto et al., 2008 
                                     epilepsy, malaria, heartburn, arthritis,         
                                     sorcery and cancer 
 
Catharanthus roseus      Used to treat diabetes and high blood pressure   Shebien El-Kom                                                                                                                        
                                                                                                    Menoufia               El-Seedi et al., 2013                                                                                                                   
 
                                      As a purgative, to treat indigestion and dyspepsia                              Noble, 1990  
                                    flowers milky sap applied topically  
                                    to treat burns                                                         South Africa          Govindasamy and Srinivasan, 2012 
                                    hypertension, cancer, scalps and sore                   China                     TCMD, 2006 
 
Carissa congest          Roots were employed as a bitter stomachic,        India                       Itankar et al., 2011 
(Carissa carandas)    vermifuge and as an ingredient in the  
   Dyera costulata         Leaves and barks used for fever, 
  Hook                          Inflammation, pain                                                                               Subhadhirasakul et al., 2003 
      
  Ervatamia coronaria    Various parts used as anticancer, also for wounds) Stapf                Atta-ur-Rahman et al., 1986 
 (Jacq) Stapf                  remedy for itches                                                                             Talapatra et al., 1975                                                                                                                                             
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Table 2.1. Continued Ethno medicinal usage of some Apocynaceae species 
   Scientific names        Ethno medicinal uses                                       Region                     References                                         
                                                                                                                        
   Himatanthus    
   lancifolius                   Treatment of dysmenorrhea and in the 
                                      amelioration of menopausal symptoms.           Brazil                       Rattmann et al., 2005 
                                
                                     The dried stem bark of this specie  is  
                                     commonly used as a febrifuge, as an  
                                     emenagogue and as an abortive 
  Holarrhnea  
  floribunda  
                                     Stem bark is used for malaria, dysentery,  
                                     fever, female sterility, skin infections 
                                     veneral diseases and snake bites 
                                     Convulsion in children                                   Nigeria                        Orwa et al., 2012 
 Hoodia gordonii         As food plant                                                  South Africa               van Heerden, 2008 
 
Hunteria umbellata     Use of the hot infusion of the plant seed                                           Adeneye and Adeyemi, 2009 
                                    Leaves, roots and barks for fever, pain, 
                                    abdominal colic and discomforts, diabetes mellitus    
                                    and obesity and as an immune booster 
                                    plant leaves and pulp to induce labour                                              Falodun et al., 2006 
 
 Kopsia fruticosa           To treat sore and syphilis, has cholinergic effects                            Nalwaya et al., 2009 
 (Ker.) A. DC   
       
Landolphia                    Leaves infusion  used for  wounds,  
 Buchananii                   gonorrhoea, molluscides                                Kenya                         Jeruto et al., 2008 
                
                              
Mascarenhasia           To treat intestinal disorders, intestinal spasms  
arborescens A. DC.    and diarrhea                                                   Madagascar                 Desire et al., 2010 
 
Mondia whitei               A mild laxative, to ease abdominal               Africa                         Aremu et al., 2010 
                                    pains, alleviate nausea as well as for the treatment  
                                    of fever, sexual dysfunction 
                                    A root decoction used to induce labour        Uganda                       Ssegawa and Kasenene, 2007 
                                   As antimalarial, anthelmintics                        Nigeria 
                                                                                                          Benin                         Hermans et al., 2004, Idu et al., 2010                                                                                                                                                                                                                                                                               
                                                                                                                                             Odugbemi et al., 2004, 
 
                                   To cure male infertility                                 Cameroon                   Focho et al., 2009 
                                   To treat ringworms, skin diseases,  
                                   heart diseases and asthma                             Kenya                         McGeoch, 2004. 
                                   For stress and tension in adults                    South Africa               Van Wyk and Gericke, 2000  
                                   To stimulate appetite, as an aphrodisiac,                                         Stafford et al. 2008 
                                     and for treatment of fits in children    
 
                                           
 
 
 
 
 
 
 
 
 51 
 
Table 2.1: Continued Ethno medicinal usage of some Apocynaceae species. 
 
Scientific names          Ethno medicinal uses                                                      Region                   References                                         
                               
 Nerium oleander L.     Inhalation from heated decoction from roots used to     Shebien El-Kom    El-Seedi et al., 2013 
                                     treat ,headaches and colds, leaves decoction used          Menoufia 
                                     for skin diseases, also for paralysis and serious pain   
Nerium indicum Mill.  The roots are made into a paste with                              India                       Parveen et al., 2007 
 (Kaner)                      water and are applied externally to treat  
                                   Chancre, ulcers and leprosy                                 
                          A paste of roots is applied externally on piles 
   
                                  The paste of its leaves with oil of its root bark is used  
                                    to treat ringworms and other skin diseases 
                                  The roots is used for procuring abortion both  
                                   by local application and internal administration    
                                                                       
Rauvolfia caffra           Applied topically to treat measles                                                                  McGaw et al. 2000 
Sond.                      
 
Rauwolfia serpentina  
                                     Dried leaves are used for snuff for headaches              South Africa             Stafford et al. 2008 
                                   decoctions of the bark are used as a tranquillizer  
                                   hysteria and insomnia. 
                            
Rauwolfia vomitoria  
                                  Root boiled in water to make decoction for                  Nigeria                      Ajibesin et al., 2008 
                                  mental illness 
 
Tabernaemontana cymosa  
                                                                                                                        Colombia                   Achenbach, 1996 
                                 The leaves and fruits are remedies against the 
                                 sting of millipede, and the flowers are reported to have 
                                 cardiotonic properties while the latex is used 
                                 to remove warts ] 
 
Tabernanthe iboga    Maceration of air-dried root bark used for diabetes                                     Souza et al., 2011 
                                  Fatigue and hunger                                                                                        Mash et al., 1998 
                                  AIDS  management                                                    Gabon                        Mefane et al., 1990 
 
Urechites andrieuxii   Used for the treatment of cutaneous                        Yucatan Peninsula     Chan-Bacab et al., 2003 
 Muell.-Arg.                Leishmaniasis 
 
Voacanga globosa.       Used to stupefy eels and treat ulcers and wounds                                      Macabeo et al., 2009       
 
Wrightia tomentosa    To treat cancer, snake and scorpion bites,  
                                    renal complications,menstrual disorders                                                    Chakravarti et al.,2012 
Xysmalobium undulatum 
 R.Br.                          Roots powder applied topically to treat abscesses                                     VanWyk et al. 2000 
                                                                                                                                                       Buwa and Van Staden, 2006 
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2.8 The Genus Pleiocarpa 
Pleiocarpa is a genus of flowering plants in the family of Apocynaceae, a native to tropical 
Africa and is found in roughly seven species. It is related to Hunteria and Picralima 
Pleiocarpa species generally are evergreen shrubs or trees in which the stems and leaves are 
completely glabrous. A white latex is present in all parts but is absent in the spines and tendrils. 
The leaves are opposite or present in whorls of 3-5 and elliptic to obovate. The petiole is angled, 
often narrowly winged but stipules are absent. They are inflorescences cymose, axillary, rarely 
also terminal; pedicels short or absent. The calyx is glabrous with lobes free at the base, 
herbaceous, imbricate, and not revolute, and without scales on the inner surface. The corollas are 
hypocrateriform, externally glabrous, internally pubescent below stamens and the tube is often 
found with 5 splits developing at the level of the stamens.  The lobes are contorted, overlapping 
to the left and are not ciliate. Their stamens arise at or above the middle of the corolla tube. The 
filaments are short and the anthers are dorsifixed, introrse, longitudinally dehiscent while their 
ovaries are glabrous, composed of 2-5 separate carpels with 1-4 ovules per carpel. The clavuncle 
is present and the stigma are reduced to a sessile area or rarely represented by a rudimentary 
apiculus. Their fruits are a compound berry of 2 variously shaped, fleshy to slightly fibrous 
mericarps with a rounded to hook-shaped apex. The seeds are variously shaped with smooth 
brown testa. The embryo is straight, spathulate, surrounded by a thick, rather starchy and hard 
endosperm, leaving a hole around the radicle base. The cotyledons are elliptic, thin and leafy, 
while the radicle is almost cylindrical (Louppe, 2008; GAP, 2013; Govaerts et al., 2011). 
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Photograph of P.pycnantha (Family: 
Apocynaceae)
 
Figure 2.7. The photograph of Pleiocarpa pycnantha leaves. 
 
Kingdom: Plantae  
Phylum: Magnoliophyta  
Class: Magnoliopsida  
Subclass: Asteridae  
Order: Gentianales  
Family: Apocynaceae  
Genus: Pleiocarpa  
Figure 2.8. Scientific classification of Pleiocarpa pycnantha. 
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Chemical constituents found in Pleiocarpa species includes alkaloids: (+)-pycnanthine, 
pleiomutinine,(+)-pleiocarpamine, (+)-quebrachamine, (+)-macusine B, (-)-eburnamine, tubicine, 
Tubifoline,(+)-pycnanthinine, kopsinine, tubotaiwine, tubifolidine, kopsinilam  
19, 20-dihydroakuammicine tuboxenine and (-) 1, 2-dehydroaspidospermidine. Others are  
(-)-pleiocarpinine, (-)-aspidofractinine, (+)-aspidospermidine, pleiocarpinilam, huntrabrin 
methochloride, kopsinic acid methochloride, Na methylsarpagin methochloride, pleiocarpine, 
macusine B chloride, macusine B rhodanide, pleiomutine, pleiomutinone, pleiomutinol, 
eburnamylpleiocarpinine, 10,11-dioxopleiocarpine,1-carbomethoxy-β-carboline, isotuboflavine 
and norisotuboflavine. Also, triterpenes lupeol, α- and β-amyrin and their corresponding acetates 
(Thomas et al., 1965, 1966; Achenbach and Biemann, 1965). 
2.8.1 Phytochemistry of selected Pleiocarpa species 
2.8.1.1 Pleiocarpa tubicina 
Some alkaloids have been reported from the leaves of Pleiocarpa tubicina STAPF; 
(+)-quebrachamine ((+)-I), (−)-1, 2-dehydroaspidospermidine ((−)-II) and (−)-aspidofractinine 
(IV) have been isolated in small quantities. The interesting conversion of (−)-quebrachamine 
((−)-I) into (+)-1, 2-dehydroaspidospemidine ((+)-II) has been achieved by controlled  
per-manganate oxidation (Bycroft et al., 1964). Others are quaternary indole alkaloids from the 
root bark: huntrabrine methochloride, kopsinic acid methochloride, N(a)-methyl-sarpagine 
methochloride and macusine B chloride (Khan et al., 1967). Tuboxenin isolation was reported by 
Kump et al., (1964) and tubotaiwine (Schripsema et al., 1987). 
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2.8.1.2 Pleiocarpa mutica 
Three new β-carboline derivatives were isolated from the stem bark of Pleiocarpa mutica Benth. 
which are 1-carbomethoxy-β-carboline, isotuboflavine and norisotuboflavine. Other known 
compounds reported are; pleiocarpine, 1,2-dehydro- aspidospermidine, quebrachamine, 
eburnamine, pleiocarpamine (Schmid and Kump, 1961; Achenbach and Biemann, 1965).  
The roots have been reported to contain five known alkaloids, pleiocarpine, kopsinine, 
pleiocarpamine, eburnamine and pleiomutinine (Addae-Kyereme et al., 2001).  
The stem bark also contained eburnamyl pleiocarpinine (Thomas et al., 1965), flavocarpine 
(Buchi, 1962) and pleiocarpoline (pleiocarpine Nb,-oxide), pleiocarpolinine (pleiocarpinine Nb,-
oxide) and kopsinoline (kopsinine Nb,-oxide) (Thomas et al., 1966). 
2.8.1.3 Pleiocarpa talbotii 
Several alkaloids have been isolated from the bark and root bark of P.talbotii which includes; 
talbotine, talpinine, talcarpine, and 16-epi-affinine (Naranjo et al., 1972). 
2.8.1.4 Pleiocarpa pycnantha 
Some indole alkaloids: pycnanthine, pleiocarpamine, quebrachamine, macusine and  
(-) ebunarmine have been isolated from Pleiocarpa pycnantha roots and bark (Gorman and 
Schmid, 1967; Gorman et al., 1969). 
2.9 Pharmacological activity of some Pleiocarpa species 
Alkaloids from the roots of Pleiocarpa tubicina Stapf and the leaves, roots and seeds from 
Pleiocarpa mutica Benth have been shown to be hypotensically active (Tsao et al., 1961; Schmid 
and Kump, 1961). Pleiomutinine from the roots of P. mutica was found to show significant 
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antiplasmodial activity against P. falciparum (IC50=5 μM). Pleiocarpine was inactive against 
malaria parasites in vitro, but moderately active against P. berghei in mice. A dose of 25 mg kg
−1
 
daily for 4 days reduced parasitaemia by 28.5% compared to untreated controls  
(Addae-Kyereme et al., 2001). Aqueous and organic extracts were prepared from P. mutica 
Benth from Belgium Congo; all the aqueous extracts lowered the blood pressure when 
administered to rats while the ethyl acetate extracts produced the most significant hypotensive 
activity. The mechanism of action was traced to epinephrine blockade but was not altered by 
atropine. These extracts also showed some nematocidal activity on Panagrellus redivivus (L.) 
(Tsao et al., 1961). 
Pleiocarpine, kopsinine, pleiocarpamine from P. mutica were analyzed for their anti-cholinergic 
action through docking with acetylcholinesterase (AChE) as target.of all the alkaloids tested 
Pleiocarpine showed promising anti-cholinergic potential, while its amino derivative showed 
about six-fold higher anti-cholinergic potential than pleiocarpine. Pleiocarpine and its amino 
derivative were found to be better inhibitors of AChE, as compared to commonly used drugs 
Tacrine (brand name : Cognex) and Rivastigmine (brand name: Exelon), indicating that the 
molecules could serve as potential therapeutics in future (Naaz et al., 2013). Kopsinine also 
displayed some hepaprotective activity against CCl4 – toxicity in mice and also shortened the 
barbital-induced sleeping time in mice. Eburnamine had a similar biological activity as 
strychnine and has been found to be a useful cerebrovascular agent (Schmelzer et al., 2008). 
A comprehensive project was conducted as part of the Associated Project #3 of the International 
Cooperative Biodiversity Group Program under the direction of the Walter Reed Army Institute 
for Research which focuses on the study of West and Central Africa plants.  
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In this study, a total of 41 plant extracts and eight compounds were tested in vitro on strains of 
African trypanosomes (Trypanosoma brucei group) and of pathogenic trichomonads 
(Trichomonas vaginalis and Tri-trichomonas foetus). P. pycnantha was one of the plants that 
showed IC50 value of ≤ 20 µg/ml. The leaf extract did not show any positive results for the 
antimicrobial study (Iwu, 2001; Bacchi, 2002). 
2.10 Ethnobotanical information on Pleiocarpa genus 
The ground bark of Pleiocarpa mutica is rubbed against the bodies of inhabitants in Sierra Leone 
to prevent fever. A drink decoction of the grated bark is used to treat stomach ache in Côte 
d’Ivoire while it is used for oedema of legs by the Ebrié people. The root bark decoction can also 
be used to treat kidney diseases and malaria. In Ghana, the decoction from roots is taken as a 
febrifuge, antimalarial and also for jaundice and convulsions. The ground bark in palm wine is 
used as laxative (Schmelzer et al., 2008). Pleiocarpa pycnantha roots are added to palm-wine in 
Ghana to give it potency. Ground roots mixed with seeds of Aframomum melegueta K.Schum 
and palm wine is taken as a laxative. In Benin, leaf maceration with lemon juice is given to 
patients suffering from jaundice, oedema, reduced urine excretion and infection by roundworms 
(Burkill, 1985). The Yoruba speaking part of West Africa combine a blend of leaves of 
Pleiocarpa pycnantha (Apocynaceae), leaves of Spondias mombin (Anacardiaceae) and a fruit of 
Aframomum melegueta (Zingiberaceae) which is then administered to gain and retain good 
memory (Fatumbi, 1995). The Ekiti people of Nigeria administer the leaf decoction with lime 
juice for people suffering from roundworm (Personal Information). The cold infusion from the 
bark of Pleiocarpa talbotii can be used to treat stomach pain (Schmelzer et al., 2008). 
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2.11 Pleiocarpa pycnantha(K.Schum.) Stapf. 
Protologue Oliv., Fl.trop.Afr.4 (1):99(1902) 
Family Apocynaceae 
Synonyms: Pleiocarpaflavescens Stapf (1902) 
                 Pleiocarpa micrantha Stapf (1902) 
Origin and geographical distribution: It is widespread from Senegal east to Kenya and South 
to Angola and Mozambigue.It is widely distributed throughout tropical Africa. 
Uses: The wood is used for local construction, plane blocks, comb, and pestles and in carving in 
which case it is used to make pipe stem in Uganda. Its ground roots with seeds of Aframomum 
melegueta K.Schum are taken as laxatives. The leaf maceration with lemon juice is given to 
patients suffering from jaundice, oedema, reduced urine excretion and worm infestion in Benin  
(Burkill, 1985). 
Properties: The wood is yellow to brown, hard and durable. 
Isolated compounds: Some indole alkaloids have been isolated from P. pycnantha namely: 
pycnanthine, pleiocarpamine, macusine B and quebrachamine. 
Botanical description: An evergreen shrub or tree 1·5–30 m. tall; bark grey, smooth or slightly 
scaly; slash whitish, cream or pale brown with darker yellow striations, brownish yellow 
beneath, yielding milky latex  and the branches are subsarmentose. Young twigs are glabrous, 
angled and sometimes may have a verticillate branching-pattern.  
The leaves thinly coriaceous, opposite or in whorls of 3–5, completely glabrous; petiole 3–20 
mm. long, angled, often narrowly winged almost to the base by a continuation of the lamina; 
lamina (4) 6–13·5 x (1·3) 2·2–5·5 cm., elliptic to obovate or narrowly obovate, the apex 
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cuspidate with short rounded acumen or acute with rounded tip, the base attenuate; upper surface 
glossy, with all nerves raised (midrib both prominent and channeled); lower surface paler and 
mat, all nerves raised; lateral nerves ± parallel, 2–4 mm apart, joining near the margin in a neatly 
looped vein; edge of leaf forming little pleats when pressed flat.The flowers are white, fragrant, 
in dense axillary fascicles on new and old wood; pedicels up to 1 mm long, glabrous. Calyx 1·5–
2 mm long; sepals ovate, free, glabrous,corolla tube 5–8 mm long, narrowed in the middle, 
glabrous externally, pubescent internally in upper half, hairs longest just below the anthers; 
corolla lobes 2–4 x 1·5–2·5 mm, elliptic, glabrous, not strongly overlapping. Their stamens are 
inserted at about 4-6 mm above the base of the corolla tube, the filaments are minute,and the 
anthers is usually about 0·5–1 mm long. Gynoecium 4–6·5 mm long; ovary c. 1 mm long, 
cylindrical, glabrous, of 2 free carpels each containing 1–4 ovules; style slender, flattened; 
clavuncle 2-lobed; stigma reduced to a flat region at apex of clavuncle. Pleiocarpa fruit 
comprising 2 clavate mericarps 7–20 x 4·5–18 mm, pale green to orange when ripe, each 
containing 1 or 2 salmon-pink seeds (Burkill, 1985; Hyde et al., 2013). It has about five species 
and it is related to Hunteria and Picralima. P. pycnantha flowers and fruits throughout the year. 
Ecology: It occurs in the understorey of rainforests as well as in gallery and montane forests up 
to 2300m altitude. It can also be found in disturbed forests. 
Genetic resources and breeding: It is generally not threatened by erosion because it is found in 
various forest types and it is widely distributed.  
Future prospects: It is unlikely to become an economically important timber tree due to its 
relatively small size, but will retain its usage in the construction of local houses and production 
of implements because of its hardness and durability.  
Some isolated compounds from Pleiocarpa genus are documented in Fig.2.9. 
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1-Carbomethoxy-β-Carboline 
Figure 2.9. Some isolated compounds from Pleiocarpa genus. 
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Figure 2.9. Some isolated compounds from Pleiocarpa genus continued. 
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2.12 The development of Apoptosis 
Cell death plays a considerable role during physiological processes of multicellular organisms, 
particularly during embryogenesis and metamorphosis (Lockshin and Zakeri, 2001). The term 
programmed cell death was introduced in 1964 in which it was proposed that cell death during 
the development stage is not accidental but occurs in a well regulated fashion. The term 
apoptosis had been used to describe the morphological processes leading to controlled cellular 
self-destruction and was first introduced in a publication by Kerr, Wyllie and Currie (Kerr, 
1972).  
It is of Greek origin, with the meaning "falling off or dropping off", in analogy to leaves falling 
off trees or petals dropping off flowers. This emphasizes that the death of living matter is an 
integral and necessary part of the life cycle of organisms. Apoptosis is different from other forms 
of cell death called necrosis in which uncontrolled cell death leads to lysis of cells, inflammatory 
responses and, potentially, to serious health problems. Apoptosis seemed to be the most common 
type of programmed cell death. Other non-apoptotic deaths are also of great biological 
significance (Liest, 2001). 
2.13 The importance of Apoptosis  
The development and maintenance of healthy multicellular biological systems depends on a 
sophisticated interplay between the cells forming the organism z and that the way in which most 
cells die is conserved from worm to mammal. Optimum body maintenance means that about  
10 billion of our cells will die on a normal day just to counter the number of new cells that arise 
through mitosis. During development, many cells are produced in excess, which eventually 
undergo programmed cell death and thereby contribute to sculpturing many organs and tissues 
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(Meier, 2000). Apoptosis is of great biological importance, and it is involved in differentiation, 
development, proliferation, homoeostasis, regulation and function of the immune system. Thus, 
failures in apoptosis may result in autoimmune diseases, neoplasia and spreading of viral 
infections. Conversely, excessive apoptosis has been associated with other sorts of diseases, such 
as AIDS, neurodegenerative disorders and ischemic diseases (Gewies, 2003).  
2.14 Morphological features of apoptosis  
Apoptotic cells may be recognized by stereotypical morphological changes namely; cell 
shrinkage, deformation and lost contact with the neighboring cells. Its chromatin condenses and 
marginates at the nuclear membrane, the plasma membrane blebbs or budds, and finally the cell 
is fragmented into compact membrane-enclosed structures, called ‘apoptotic bodies’ which 
contain cytosol, the condensed chromatin, and organdies (Fig.2.10). The apoptotic bodies are 
engulfed by macrophages and thus are removed from the tissue without causing an inflammatory 
response. These morphological changes are as a result of characteristic molecular and 
biochemical events occurring in an apoptotic cell, most notably the activation of proteolytic 
enzymes, which eventually mediate the cleavage of DNA into oligonucleosomal fragments as 
well as the cleavage of a multitude of specific protein substrates which determines the integrity 
and shape of the cytoplasm or organelles (Saraste, 2000; Gewies, 2003). 
Apoptosis is therefore in direct contrast to the necrotic mode of cell-death.  In necrosis, the cells 
suffer a major insult that results in a loss of membrane integrity, swelling and the consequent 
disruption of cells. During necrosis, the cellular contents are released in an uncontrolled manner 
into the cell’s environment which results in damage of the surrounding cells and a strong 
inflammatory response in the corresponding tissue (Leist, 2001). 
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Figure 2.10. Dinstinction between apoptotic and necrotic cell death (Gewies, 2003). 
 
 2.14 Stimuli for apoptosis 
Several factors can trigger apoptosis from both external and internal stimulus, for example; 
ligation of cell surface receptors, DNA damage as a cause of defects in DNA repair mechanisms, 
treatment with cytotoxic drugs, irradiation, lack of survival signals, contradictory cell cycle 
signaling developmental death signals.  
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Figure 2.11. Apoptosis stimuli factors (Kelly and Strasser, 2011). 
 
There are four main groups of stimuli for apoptosis; Group I stimuli includes ionizing radiation 
and alkylating anticancer agents, causing DNA damage as shown in Fig.2.10. Group II stimuli 
induce apoptosis through receptor mechanisms either by receptor activation mediated by 
glucocorticoids (acting on the thymus) see Fig.2.11, tumour necrosis factor-a (TNT-a), or by 
withdrawal of growth factors (nerve growth factor and interleukin (IL)-3. Group III stimuli 
comprise biochemical agents that enhance the downstream components of the apoptotic pathway 
which includes phosphatases and kinase inhibitors like calphostin C, staurosporine.  
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The Group IV agents cause direct cell membrane damage and includes heat, UV light and 
oxidizing agents like superoxide anion and hydrogen peroxide (Wyllie, 1980; Santana, 1996).  
Excessive production of reactive oxygen species (ROS) may generate free radicals that can 
damage the lipid membranes, proteins and nucleic acids. Many of these stimuli cause necrosis in 
larger doses. Following an appropriate stimulus, the first stage or ‘decision’ phase of apoptosis is 
the genetic control point of cell death which is followed by the second stage or ‘execution’ 
phase, responsible for the morphological changes of apoptosis. Two main pathways trigger the 
cell to enter the first stage or apoptosis viz. signaling via mitochondria, and signaling via ‘death-
receptors’ such as CD95 or Fas and both result in the destruction of the same apoptotic substrates 
(Wyllie, 1980; Santana, 1996; Kam and Ferch, 2000).  
2.15 Apoptotic pathways 
2.15.1 The extrinsic (receptor) pathway 
The extrinsic apoptosis pathway is mediated by the activation of death receptors, which are at the 
cell surface and transmit apoptotic signals after binding to specific ligands as indicated in 
Fig.2.12. The extrinsic apoptosis pathway involves procaspase-8 which is recruited by its death 
effector domains (DEDs) to the death inducing signaling complex (DISC), a membrane receptor 
complex formed to the ligation of a member of the tumor necrosis factor receptor (TNFR) 
family. Once bound to the DISC, several procaspase-8 molecules are joined in close proximity 
and then are capable to activate each other by autoproteolysis. Death receptors belong to the 
tumor necrosis factor receptor (TNFR) gene superfamily, including TNFR-1, Fas/CD95 and the 
TRAIL receptors DR-4 and DR-5, after which the signaling is transmitted through the 
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cytoplasmic part of the death receptor, which contains a conserved sequence termed the death 
domain (DD). Adapter molecules like FADD (Fas-activated Death Domain) or TRADD  
(Toll receptor activated death domain) have their own DDs by which they are recruited to the 
DDs of the activated death receptor, thereby forming the DISC and the local concentration of 
several procaspase-8 molecules at the DISC leads to their autocatalytic activation and release of 
active caspase-8. Active caspase-8 then processes downstream effector caspases, which 
subsequently cleave specific substrates resulting in apoptosis (Denault and Salvesen, 2002; 
Gewies, 2003).  
Cells that possess the capacity to induce this direct and mainly caspase-dependent apoptosis 
pathway are classified as type I cells. On the other hand, in type II cells, the signal coming from 
the activated receptor does not mediate a caspase signaling cascade strong enough for execution 
of cell death on its own. In this case, the signal needs to be amplified via mitochondria-
dependent apoptotic pathways. The link between the caspase signaling cascade and the 
mitochondria is provided by the Bc1-2 family member Bid. 
Bid is cleaved by caspase-8 into the truncated form (t-BID), which translocates to the 
mitochondria where it acts in concert with the pro-apoptotic Bcl-2 family members Bax and Bak 
to induce the release of cytochrome c and other mitochondrial pro-apoptotic factors into the 
cytosol (Denault and Salvesen, 2002; Gewies, 2003). 
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Figure 2.12. Receptor mediated apoptosis (Fulda, 2009). 
2.15.2 The intrinsic (mitochondrial) pathway 
The mitochondrial pathway is activated by a variety of extracellular and intracellular stresses, 
including oxidative stress and treatment with cytotoxic drugs. The apoptotic signal leads tothe 
release of cytochrome c from the mitochondrial intermembrane space into the cytosol, where it 
binds to the Apoptotic Protease Activating Factor-1 (Apaf-1), and a mammalian CED-4 
homologue. Intrinsic apoptosis pathways involve procaspase-9 which is activated downstream of 
mitochondrial pro-apoptotic events at the so called apoptosome, a cytosolic death signaling 
protein complex that is formed upon release of cytochrome C from the mitochondria, see 
Fig.2.13. In cancer, the intrinsic pathway is activated by DNA damage resulting from cytotoxic 
chemotherapy as well as irradiation, and also mediates apoptosis from other stimuli including 
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hypoxia, defective cell cycle events, and deprivation at growth factors (Denault and Salvesen, 
2002). 
 
 Figure 2.13. Apoptotic intrinsic pathway (Lawen, 2003). 
Following an apoptotic stimulus, Bax (the pro-apoptotic protein), undergoes homodimerization 
and oligodimerization through interaction with the BH3-regions and associates with the 
mitochondrial membrane with insertion into the mitochondrial membrane (Denault and Salvesen, 
2002). Permeabilization results in loss of membrane potential, and consequently release of 
apoptogenic factors including cytochrome C, ATP and SMAC/DIABLO (second mitochondria-
derived activator of caspase/direct IAP binding protein with low p1). ATP binds to the 
nucleotide-binding domain of apoptotic protease-activating factor 1 (APAFI) resulting in the 
formation of large oligomers (heptamers). Cytochrome c binds to APAF1 and through a CARD 
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in APAFI, binds to a complementary CARD on precaspase-9 leading to activation of caspases 9 
and of the downstream ”executioner” caspases 3, 6, and 7.  These activated caspases auto-induce 
activation of themselves as well as downstream caspases and the protocolytic cascade, that 
ultimately cleaves substrates essential for cell viability finally resulting in the characteristic 
biochemical sad morphological changes of apoptosis (Denault and Salvesen, 2002).  
2.16 Reactive Oxygen Species (ROS) 
Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen which 
includes oxygen ions and peroxides. It forms as a natural byproduct of the normal metabolism of 
oxygen and plays an important role in cell signaling and homeostasis. However, during 
environmental stress like UV or heat exposure, ROS levels increase (Devasagayam et al., 2004). 
This may consequently result in significant damage to cell structures with the resultant effect 
known as oxidative stress. ROS can be generated exogenously or endogenously.  
Exogenous sources include ionizing radiation, pollutants, tobacco, smoke, drugs or xenobiotics 
while endogenous sources are intracellularly generated through multiple mechanisms and 
depending on the cell and tissue types, may result in being the major sources of the 
"professional" producers of ROS NADPH oxidase (NOX) complexes (7 distinct isoforms) in cell 
membranes, mitochondria, peroxisomes and endoplasmic reticulum (Muller, 2000; Han et al., 
2001). 
Reactive oxygen species are implicated in cellular activity towards a variety of inflammatory 
responses including cardiovascular disease. They may also be involved in hearing impairment 
via cochlear damage induced by elevated sound levels. ROS are also implicated in mediation of 
apoptosis and ischemic injury. Other harmful effects of reactive oxygen species on the cell are 
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DNA damage, lipid peroxidation, amino acid oxidation and inactivation of specific enzymes by 
co-factors in the oxidation process (Brooker, 2011). 
2.17 ROS and Cancer 
ROS are constantly generated and eliminated in biological systems and are required to drive 
regulatory pathways (Dickinson and Chang, 2011). Under normal physiological conditions, cells 
control ROS levels by balancing the generation of ROS with their elimination by scavenging 
systems. Under oxidative stress conditions, excessive ROS can damage cellular proteins, lipids 
and DNA, leading to fatal lesions in cells that contribute to carcinogenesis (Kang et al., 2013). 
Cancer cells exhibit greater ROS stress than normal cells do, partly due to oncogenic stimulation, 
increased metabolic activity and mitochondrial malfunction. At low levels, ROS facilitates 
cancer cell survival since cell-cycle progression driven by growth factors and receptor tyrosine 
kinases (RTK) require ROS for activation and chronic inflammation, a major mediator of cancer, 
is regulated by ROS while at high level can suppress tumor growth through the sustained 
activation of cell-cycle inhibitor and induction of cell death as well as senescence by damaging 
macromolecules. In fact, most of the chemotherapeutic and radiotherapeutic agents kill cancer 
cells by augmenting ROS stress (Irani et al., 1997; Ramsey and Sharpless, 2006; Takahashi et al., 
2006; Renschler, 2004; Toler et al., 2006). The ability of cancer cells to distinguish between 
ROS as a survival or apoptotic signal is controlled by the dosage, duration, type and site of ROS 
production. Modest levels of ROS are required for cancer cells to survive, whereas excessive 
levels kill them (Gupta et al., 2012). 
Metabolic adaptation in tumors balances the cells' need for energy with an equally important 
need for macromolecular building blocks and tighter control of redox balance. As a result, 
 
 
 
 
 72 
 
production of NADPH is greatly enhanced, which functions as a cofactor to provide reducing 
power in many enzymatic reactions for macromolecular biosynthesis and at the same time 
rescuing the cells from excessive ROS produced during rapid proliferation. Cells counterbalance 
the detrimental effects of ROS by producing antioxidant molecules, such as reduced glutathione 
(GSH) and thioredoxin (TRX), which rely on the reducing power of NADPH to maintain their 
activities (Cairns et al., 2011). Most of the risk factors associated with cancer interact with cells 
through the generation of ROS, which then  activate various transcription factors such as nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB), activator protein-1 (AP-1), 
hypoxia-inducible factor-1α and signal transducer and activator of transcription 3 (STAT3), 
leading to expression of proteins that control inflammation, cellular transformation, tumor cell 
survival, tumor cell proliferation, invasion, agiogenesis and metastasis. ROS can also control the 
expression of various tumor suppressor genes such as p53, retinoblastoma gene (Rb), 
phosphatase and tensin homolog (PTEN) (Gupta et al., 2012).
 
2.18 ROS and cell death 
Cancer cells can die in three ways: apoptosis, necrosis and autophagy. Excessive ROS can 
induce apoptosis through both the extrinsic and intrinsic pathways as earlier stated. In the 
extrinsic pathway of apoptosis, ROS are generated by Fas ligand as an upstream event for Fas 
activation via phosphorylation, which is necessary for subsequent recruitment of Fas-associated 
protein with death domain and caspase 8 as well as apoptosis induction (Gupta et al., 2012). 
In the intrinsic pathway, ROS functions to facilitate cytochrome c release by activating  pore-
stabilizing proteins (Bcl-2 and Bcl-xL) as well as inhibiting pore-destabilizing proteins (Bcl-2-
associated X protein, Bcl-2 homologous antagonist/killer) (Martindale and Holbrook, 2002).  
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A high level of ROS can result in both apoptosis and necrosis in cancer cells. ROS can also 
induce cell death through autophagy; a self-catabolic process involving sequestration of the 
cytoplasmic contents (exhausted organelles and protein aggregates) for degradation in lyposomes 
(Hampton and Orrenius, 1997; Shrivastava et al., 2011).  
2.19 Caspases 
Caspases (cysteine-aspartic proteases or cysteine-dependent aspartate-directed proteases) are a 
family of proteases that play an essential role in apoptosis, necrosis and inflammation. They are a 
large family of evolutionarily conserved proteases found from Caenorhabditis elegans to 
humans and the structure is shown in Fig.2.15. Although the first caspase was identified as a 
processing enzyme for interleukin-1β, genetic and biochemical data have collectively revealed 
that many caspases are key mediators of apoptosis, the intrinsic cell suicide program essential for 
the development of and tissue homeostasis. Each caspase is a cysteine aspartase and employs a 
nucleophilic cysteine in its active site to cleave aspartic acid peptide bonds within proteins  
(Shi, 2002; Alnemri et al., 1996; Thornberry et al., 1992, 1998).  
Two major general pathways for the induction of apoptosis exists viz., the receptor or extrinsic 
pathway and the mitochondrial or intrinsic pathway. Both apoptotic signaling pathways converge 
at the level of the specific proteases—the caspases (Fig. 2.13). Currently about 14 mammalian 
caspases has been identified (Fig. 2.14). They are synthesized as pro-enzymes, which usually 
undergo proteolysis and activation by other caspases in a cascade (Earnshaw et al., 1999). 
Peptide caspase inhibitors can inhibit downstream caspase activation and subsequently apoptosis, 
of the caspases, about 30 can be grouped into subclasses in various ways. Functionally, one can 
distinguish three classes of caspases; (i) the initiator caspases that are characterized by long 
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prodomains (>90 amino acids) containing either DED domains (caspase-8 and caspase-10) or a 
caspase recruitment domain (CARD) (caspase-2 and caspase-9; CED-3); (ii) the executioner or 
effector caspases containing short prodomains (caspase-3, caspase-6 and caspase-7) and (iii) the 
remaining caspases whose main role lies in cytokine maturation rather than apoptosis.  
Upon activation, the prodomains are cleaved off and the large and small subunits are separated 
by caspase action (all cleavages occur after Asp residues). The active site is formed by the 
interface of the two subunits by 1 Arg, 1 His, 1 Cys of the large subunit and 1 Arg of the small 
subunit. 
The active caspases form heterotetramers, Grütter (2000) while the initiator caspases cleave and 
activate effector caspases. These then cleave cellular substrates, which leads to the apoptotic 
morphology. One effector caspase, caspase-3, when activated is capable of cleaving many 
important cellular substrates, including ICAD (inhibitor of caspase-activated DNase), ROCKI 
(Rho-associated coiled coil forming kinase I), poly (ADP-ribose) polymerase (PARP, a DNA 
repair enzyme), actin, fodrin and lamin. Active caspase-3 can cause membrane blebbing (via 
ROCKI cleavage that leaves the kinase constitutively active, permanently phosphorylating 
myosin light chain, disassembly of the cell structure and DNA fragmentation [via ICAD 
(inhibitor of caspase-activated DNase)] cleavage that sets CAD (caspase activated DNase) free to 
move into the nucleus and cleave DNA internucleosomally, which eventually leads to cell death 
(Lawen, 2003). 
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Figure 2.14. Mammalian caspase family and C.elegans caspase CED-3 (Chang and Yang, 
2000). 
 
Figure 2.15. Structure of caspase -3 tetramer in complex with AC-DEVD-CHO (Chang and 
Yang, 2000). 
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CHAPTER 3 
3.0 MATERIALS AND METHODS 
This chapter deals with the description of the materials and methods used in this research. 
The plant was collected, identified and extracted using 95% ethanol by cold maceration for 72 h. 
The resultant product (ethanolic extract) was subjected to phytochemical screening to ascertain 
the secondary metabolites after which it was fractionated on column chromatography. 
The crude extract and the various fractions P1-13 was screened using WST-1 assay for 
cytotoxicity on HeLa, HT-29, MCF-7 and KMST-6. Based on the result obtained from the 
cytotoxicity profile, some fractions were selected for further purification and tested for their 
ability to reduce the cell viability on both cancer and normal cells. The details of the procedure 
for isolation, cell culture, cytotoxicity and mechanistic studies are described in this chapter. 
3.1 Materials and Instrumentation 
The details of the material and specific instrumentation conditions are described in sections 3.1.1 
and 3.2.1. 
3.1.1 General conditions 
Melting points (uncorrected) were determined using Stuart melting point SMP10 apparatus. 
UV spectra were recorded in methanol on a Shimadzu UV-2501, and Shimadzu UV2UO PC 
spectrophotometer. IR spectra were acquired on a Varian 1000 FT-IR (Scimitar Series).  
1
H-NMR, 
13
C-NMR and 2D-NMR spectra (COSY, HSQC, HMBC, NOESY and DEPT) spectra 
were recorded on Bruker Avance 200, 400 and 600 MHz spectrometers using TMS as reference. 
Mass spectrometry studies were carried out on Varian MAC 112 mass spectrometer. Column 
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chromatography was carried out using 60 Å silica gel (230-400 mesh), as the stationary phase 
and HPLC was also used to purify the polar fractions.  
The size-exclusion column- chromatography was performed using Sephadex LH-20 (Sigma) 
pre-swollen in the specified solvent before loading onto the column. Unless otherwise 
specified, a glass column (2.5 x 50 cm) was used and 5 ml volumes were collected.  
The preparative TLC was performed using Merck Silica gel 60 PF254 on glass plates (20 cm 
x 20 cm) and with a thickness of 0.5 mm. A l s o  t h e  a nalytical TLC was conducted on 
normal-phase Merck Silica gel 60 PF254 on precoated aluminium plates. Separated 
compounds on TLC and PTLC plates were visualized under UV light at (254 and 366 nm), and 
spraying of the plates where required was carried out using 2% vanillin in H2SO4 reagent 
followed by heating at 110oC for 2– 4 mins.  
All solvents used in this research were of Analytical, NMR and HPLC grade, those that required 
distillation were distilled prior to use.  
Materials for the biological analysis includes; DMSO, APO-DIRECT 
TM
 kit, RNase, Propidium 
Iodide, crystal violet, Phosphate buffer saline (PBS), Dubelco’s modified eagles medium 
(DMEM), Foecal calf serum (FCS), Caspase 9 and 3/7 , trypsin, Tissue culture flasks, 12-well 
and 96-well plates. Others are Tetrazolium salt (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate) (WST-1) reagent, Topoisomerase I enzyme, 5-(and-6)-
chloromethyl-2',7’-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) and 
NucBlue
TM
 Live Cell Stain Hoechst 33342. 
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3.2 Plant collection, authentication and preparation 
3.2.1 Plant collection and Identification 
Fresh leaves of Pleiocarpa pycnantha was collected in January 2011 at Ikere Ekiti, Ekiti State, 
South West Nigeria and authenticated b y t h e  herbarium curator, Mr. Femi Omotayo of the 
Department of Plant Sciences, Ekiti State University (EKSU), Ado-Ekiti where a voucher 
specimen e-Herbarium UHAA 45 was deposited. 
3.2.2 Plant preparation 
The leaves were washed with distilled water and dried at room temperature in a ventilated 
room for three weeks based on the nature of the plant materials. They were then milled 
separately to a fine powder using an electric grinder and 1.0 kg of the powder was stored in a 
well labeled air-tight container prior to analysis. 
 3.3 Plant extraction 
1.0 kg of the dried and powdered plant material was extracted for three days with 6L of 95% 
ethanol. The resulting extract was filtered and the filtrate concentrated with a rotary evaporator at 
50
0
C to afford 81g of crude Pleiocarpa pycnantha extract.  
3.4. Phytochemical Screening 
1.0 mg samples of the plant extract was dissolved in methanol or dichloromethane for the 
purpose of being screened for various secondary metabolites using standard procedures  
(Wagner and Bladt, 2001; Trease and Evans, 1996) which were identified based on the colour 
produced after spraying with respective identifying reagents. 
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 3.6 Chromatographic Techniques 
 3.6.1 Thin Layer Chromatography (TLC) 
The analytical TLC was performed on silica gel precoated aluminium plates (GF254) 0.25mm 
thick while the preparative TLC was performed using Merck Silica gel 60 PF254 on glass 
plates (20 cm x 20 cm) and with a thickness of 0.5 mm. 
 3.6.1.1 Solvent systems for TLC 
The solvent systems used for the analytical TLC are:  
Dichloromethane: Methanol (95:5). 
Dichloromethane: Methanol (90:10). 
Ethyl acetate (100%). 
Ethyl acetate: formic acid: glacial acetic acid: water (100:11:11:26). 
3.6.2 Visualization/chromogenic reagents 
Analytical TLC plates were treated with the following chromogenic reagents; 
(i). 1%w/v Aluminium chloride in ethanol. 
This was prepared by dissolving 1g of AlCl3 in 100ml of ethanol and sprayed on analytical 
plates. Observation was in daylight and under UV. 
(ii). Vanillin –Sulphuric acid reagent. 
15g of Vanillin was added to 250mL of ethanol and 1.0mL of sulphuric acid was slowly added 
to make Vanillin reagent. 
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(iii). Ammonia vapor. 
3.7 Column chromatography 
A portion of the crude ethanolic extract of P.pycnantha (62.22g) was adsorbed on silica gel 
(Merck, 0.040- 0.063 mm particle size) and fractionated by AGC using the following solvent 
mixtures: Hexane-EtOAc ( 5L each, 90%-50% ), then 3L (30%), 2L (20%), 2L (100% EtOAc) 
and 2L (20%) EtOAc-MeOH. Fractions collected (1L each) were analyzed by TLC using 
DCM–M e O H  (99%, 97%, 95% and 90%), then 70% a n d  99%  ( H e x - E t O A c )  as the 
mobile phase. Fractions showing the same TLC characteristics were bulked together and 
concentrated in vacuo. T h i r t e e n  fractions coded P 1 – P 13 were obtained and the results 
are summarized in Table 3.1. The general scheme of the fractionation of the crude extract is 
given in Fig. 3.1. 
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Table 3.1. Fractions grouped from the column. 
Tubes Weight Fractions 
1 
2 
3 
4-6 
7-9 
10 
11-12 
13-16 
17-19 
20-22 
23-27 
28-31 
32 
0.16g 
9.78g 
0.74g 
9.79g 
4.94g 
0.91g 
2.93g 
3.28g 
3.62g 
5.91g 
5.96g 
1.70g 
1.62g 
P1 
P2 
P3 
P4 
P5 
P6 
P7  
P8 
P9 
P10 
P11 
P12 
P13 
 
3.7.1 Column chromatography of P12 fraction 
Fraction P12 (1.60g) was rechromatographed on a silica gel column using the solvent system: 
Hex-EtOAc [(5L, 50%), (6L, 60%)] and (0.3L, 100%) EtOAC, 100mL fractions were collected. 
The solvent systems used to evaluate the fractions were, 95% DCM-MeOH, 50 and  
70% Hex-EtOAc. Fractions were bulked together according to their TLC characteristics and 
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were coded A-H.  
The table below summarizes the result and the scheme of the fractionation is presented in Fig. 
3.2. 
 
Table 3.2. Fractions obtained from P12. 
Tubes Weight(mg) Code 
1-2 
3-4 
5 
6-10 
11-16 
17-21 
22-27 
28-56 
10.0 
230.0 
120.0 
240.0 
140.0 
10.0 
40.0 
360.0 
A 
B 
C 
D 
E 
F 
G 
H 
 
P12C was washed with 10% EtOAc –Hex and then with 100% DCM to afford a white amorphous 
powder identified as C1 (33mg). 
The chromatography of P12D (220mg) on a silica gel column using the solvent system 70% 
EtOAc –Hex (1.5L) for the main column, 95% DCM-MeOH and 50% EtOAc -Hex for TLC 
afforded five fractions (DI-DV) illustrated in Table 3.3. The volume collected was 50mL per 
tube.  
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Fraction (DIII) when washed as described above was found to be similar to C1 obtained 
previously.  
The sub fraction DV (20mg) could not be further purified on HPLC due to its limited quantity.  
Table 3.3 summarizes the results. 
Table 3.3. Showing the sub- fractions collected from P12D. 
Tubes Weight(mg) Code 
1-2 
3-4 
5-6 
7-8 
9-14 
5.0 
20.0 
70.0 
40.0 
20.0 
DI 
DII 
DIII 
DIV 
DV 
 
Chromatography of P12E (140mg) on a sephadex column using 100% ethanol as the solvent 
system was then effected with 5mL fractions being collected from the column. The fractions 
were monitored with 97, 95 and 90% DCM-MeOH on TLC to afford three sub-fractions  
(EI-EIII). The results are presented in Table 3.4. 
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Table 3.4. Showing the sub-fractions from P12E column. 
Tubes Weight(mg) Code 
1-38 
39-46 
47-66 
10.0 
80.0 
20.0 
EI 
EII 
EIII 
 
Fraction EIII was combined with P12F fractions for further purification. 
3.7.2 Column chromatography of (P11) fraction 
Fraction P11 (5.60g) was rechromatographed on a silica gel column using the solvent system: 
Hex-EtOAc [(1L, 80%), (2L, 70%), (2L, 60%), (2L, 50%) and (1L, 40%)]. Fractions of 250 mL 
were collected, 95% DCM-MeOH, 50 and 70% Hex-EtOAc were used as solvent systems to 
monitor fractions from the column. The fractions were bulked together according to their TLC 
characteristics and were coded I-N, Table 3.5 summarizes the result and the scheme of the 
fractionation is given in Fig. 3.3. 
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Table 3.5. Sub-fractions from P11 column. 
Tubes Weight(g) Codes 
1-4 
5-13 
14-15 
16-17 
18-20 
21-31 
0.03 
2.03 
0.22 
0.48 
0.91 
2.20 
I 
J 
K 
L 
M 
N 
 
The fraction P11M (0.91g) precipitated in the tube and the supernatant liquid was carefully 
decanted, concentrated in vacuo to afford two sub fractions; P11M (0.74g) supernatant and P11M 
(0.17g) residue.  
The sub fraction P11M (0.74g) supernatant was further chromatographed on Sephadex column 
using 100% ethanol as the solvent. Fractions of 5mL each was collected from the column. Based 
on the TLC profile of the fractions, four fractions (MI-MIV) were obtained and the result is 
hereby presented in Table 3.6.  
 
 
 
 
 
 
 
 
 86 
 
Table 3.6. Sub-fractions from P11M. 
Tubes Weight(mg) Codes 
1-7 
8-24 
25-39 
40-62 
5.0 
30.0 
540.0 
110.0 
MI 
MII 
MIII 
MIV 
 
P11L (0.48g) and P11M (0.17g) residues were found to be similar on TLC and therefore they were 
rechromatographed together on silica gel column using EtOAc -Hex (25%, 1L and 30%, 5L). 
From the TLC analysis of fractions, four fractions coded LI-LIV were obtained.  
Table 3.7 summarizes the result. 
Table 3.7. Sub-fractions from the combined extracts P11L and M.  
Tubes Weight(mg) Codes 
1-8 
9-18 
19-24 
25-50 
15.0 
150.0 
20.0 
30.0 
LI 
LII 
LIII 
LIV 
 
Fractions MIII (supernatant) 0.54mg, P11N (2.20g) and P12 E(0.02g) were pooled together and 
renamed as P11O based on their TLC profile and rechromatographed on a silica gel column using 
the solvent system EtOAc-Hex(25%, 18L), EtOAC(100%, 0.8L) and EtOAc -MeOH(50%, 
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0.8L). Fractions of 100mL were collected in tubes numbered 1-147 while 250mL volumes were 
collected in tubes numbered 148-168. Mobile phases of 90% DCM-MeOH, 95% DCM-MeOH 
and 50% EtOAc-Hex (double run) were used to monitor fractions on aluminium precoated 
plates, based on the TLC profile, fractions were pooled together to afford twenty one fractions.  
The result is summarized in Table 3.8.  
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Table 3.8. Sub-fractions obtained from combined extracts from P11O. 
Tubes Weight(mg) Codes 
1-6 
7-13 
14-16 
17-32 
33-45 
46-52 
53-78 
79-91 
92-97 
98-102 
103-113 
114-120 
121-129 
130-136 
137-146 
147-153 
154-168 
169-170 
171 
172-173 
174-179 
180-182 
           1.1 
           1.0 
           2.0 
110.0 
75.0 
30.0 
0.5 
2.0 
2.0 
10.0 
5.0 
4.0 
5.0 
20.0 
30.0 
20.0 
80.0 
10.0 
130.0 
90.0 
40.0 
50.0 
I 
II 
III 
IV 
V 
VI 
VII 
VIII 
IX 
X 
XI 
XII 
XIII 
XIV 
XV 
XVI 
XVII 
XVIII 
XIX 
XX 
XXI 
XXII 
 
Fractions VIII-XXII were washed with DCM-Hex (50%) to afford precipitates while the  
sub-fractions XIX (130mg) and XX (90mg) were further chromatographed repeatedly on a 
sephadex L-H 20 column using DCM-MeOH (95%) as solvent and then on HPLC using 80% 
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(MeOH-H2O) with UV detector to afford compounds C2 (5.5mg) and C3 (7.3mg).  
The scheme of the fractionation of P11O sub fraction is given in Fig. 3.4. 
3.7.3 Column chromatography of P9 fraction 
P9 (3.20g) was placed on silical gel column using the solvent systems EtOAc-Hex (20%, 14L) 
and100% EtOAc (1L). Fractions of 0.1L were collected in tubes 1-5 while fractions of 0.2L 
were collected in tubes 6-74. These were combined based on their TLC profiles and coded  
Q1-13. Table 3.9 summarizes the results, while Fig. 3.5 gives the fractionation scheme. 
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Table 3.9. Sub-fractions from P9. 
Tubes Weight(mg) Codes 
1-6 
7-12 
13-17 
18-21 
22-27 
28-31 
32-37 
38-44 
45-50 
51-55 
56-61 
62-68 
69-74 
30.0 
10.0 
120.0 
310.0 
590.0 
300.0 
470.0 
270.0 
100.0 
80.0 
90.0 
70.0 
380.0 
Q1 
Q2 
Q3 
Q4 
Q5 
Q6 
Q7 
Q8 
Q9 
Q10 
Q11 
Q12 
Q13 
 
Fractions Q3-Q8 was washed with 100% DCM to yield some precipitates which were not 
purified further. Q4 (310mg) was washed in a mixture of 10% Hexane/EtOAc to give compound 
C1 (100mg) which has already been isolated before. 
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3.7.4 Column chromatography of P7 fraction 
Fraction P7 (2.53g) was chromatographed on a Silical gel column using the solvent systems 
EtOAc-Hex [(10%, 8L), (20%, 4L)] and 100% EtOAc (1L). 100mL was collected in tubes 1-30 
while 200mL was collected in tubes 31-64. Fractions were combined based on their TLC 
profiles and coded R1-R11. Table 3.10 summarizes the results.  
 
Table 3.10. Sub-fractions from P7.  
Tubes Weight(mg) Codes 
1-6 
7-12 
13-20 
21-25 
26-28 
29-34 
35-40 
41-47 
48-51 
52-60 
61-64 
20.0 
30.0 
60.0 
60.0 
130.0 
120.0 
220.0 
220.0 
170.0 
710.0 
180.0 
R1 
R2 
R3 
R4 
R5 
R6 
R7 
R8 
R9 
R10 
R11 
 
Fraction P7 (2.53g) was chromatographed on a silical gel column to afford sub-fractions R1-11 
R8 and R10 were washed with 10% EtOAc-Hex to afford a white precipitate which was fairly 
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clean. R8 was further separated on Prep TLC to give compounds C1 (15mg) (already isolated) 
and C4 (6.1mg) as an inseparable mixture of two triterpenes, the structure of which was not 
elucidated in this study. The fractionation of P7 is further presented in Fig. 3.6. 
Based on their 
1
H-NMR spectra, R6 and R7 (340mg) was combined and renamed as R7A and 
further purified on a Sephadex L-H 20 column using 100% ethanol as the solvent with fractions 
of 5mL being collected. TLC was used to pool the various fractions together to afford a total of 
four fractions (R7AI-IV). Table 3.11 summarizes the results.  
Table 3.11. Sub-fractions from R7A. 
Tubes Weight(mg) Codes 
1-13 
14-28 
29-36 
37-52 
10.0 
280.0 
10.0 
5.0 
I 
II 
III 
IV 
 
R7A (280mg) could not be separated further by chromatography. Fraction R7A (III) was fairly 
clean but too little to be further purified. The sub-fraction R7A (II) were then purified on a 
Sephadex L-H 20 column using 100% ethanol as the solvent with fractions of 5mL being 
collected per tube. TLC was used to pool the fractions together to afford a total of five fractions 
(IIa-IIe). Table 3.12 summarizes the results.  
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Table 3.12 .Sub-fractions from R7A.  
Tubes Weight(mg) Codes 
1-17 
18-22 
23-24 
25-34 
35-44 
30.0 
170.0 
10.0 
50.0 
5.0 
II a 
II b 
II c 
II d 
II e 
Fraction R10 (710mg)was chromatographed on a Sephadex L-H 20 column using 100% ethanol 
as the solvent with fractions of 5mL being collected per tube . TLC was used to pool the various 
fractions together to afford a total of six fractions (I-IV). Table 3.13 summarizes the result.  
 
Table 3.13 Sub-fractions from R10. 
Tubes Weight(mg) Codes 
1-17 
18-31 
32-48 
47-98 
99-112 
113-160 
30.0 
140.0 
310.0 
70.0 
30.0 
87.0 
I 
II 
III 
IV 
V 
IV 
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3.7.5 Column chromatography of (P4) fraction 
Fractions P4 (6.00g) was chromatographed on a Silical gel column using the solvent system 
EtOAc-Hex [(2%, 500 mL), (4%, 2L), (6%, 2L), (8%, 2L), (10%, 2L), (15%, 2L), (20%, 2L), 
(30%, 1L)] and 100% EtOAc (500 mL). Fractions of 100 mL were collected per tube and these 
were combined based on their TLC profiles to afford fractions T1-T10, Table 3.14 summarizes 
the result.  
 
Table 3.14 Sub-fractions from P4. 
Tubes Weight(g) Codes 
1-6 
7-11 
12-16 
17-18 
19-25 
26-30 
31-37 
38-40 
41-45 
46-72 
0.03 
0.03 
0.06 
0.06 
2.01 
3.02 
0.52 
0.04 
0.17 
0.05 
T1 
T2 
T3 
T4 
T5 
T6 
T7 
T8 
T9 
T10 
 
Fractions T6 needle- like crystals were washed with 100% Hexane to afford a novel compound 
C5 (0.97g). Several attempts to purify T5 and T7 on sephadex, silica column and silver nitrate 
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impregnated silica were not successful. The scheme of fractionation of P4 is presented in Fig. 
3.7. 
3.8 Synthesis of compound C6 
33 mg of C5 was dissolved in methanol to which methanolic –KOH was added and the mixture 
was refluxed for 3hours then cooled and acidified. Extraction of the mixture with EtOAc 
afforded a residue which was chromatographed using 70% Hex – EtOAc as eluent to afford 
compound C6 (20 mg). 
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Plant Material 
(1kg) 
P1(0.16g), P2(9.78g), P3(0.74g), P4(9.79g), P5(4.94g), 
P6(0.91g), P7(2.93g), P8(3.28g), P9(1.62g), P10(5.91g), 
P11(5.96g), P12(1.70g), P13(3.62g). 
 
 
3.9 Scheme of extraction 
 
 A general overview of the extraction protocol for the dried plant material is presented in scheme 
3.9.  
3.9.1 The crude fractionation 
 
 
 
 
 
 
 
                                      95% Ethanol                           
 
                                                            
                                             
  
 
                                                                        
                          Hex-EtOAc (10%-100%) 
                          EtOAc-MeOH (20%)  
 
 
 
 
 
 
Figure 3.1. Generalized scheme of extraction for total extract. 
62.2g 
Extract 
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                                 Hex-EtOAc (50% and 60%) 
                                      100% EtOAc 
 
 
A(10.0mg) 
 
 
B(230.0mg) 
 
C(120.0mg) 
 
D(240.0mg) 
 
E(140.0mg) 
 
F(10.0mg) 
 
G(40.0mg) 
 
H(360.0mg) 
  Sephadex column 
             Washed with 10%EtoAc-Hex 
                                       100%DCM                                                     
                                                                                                       Silica gel column  
  
                                                                                                           
  
 
  
Figure 3.2. Isolation scheme for fraction P12. 
 
  
 
 
          
      P12 (1.60g) 
 
C1 
33mg 
DI 5mg D II 
2mg 
D III 
70mg 
D 
IV40mg 
D V 
40mg 
20mg 
E I10mg 
 
EII 80mg 
 
EIII 20mg 
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                                                             Hex-EtOAc (80-40%) 
 
 
  
                                     
                             + P11M Residue/Sephadex column Precipitation 
                                                      (0.65g) 
 
 
 
 Sephadex column 
 
 
 
Figure 3.3. Isolation scheme for fraction P11. 
 
 
 
 
 
P11(5.60g) 
 
I 0.03g J 2.03g K 0.22g L 0.48g  M 0.91g 
P11M Supernatant 
(0.74g) 
 
N 0.22g 
P11M Residue 
(0.17g) 
MII 30mg 
 
MI   5mg 
 
MIV 110mg 
 
MIII 540mg 
 
LI 15mg 
 
LIV 30mg 
 
LIII 20mg 
 
LII 150mg 
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                                     Not washed 
  
                                                                                     
                                   
                        
 
                                                                                  Washed (50%DCM-Hex) 
 
 
 
 
  
     
 
                                        HPLC/Sephadex column 
 
 
 
  
Figure 3.4. Isolation scheme for fraction P11O. 
 
 
P11O(2.76g) 
XVI  
30mg 
XVII 
20mg 
XVIII  
80mg 
XIX 
130mg 
 130mg 
XX  
90mg 
XXII  
40mg 
XXII  
50mg 
XV 
20mg 
XIV 
5mg 
XIII 
4mg 
XII 
5mg 
XI 
10mg 
I (1.1mg) II(1.0mg) III (2.0mg) 
 IV (110)mg  V(75mg) VI(30mg)  
VII (0.5mg) VIII (2.0mg) IX(2.5mg) 
         C2(5.5mg) 
        C3(7.3mg) 
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                                                    Not Washed 
                                            Silical gel column                                                    
 
 
 
                                                                 
           Washed (100%DCM)    
            Silical gel column 
 
 
 
Figure 3.5. Isolation scheme for fraction P9. 
 
 
 
 
 
 
 
 
 
P9(3.20g) 
Q11 
90mg 
Q10 
80mg 
Q8 
270mg 
Q7 
470mg 
Q9 
100mg 
Q6 
300mg 
Q4 
310mg 
Q5 
590mg 
Q12 
70mg 
Q3 
120mg 
Q13 
380mg 
Q2 
10mg 
Q1 
30mg 
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                                  EtOAc-Hex (10 and 20%) 
EtOAc 100%                                Silical gel column 
 
 
 
 
          Washed (10%EtOAc-Hex) 
         PTLC 
                                                      Sephadex column                                                           
                                                      100%EtOH  
  
 
 
  
 
  
 
   
Figure 3.6. Isolation scheme for fraction P7. 
 
P7 (2.53g) 
R6 
120mg 
R10 
710mg 
R9 
170mg 
R8 
220mg 
R7 
220mg 
R1 
20mg 
R2 
30mg 
R3 
60mg 
R4 
60mg 
R11 
180mg 
R5 
130mg 
C1 (15mg) 
C4 (6.1mg) 
III 
10mg 
II 
280mg 
I  
10mg 
IV  
5mg 
IId 
50mg 
 
IIc 
10mg 
 
IIb 
170mg 
 
IIa 
30mg 
 
IIe   
5mg 
 
I 
30mg 
 
III 
310mg 
 
IV 
70mg 
 
II  
140mg 
 
V    
87mg 
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                                        Silical gel column 
 
 
 
                     
 
  
                                     Washed (100%Hex) 
 
Figure 3.7. Isolation scheme for fraction P4. 
 
 
 
 
 
 
 
 
 
P4 (6.00g) 
    C5 
(0.97g) 
T1
0.03mg 
 
T2 
0.03mg 
 
T3 
0.06mg 
 
T4 
0.06mg 
 
T5 
2.01mg 
 
T6 
3.02mg 
 
T7 
0.52mg 
 
T8 
0.04mg 
 
T9 
0.17mg 
 
T10 
0.05mg 
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3.10 BIOLOGICAL EVALUATIONS CONDUCTED 
3.10.1 In vitro culturing of mammalian cells 
3.10.1.1 Seeding of cells 
A vial of the respective frozen cells was taken from the -150
o
C freezer and rapidly thawed in a 
water bath set at 37
o
C by submerging the vial in water. The cells were transferred into tissue 
culture flasks containing the pre-warmed media DMEM and incubated at 37
o
C in a 5% CO2 
humidified incubator. 
3.10.1.2 Trypsinization and cryo-preservation of cell lines 
Once the cells approached 70-90% confluency, they were washed with 1X PBS and incubated 
for 5-10 minutes in 5 ml of 0.125% trypsin if cells were cultured in T-25 cm
2
 flasks or in 10 ml 
of the 0.125% trypsin if 75 cm
2
 flasks were used. Trypsinization was stopped by the addition of  
2-3 ml of culture medium. The detached cells were recovered by aspiration and transferred into a 
centrifuge tube which was centrifuged for 3 minutes at 200 xg in a bench top centrifuge.  
The supernatant was discarded and the cell pellet resuspended in a solution of 90% media and 
10% DMSO, a small aliquot of cells (100-200 µl) was removed and a cell viability count 
performed. If the cell viability was in excess of 90%, the cells were frozen and if not, the cells 
were discarded and a new culture grown.  
The cells were dispensed in 1ml aliquots in labeled cryo vials at a concentration of 2x10
6
 cells 
per ml and frozen immediately at -150
o
C. A quality control was set up by removing another 
aliquot of 50-100 µl from the cell solution to be frozen to confirm whether they were 
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contaminated or not. This would be done for 24-48 hours and if they were found to be 
contaminated, the vials were withdrawn and discarded. 
3.10.1.3 Cell counting 
Cell count was performed using a Countess
TM
 automated cell counter (Invitrogen). 
10 µL of cell solution already tripsinized and in fresh media was withdrawn from stock into an 
eppendorf tube and 10 µL of trypan blue added. The two solutions were thoroughly mixed to 
homogenize them efficiently after which 10 µl of the mixture was transferred onto a cell counter 
slide to calculate the percentage viability of the live cells using trypan blue staining solution. 
Visually, the dead cells appeared dark in colour, while the live cells had bright centers. 
3.10.1.4 Morphological evaluation of treated and untreated cells 
Cell lines were cultured in 6well plates to 90% confluency and induced to undergo apopotosis 
with various concentrations of the isolated compounds ranging from 3.125-50 µg/ml with both 
negative and positive controls as monitoring vectors. The cells were incubated for 24 hours at 
37
o
C in a CO2 incubator. The cells were inspected under a Nikon inverted light microscope using 
a 10X and 20X objective and photographs were taken using a Leica EC3 digital camera. 
3.10.2 Tetrazolium salt WST-1-(4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 
z3-benzene disulfonate) Assay 
Cells were seeded at a concentration of 5 × 10
4
 cells/well in 100 µl culture medium containing 
Penicillin/FBS(1g/ml) and various amounts of extract, fractions and compounds were added at 
different concentrations into microplates (96 wells - flat bottomed tissue culture grade). 
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The cells were incubated for 24 hours at 37
o
C in a CO2 incubator. A volume of 10 µl of cell 
proliferation reagent WST-1 was added and incubated for 4 h at 37°C and 5% CO2.  
Mixtures were thoroughly shaken for about 5minutes and the absorbance measured against a 
background control as blank using a micro- plate (ELISA) reader at 450 and 750 nm. 
% Viability = OD of treated well –blank/OD of untreated control well –blank 
IC50 values were calculated using Graphpad prism software. Triplicate experiments were 
conducted and the results expressed as mean±SD. 
3.10.3 The APOPercentage
TM
 apoptosis assay 
This assay was done as described by Masalu et al., (2010). Briefly, the cells were cultured to 
90% confluence in 12 well plates at a density of 1x10
5
cells/ml and incubated for 24 hours at 
37
o
C in a 5% CO2 incubator. The cells were treated with various concentrations of the test 
fraction or isolated material at concentrations varying from 3.125-50 µg/ml while the positive 
control was 50µM Camptothecin. Floating cells were transferred to 15ml centrifuge tubes while 
adherent cells were tripsinized and added to the tubes containing floating cells.  
The cells were harvested by centrifugation and washed twice with 1X PBS and then stained with 
Apopercentage
TM
 dye (1:160) in complete media for 30 minutes and incubated at 37
o
C in a 5% 
CO2 incubator. The cells were washed twice with 1X PBS again and the pellet resuspended in 
400 µl 1X PBS and analyzed on an Attune flow cytometer (Applied Biosystems) apparatus with 
a 488nm Argon laser as the light source. Apopercentage
TM
 dye fluorescence was measured using 
the FL3 channel and the results are expressed as percentage cell death against concentration. 
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3.10.4 Determination of ROS 
To evaluate the intracellular ROS generation, the molecular probe 5-(and 6)-chloromethyl-2´, 7´-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) was employed using the 
method described by Wei et al., (2000) with slight modifications. The cells were cultured in 12 
and 6well plates and treated with 12.5 or 25 µg/ml of compounds on HeLa, MCF-7 and HT-29 
cells with 50 µM of Camptothecin being used as a positive control in a 5% CO2 humidified 
incubator at 37
o
C for 24 hours. The adherent cells were transferred to 15 ml tubes and washed 
twice with PBS after which they were spun at 300 xg for 5 minutes. The cells were stained in  
7.5 µM of the probe prepared in DMSO and reconstituted in PBS for 30minutes in a 5% CO2 
humidified incubator at 37
o
C and analyzed on a flow cytometer (BD Calibur) instrument 
equipped with a 488nm argon laser and the cell fluorescence (DCF) measured using the FL-1 
channel. 
3.10.5 ROS determination by fluorescence imaging 
To further investigate apoptotic effects of isolated compounds, the cells were treated with  
12.5 µg/ml of compounds for 4 hours and stained the nucleus with NucBlue
TM 
live cell staining 
dye for 20 mins and then with 1 µM CM-H2DCFDA molecular ROS probe for another 30 mins 
and viewed under Axio vision fluorescence microscope. 
3.10.6 Measurement of Caspase 3/7activity 
Caspases 3/7 were measured using the assay kits from Promega (Promega, Corp., Madison, WI) 
according to the manufacturer’s instructions and the method described by Thaler et al., (2013) 
with slight modifications. In brief, after treatment, cells were lysed and the substrates cleaved by 
caspases 3/7 were measured using the luminescent signal obtained with a 96 well Luminometer 
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(Glomax, Promega) and the assays were done in triplicate and repeated as and when the need 
arose. 
3.10.7 Measurement of Caspase 9 activity 
Caspases 3/7 were measured using the assay kits from Promega (Promega, Corp., Madison, WI) 
according to the manufacturer’s instructions and the method described by Thaler et al., (2013) 
with slight modifications. Cells were seeded in 96well tissue culture plates at a concentration of 
5x10
4
ml per well, after treatments cells were lysed and the substrates cleaved by the caspases 9 
were measured using the luminescent signal obtained from Luminometer (Glomax, Promega). 
The assay was done in triplicates. 
3.10.8 Topoisomerase inhibition determination 
Topoisomerase I assay is based on the inhibition of the relaxation of supercoiled circular DNA 
by topoisomerase I (Osheroff et al., 1983).  
1 U of topoisomerase I will relax 0.5 µg of supercoiled pBR322 when incubated in assay buffer 
in a total reaction volume of 30µl. A master mix containing ddH2O, 1X assay buffer [20mM 
Tris. HCl (pH 7.5), 200mM NaCl, 0.25 mM EDTA & 5% glycerol], 0.5 µg supercoiled DNA, 
1U topoisomerase I enzyme and the test fractions was prepared. 5 µl of the stock solutions of test 
fractions was added to 30 µl of the total reaction volume. Preparation was done on ice before 
incubating the mixtures at 37
0
C for 2 h, after which it was terminated with 6 µl 6x stop buffer 
(3% SDS, 60 mM EDTA, 50% glycerol, 0.25% bromophenol blue). The reaction products were 
determined by electrophoresis on 1% agarose gel in Tris-acetate-EDTA (TAE) running buffer at 
6.5 V/cm for 2 h. The gels were stained with 0.5 µg/ml ethidium bromide for 30 mins. Gels were 
directly scanned with an image analyzer (Biometra, Germany) for visualization. 
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3.10.9 Cell cycle analysis 
The effect of compounds on cell cycle phase distribution was analyzed using the method 
described by Shao et al., (2011) with slight modifications. 
2× 10
5 
of cells were seeded in each well of a 6-well plate and treated with 5 compounds; C2 
(12.5 μg/ml), C3 (12.5 μg/ml), C4 (12.5 μg/ml), C5 (12.5 μg/ml) and C6 (6.25 μg/ml) . 
Untreated cells were also included as controls. After incubation for 24 h cells were trypsinized 
and washed with PBS, centrifuged and resuspended repeatedly into single cells prior fixation 
with 70% ethanol. Fixed cells were kept at -20°C for 48 h and later washed with 1X PBS twice 
and the supernatant was discarded. Cell pellets were resuspended in 200 μl of 1X PBS and 500 
μl of PI master mix and the cell suspension incubated for 15 minutes on ice in the dark. FACS 
Calibur (BDBiosciences, USA) and Cell Quest Pro software (BD Biosciences, USA) was used to 
determine the cell cycle distribution.  
A total of 10,000 of cells were acquired each time using FACS Calibur flowcytometer. 
Flowcytometric data were analyzed using Modfit software and displayed in histogram cell count 
versus DNA content. 
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CHAPTER 4 
The rundown of the isolation procedure is given in this chapter. It further explained in detail the 
identification of the isolated compounds with the use of spectroscopic, chromatographic and  
X-ray crystallographic techniques in their structural elucidation. The structures of isolated 
compounds and similar compounds from literatures are shown in Fig. 4.2 – 5.0 while their NMR 
spectra are given in Tables 4.2 – 4.6. 
4.1 STRUCTURAL ELUCIDATION OF ISOLATED COMPOUNDS  
4.1.1 Summary of isolation procedure 
The ground air-dried leaves (1 kg) were soaked in 95% ethanol for three days and the extract 
filtered and concentrated in vacuo to yield 81.00 g of the crude extract. The crude extract was 
screened separately phytochemically using GC-MS coupled with a library search within the  
GC-MS instrument’s memory as well as other standard procedures (Wagner and Bladt, 2001).  
For the fractionation of the extract, 62.22 g of the ethanolic extract was adsorbed on silica gel 
(Merck, 0.040-0.063mm particle size) and chromatographed using column chromatography 
coupled with a gradient elution of a Hexane-EtOAc mixture a s  mobile phase.  
Fractions showing similar TLC characteristics were bulked together and concentrated in 
vacuo; giving rise to t h i r t e e n  fractions coded P 1 – P 13. Fractions P1 - 13 were screened 
for cytotoxicity using the WST-1 assay and were further purified either based on bioassay or 
NMR results. Fractions P4, P7, P8, P9 and P12 displayed significant cytotoxicity and were 
chosen for further purification while P11 was chosen because of its proapoptotic effect and the 
unusual signals in the NMR spectra to evaluate the compounds present for biological activity. 
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P9 was further chromatographed on a silical gel column using gradient elution with Hexane-
EtOAC mixture to afford Q1-13. In this case fraction Q4 (310 mg) was washed in a mixture of 
10% Hexane/EtOAc several times to give compound C1 (100 mg).  
P11 (5.60 g) was adsorbed on a silical gel column using a Hex-EtOAc mixture 80-40% as eluting 
solvent to afford sub fractions P11I-N. P11M (0.91 g) precipitated in the tube and was carefully 
decanted to give P11Ma (0.74 g) supernatant and P11Mb (0.17 g) residue. The supernatant fraction 
was further chromatographed on a sephadex LH-20 column using absolute EtOH as eluting solvent 
to give sub fractions (P11MI-MIV). The fractions P11L (0.48 g) and P11Mb (0.17 g) were found 
to be similar by TLC and thus pooled together to be run on a separate silical gel column using 
EtOAc-Hex 25% and 30% as solvent system to produce sub-fractions P11LI-LIV. 
Fractions P11MIII (supernatant) 0.54mg, P11N (2.20g) and P12 E(0.02 g) were pooled together 
and renamed as P11O based on TLC profile and separated on silica gel column using the solvent 
system EtOAc –Hexane (25%, 100%), and EtOAc -MeOH (50%,), giving rise to twenty two 
fractions coded as sub-fraction I-XXII. Sub-fractions XIX (130 mg) and XX (90 mg) were 
further chromatographed repeatedly on sephadex L-H 20 using DCM-MeOH (95%) as solvent 
and HPLC (MeOH-H2O) 80% with UV detector to afford compound C2 (5.5 mg) and C3 (7.3 
mg) which was initially pure, but later isomerized into a mixture of C2 and C3. 
Fraction P7 (2.53g) was chromatographed on silical gel to afford sub-fractions R1-R10. 
R10 was further separated on Prep TLC to give compound C4 which is a mixture of two 
triterpenes but the structure was not elucidated in this study. 
Fraction P4 (6.00g) was adsorbed on a silical gel column using a gradient elution of Hexane-EtOAc 
98%-70% and 100% EtOAc as eluent solvent system to afford sub-fractions T1-T10, sub fraction 
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T6 crystallized overnight to form needle-like crystals which were carefully decanted and 
recrystallized in Hexane-DCM mixture to produce compound C5 (0.97g).  
Compound C6 was synthesized by refluxing 33 mg of C5 dissolved in methanolic - KOH for 
3hours to afford Z1 mixture. The cooled mixture was acidified and extracted into ethyl acetate 
and purified on a silical gel column to give C6 (20.0mg, 60.6%).  
Further detailed isolation procedures were discussed and illustrated in Chapter 3.  
It should be noted that the plant parts used in this study were air-dried to prevent the 
decomposition of thermo labile constituents which might occur at high temperatures.  
Ethanol was chosen as solvent to mimic the preparation of herbal extracts as used in South -West 
Nigeria and the percentage (95%) was chosen to represent organic and aqueous extracts. 
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Table 4.2. Qualitative phytochemical analysis of Pleiocarpa pycnantha. 
Test                                                                                                                       Results 
Alkaloids 
Draggendorf                                                                                                          Absent 
Wagner                                                                                                                  Absent 
Hager                                                                                                                     Absent 
Terpenoids                                                                                                           Present 
Saponins                                                                                                              Present 
Flavonoids 
FeCl3                                                                                                                     Absent 
AlCl3                                                                                                                    Absent 
Lead Acetate                                                                                                       Absent 
 
 
 
 
 
 
 113 
 
 
Figure 4.1. Showing TLC characteristics of fractions  P1 to P15 (now P1-P13) from P. 
pycnantha leaves when sprayed with vanillin-sulphuric acid reagent. 
 
The preliminary phytochemical screening of the ethanolic extract obtained from P. pycnantha 
leaves as illustrated in Table 4.1 and Figure 4.1 indicated that the major component of the leaves 
are Terpenoids which have been reported to be useful anticancer agents (Neto, 2007). 
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4.2 Physico-chemical/spectroscopic parameters of isolated compounds 
Any minor discrepancies in δ and J values are due to the different solvent system used in 
determining the NMR spectra. 
Compound C1 (Ursolic acid) 
White amorphous powder (MeOH)  
Melting point: 273-274
o
C 
HREIMS m/z (rel.int.): 456.3856 [M+H]
 + 
(calculated 456.7003) 
Molecular formula C30H48O3 
COOH1
2
4
5 7
9
11
12
15
17
19 21
22
24 23
2625
27
30
29
HO
28
 
Figure 4. 2. Molecular structure of compound C1.  
The HREIMS of compound 1(C1) gave the ion [M+H]
 + 
at 456. 3856 which has the molecular 
formula C30H48O3 (calculated 456.7003) and assigned for ursolic acid as deduced from an 
analysis of 
1
H,
 13
C NMR and DEPT spectra. The proton spectrum indicated the presence of seven 
methyl groups in the molecule with characteristic peaks typically at high field and supported by 
the DEPT spectrum (Table 4.2). One acid carbonyl signal appeared at δ 181.6 in the 13C NMR 
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spectrum. The signals at δ 139.6 and 126.9 are assigned to the two olefinic carbons C-13 and C-12 
respectively based on the DEPT spectrum.  
The 
1
H NMR spectrum further showed the presence of an oxygenated methine signal at δ 3.13 (1H, 
dd, J = 6.0 and 2.0 Hz, H-3) and a trisubstituted olefinic signal at δ 5.22 (1H, br s, H-12).  
On this basis, compound C1 was identified as ursolic acid, which had similar spectra to those 
reported by Murphy et al., (2003) as well as Hamzah and Lajis, (1998) and is illustrated in Table 
4.2. 
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Table 4.2. ¹H and ¹³C NMR data of C1 and Ursolic acid in CD3OD (δ values, J in 
parenthesis in Hz).  
Position  
 
 
Compound C1  
δ13C                                      δ1H 
                   Ursolic acid 
δ13C                                      δ1H 
1 39.8  39.8  
2 27.8                                                                             27.8  
3 79.7                                                                            3.13dd 1H
(6.0,2.0) 
79.6 3.14m 1H 
4 39.9                                                                             39.9  
5 56.7                                                                             56.7  
6 19.4                                                                             19.4  
7 34.3                                                                             34.3  
8 40.7                                                                             40.7  
9 47.6                                                                             47.6  
10 38.1                                                                             38.1  
11 24.3                                                                             24.3  
12 126.9                                                                          5.23m 1H 126.8 5.21m 1H 
13 139.6                                                                          139.6  
14 42.8                                                                             42.8  
15 29.2                                                                             29.2  
16 25.3                                                                             25.3  
17 48.0*                                                                          47.6  
18 54.3                                                                            2.18d 1H (11.2) 54.3 2.20d 1H (11.3) 
19 40.4                                                                             40.4  
20 40.4                                                                             40.4  
21 31.7                                                                             31.7  
22 38.1                                                                            1.54m 38.1 1.55m 
23 28.7                                                                            1.12s 3H 28.7 1.10 s 3H 
24 16.0                                                                            0.94 s 3H 16.0 0.93 s 3H 
25 16.4                                                                            0.78 s 3H 16.3 0.76 s 3H 
26 17.6                                                                            0.90 s 3H 17.6 0.95 s 3H 
27 24.0                                                                            0.98 s 3H 24.0 0.96 s 3H 
28 181.6                                                                          181.6  
29 17.8                                                                            0.87 d 3H 17.8 0.87 d 3H 
30 21.6                                                                            0.83 d 3H 21.5 0.83 d 3H 
Ursolic acid 
1
H and 
13
C in CD3OD (Hamzah and Lajis, 1998) 
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Compound C2 (27- p-E-coumaroloxy ursolic acid) 
An off-white amorphous powder (MeOH)  
Melting point: 284-286
o
C 
HREIMS m/z (rel.int.): 618.3914 [M+H]
 +
  
Molecular formula C39H54O6 (calculated 618.8423) 
COOH1
2
4
5 7
9
11
12
15
17
19 21
22
24 23
2625
27
30
29
O
O
OH
1'
2'
3'
5'
6'
8'
9'
28
HO
 
Figure 4.3. Molecular structure of compound C2.  
High Resolution EIMS was used to determine the molecular formulae of both C2 and C3 which 
were found to be C39H54O6. The two compounds were isolated in pure form initially and it was 
subsequently discovered that C3 had over a short period of time isomerized into a mixture of the 
two geometric isomers C2 and C3. Inspection of the downfield signals in the proton NMR 
spectra indicated the presence of a p-hydroxycoumaric acid ester moiety.  
Compound C2 displayed characteristics peaks at δ 7.51 (1H, d, J = 16.0 Hz, H-3’), 7.38 (2H, d,  
J = 8.0 Hz, H-5’, 9’), 6.78 (2H, d, J = 8.0 Hz, H-6’, 8’) and 6.19 (1H, d, J = 16.0 Hz, H-2’)  
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(Table 4.3). The large J value of 16 Hz clearly supports the trans nature of the side chain double 
bond. The agreement of the proton chemical shifts and coupling constants of C2 with other 
reported triterpene hydroxycoumaroyls is further evidence supporting the presence of this 
moiety. 
Our spectra were also compared to the earlier reported data for Uncaria rhynchophylla  
Lee et al., (2000) and Plemeria obtusa Siddiqui et al., (1990), see Table 4.3 for NMR data.
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Table 4.3. ¹H and ¹³C NMR data of C2 (CHCl3+ 1drop CD3OD) and 27-p-E-
coumaroyloxyursolic acid (pyridine-d5) (δ values, J in parenthesis in Hz)  
Position Compound C2 
δ13C                                      δ1H 
27-p-E-coumaroloyursolic acid 
δ13C                                      δ1H 
1 37.2  37.4  
2   27.9  28.1  
3 78.8 3.38m 78.1 3.38 dd(7.8, 2.0) 
4 38.2  38.5  
5 55.0  56.0  
6 18.1  18.9  
7 33.0  33.2  
8 39.9  39.8  
9 46.1  48.2  
10 37.2  38.5  
11 23.7  23.8  
12 127.2 5.43 br s 125.6 5.46 br s 
13 137.3  134.6  
14 46.1  47.2  
15 28.1  28.3  
16 23.9  24.1  
17 48.6  48.2  
18 55.0 2.58 d (11.5) 53.3 2.60 d (11.6) 
19 38.7  39.4  
20 38.2  39.1  
21 30.7  30.7  
22 36.7  37.4  
23 29.8 1.00 s 29.3 1.00 s 
24 16.1  0.88 s 16.0 0.98 s 
25 16.5  0.90 s 16.6 0.99 s 
26 16.9  1.06 s 16.9 1.05 s 
27 65.7 4.23 d (13.2)  
4.03 d (12.6) 
66.2 4.73 d (13.0)  
4.54 d(13.0) 
28 180.8  179.9  
29 18.8 1.18 d (8.0) 17.0 1.19 d (7.2) 
30 21.2 0.83 d (8.0) 21.4 0.93 d (7.1) 
1’ 167.0  167.2  
2’ 115.2 6.19 d (16.0) 115.6 6.67 d (15.9) 
3’ 142.6 7.51 d (16.0) 145.2 7.96 d (15.9) 
4’ 132.3  134.6  
5’ 130.0 7.38 d (8.0) 130.6 7.60 d (8.5) 
6’ 116.7 6.78 d (8.0) 116.9 7.13 d (8.5) 
7’ 158.1  161.5  
8’ 116.7 6.78 d (8.0) 116.9 7.13 d (8.5) 
9’ 130.0 7.38 d (8.0) 130.6 7.60 d (8.5) 
¹H and ¹³C NMR of 27-p-E-coumaroyloxyursolic acid (Siddiqui et al., 1990). 
 
 
 
 
 120 
 
Compound C3 (27- p-Z-coumaroloxy ursolic acid) 
An off-white amorphous powder (MeOH) 
Melting point: 199-202
o
C  
HREIMS m/z (rel.int.): 618.3914 [M+H]
 +
  
Molecular formula C39H54O6 (calculated 618.8423) 
COOH1
2
4
5 7
9
11
12
15
17
19 21
22
24 23
2625
27
30
29
O
O
OH
1'
2' 3'
5'
6'
8'
9'
HO
 
Figure 4.4. Molecular structure of compound C3.
 
Compound C3 was identified as 27- p-Z-coumaroloxy ursolic acid. It later isomerized into a 
mixture of C2 and C3 on remaining in a solution of deuterated chloroform/methanol mixture. 
The cis configuration of the C2’-C3’ double bond was confirmed by comparison with published 
data on cis-hydroxycoumaroyls (Rios et al., 2001). As illustrated in Table 4.4, the respective 
proton signals for C3 appeared at δ 7.36(2H, d, J = 8.0 Hz, H-5’, 9’), 6.82(1H, d, J = 12.0 Hz,  
H-3’), 6.79 (2H, d, J = 8.0 Hz, H-6,’8’) and 6.15 (1H, d, J = 12.0 Hz, H-2’) to support the cis 
geometry within the side chain of the molecule. The 
13
C spectra for C2 and C3 are nearly 
identical with the major difference being in the signals of C2’ and C3’ being at 116.0/115.2 and 
144.8/142.6 for cis and trans isomers respectively (Tables 4.3 and 4.4). 
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Table 4.4. ¹H and ¹³C NMR data of C3 (CHCl3+ 1drop CD3OD) and 27-p-Z-
coumaroyloxyursolic acid (¹H, CD3COCD3), (¹³C, CD3OD) (δ values, J in parenthesis in 
Hz)  
Position Compound C3 
δ13C                                      δ1H 
27-p-Z-coumaroloyursolic acid 
δ13C                                      δ1H 
1 37.1  37.9  
2   27.9  28.1  
3 78.6 3.13m 78.5 3.08 m 
4 38.9  40.1  
5 55.2  56.2  
6 19.5  19.1  
7 33.6  34.3  
8 41.0  41.0  
9 48.9  49.2  
10 38.4  38.0  
11 23.9  24.3  
12 130.2 5.57 br s 130.9 5.52 t (3.5) 
13 132.3  134.5  
14 46.1  46.6  
15 29.3  28.7  
16 26.7  25.0  
17 48.6  47.9  
18 52.4 2.40m 53.6 2.38m 
19 40.9  40.9  
20 39.0  39.2  
21 30.5  30.8  
22 39.8  39.9  
23 30.3 0.94 s 30.3 0.89 s 
24 17.4  0.81 s 16.3 0.82 s 
25 17.6  0.92 d (7.8) 16.4 0.87 d (8.0) 
26 18.2  0.96 s 18.1 0.92 s 
27 65.9 4.27 d (12.0)   
4.13 d (12.0) 
66.2 4.41 d (12.8)  
4.13 d(12.8) 
28 180.5  178.6  
29 18.2 1.21s 18.8 1.25 s 
30 22.6 0.75s 21.5 0.76 s 
1’ 167.4  166.7  
2’ 116.0 6.15 d (12.0) 116.8 5.76 d (13.0) 
3’ 144.8 6.82 d (12.0) 144.1 6.87 d (13.0) 
4’ 132.3  134.4  
5’ 130.0 7.36 d (8.0) 133.7 7.78 d (8.8) 
6’ 115.0 6.79 d (8.0) 115.8 6.84 d (8.8) 
7’ 159.2  159.9  
8’ 115.0 6.79 d (8.0) 115.8 6.84 d (8.8) 
9’ 132.3 7.36 d (8.0) 133.7 7.78 d (8.8) 
¹H and ¹³C NMR of 27-p-Z-coumaroyloxyursolic acid (Rios et al., 2001). 
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Compound C5: Pycanocarpine A (2, 3-seco-taraxen-14-ene -2, 3- lactone) 
Colourless needle-like crystals (DCM) 
Melting point: 246-249
o
C 
IR (KBr) γ max 3054, 2914, 2856, 1738, 1474, 1077cm
-1
 
HREIMS m/z (rel.int.): 440.3556 [M+H]
 +  
Molecular formula C30H48O2 (calculated 440.7009) 
O
O
12
4 6
810
11
12
14
15
16
17
19 21
23 24
25 26
27
28
29 30
 
Figure 4.5. Molecular structure of compound C5. 
 
Figure 4.6. Molecular structure of compound C5 as determined by single X-ray 
crystallography. 
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Compound C5 was obtained as a needle-like white crystals with a molecular formula C30H48O2 
deduced from the HRMS of the 440.3556 [M+H]
 +
(calculated 440.7009), single X-ray 
crystallography,  2D-NMR and 
13
C DEPT spectra. The IR spectrum exhibited absorption bands 
at 3054, 2914, 2856 (C-H stretching), 1738(C=O stretching of a lactone) 1474 (C-O, carboxylate 
ion. The 
13
C DEPT spectra showed 30 signals (Table 4.5) which are attributed to 8 methyls,  
10 methylenes, 4 methines and 8 quartenary carbons. The molecule was chemically deduced to 
be a triterpenoid through a purple vanillin-sulphuric acid test and supported by the appearance of 
8 methyl groups in the 
1
H NMR spectrum (Table 4.5).  
The signal due to the olefinic proton at δ 5.54 (m) together with 13C NMR signals of C-14 
(δ 157.7) and C-15 (δ 117.1) suggested a taraxerane moiety (Mahato and Kundu, 1994;  
Giang et al., 2013). The ring A of compound C5 was compared to the ring A of 4- hydroxy-3,4-
seco-ursan-12-en-28-oic acid 3,4 lactone which is a 3,4- secoursan -12- ene derived from ursolic 
acid (Tu et al., 2009) and compared very favourably (Table 4.6 and Fig. 4.7). The C-2 carbon 
was assigned on the basis of the chemical shift at δ 174.8, the structure of C5 is as illustrated in 
Fig.4.5. The NMR data were assigned unambiguously from the hydrolyzed product of compound 
C5. The structure was finally established from X-ray diffraction studies, Fig. 4.6 illustrates the 
perspective view of the molecule with its relative configuration.  
The compound was thus assigned as 2, 3-seco-taraxer-14-en-2, 3-lactone and given the name 
pycanocarpine. 
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Figure 4.7. Molecular structure of ursolic acid seco derivatives. 
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Figure 4.8. Molecular structure of 3β-taraxerol. 
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Table 4.5. ¹H and ¹³C NMR data of C5 (CDCl3) and C6 (CDCl3+ 1drop CD3OD)  
(δ values, J in parenthesis in Hz)  
Position                        Compound C5 
       δ13C                         δ1H                              
 
                       Compound C6 
   δ13C                         δ1H                             
 
1 44.9 t 2.44 br s; 2.78 br s 43.1 t 2.36 d; 2.35 d(12.0) 
2 174.8 s  172.9 s  
3 77.9 t 3.79 br s; 4.08 br s 72.1 t 3.33 d; 3.34 d(7.0) 
4 38.4 s  38.6  s  
5 48.7 d 0.97* 44.9 d 1.72* 
6 20.6 t 1.57*; 1.66* 21.8 t 1.60*; 1.53* 
7 35.1 t 1.02*; 1.35* 35.6 t 0.95*; 1.34* 
8 35.8 s  34.9 s  
9 40.9 d  1.64*  42.8 d 1.76* 
10 46.7 s  43.6 s  
11 18.6 t 1.57*; 1.75 br s  19.5 t 1.18*      2H 
12 36.6 t 0.98 dd; 1.34*(12.0,4.5) 37.5 t 1.49*; 1.83 td (9.0,3.5) 
13 37.4 s  37.0 s  
14 157.5 s  157.3 s  
15 117.1 d 5.54 dd(8.0,3.5) 116.8 d 5.46 dd(9.0,4.5) 
16 37.8 t 1.64*; 1.92 dd(9.0,2.0) 36.5 t 0.90*; 1.22 
17 40.6 s  40.2 s  
18 48.7 d 0.97* 48.5 d 0.92*     2H 
19 39.4 t 1.37*; 2.04 dt (9.5,3.5) 39.7 t 1.33*; 1.96 dd (3.5,8.5) 
20 28.7*s  28.6 s  
21 33.1 t 1.25 dt (9.5,3.5); 1.32* 32.9 t 1.44*; 1.59* 
22 33.6 t 1.60*; 1.64* 33.8 t 1.55*; 1.60* 
23 19.4 q 1.02 s 26.3 s 0.93 s 
24 28.7 q 0.95 s 24.4 d 1.04 s 
25 17.5 q 1.13 s 18.5 q 1.02 s 
26 25.8 q 1.11 s 20.6 q 0.86 s 
27 29.6 q 0.92 s 29.5 q 0.83 s 
28 21.1 q 0.90 s 23.9 q 1.00 s 
29 33.5 q 0.95 s 33.1 q 0.87 s 
30 29.6 q 0.83 s 29.7 q 0.71 s 
*overlapped signals 
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Compound C6: Pycanocarpene A (2, 3-seco-Taraxen-4-hydroxy-14-en-2-oic acid) 
An off-white amorphous powder (MeOH) 
Melting point:  237-241
o
C 
IR (KBr) γ max 3055, 2921, 2857, 1740, 1473, 1067cm
-1
 
HREIMS m/z (rel.int.): 458.3810 [M+1]
 +
  
Molecular formula C30H50O3 (calculated 458.7162)  
 
  
Figure 4.9. Molecular structure of compound C6.  
 
Figure 5.0. Ball and Stick minimized energy model for C6. [Generated by ChemDraw Ultra 
8.0 (Cambridge)]. 
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Compound C6 was synthesized by refluxing 33.0mg of C5 (33.0mg, 0.075mmol) in 5% 
methanolic-KOH(50 ml) for 3 hours at 110
0
C after which the resultant mixture Z1 was cooled, 
diluted with deionized water (30 ml), acidified with 1M HCl and extracted with EtOAC (50 ml). 
The residue was chromatographed on silica gel column using 70% Hex-EtOAC to yield C6 
(20.0mg, 60.6%). This alkaline hydrolysis of compound C5 produced the unstable derivative viz 
2,3-seco-3-hydroxy-taraxer-14-en-3-oic acid (C6) as an off-white amorphous powder having the 
molecular formula C30H50O3 based on HREIMS of 458.3810 [M+H]
+
 (calculated 458.7162) as 
well as 
13
C NMR data. The IR spectrum exhibited a strong absorption band at 3055 cm
-1
 for an 
OH and 2921and 2857 cm
-1
 (C-H stretching), 1740 cm
_1
 (C=O stretching), 1473 cm
-1
 (C-O, 
carboxylate ion) and 1067 cm
-1
 (C-O stretching).  
The
13
C DEPT spectra showed 30 signals (Table 4.5) attributed to 8 methyls, 10 methylenes, 
4 methines and 8 quaternary carbons. The product was deduced to be a triterpenoid through a 
purple vanillin-sulphuric acid test and the appearance of the methyl groups δ 0.71, 0.83, 0.86, 
0.87, 0.93, 1.00, 1.02 and 1.04 in the 
1
H NMR spectra(Table 4.5). The olefinic proton at  
δ 5.46 (m) together with 13C NMR signals of C-14 (δ 157.3) and C-15 (δ 116.8) showed a  
tri-substituted double bond which when compared to similar molecules suggested a taraxer-14-
ene structure (Giang et al., 2013).  
It was noticeable that the free carboxylic and hydroxyl groups could easily reform the lactone 
ring after a short time in organic solvents such as methanol and chloroform. The NMR data of 
C6 is similar to the parent compound C5 and is illustrated in (Table 4.5). Minor changes were 
observed between C5 and C6 for carbons C-11, -23, -24 and -26. The stereochemistry of both 
compounds, especially ring A, may partially explain this. 
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In compound C5 the carbonyl group is directed into the same plane similar to C-24, -26 and -11. 
On the other hand, in the derivative C6, the minimized energy conformation (Fig. 5.0) showed 
different orientations and distances for the C3-OH and C2-OOH groups.  
Seco-taraxerane triterpenoids have not been reported in the Apocynaceae family and Pleiocarpa 
genus. This is the first report of the isolation of triterpenes from Pleiocarpa pycnantha and the 
second from the genus.  
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Table 4.6. ¹H and ¹³C NMR data of Taraxerol CDCl3, 4-Hyroxy-3, 4-seco-ursan-12-en-28-oic acid  
3, 4 lactone and 3, 4-seco-Ursan-12-en-3, 28-dioic in CD3OD (δ values, J in parenthesis in Hz)  
Position Taraxerol                                                                   
δ13C                  δ1H                                                      
4-Hydroxy-3,4-seco-ursan-
12-en-28-oic acid 3,4
lactone(Ring A)                                                                 
δ13C                      δ1H                                                             
3, 4-seco-Ursan-12-en-3, 28-
dioic (Ring A)                                                                                                                                                                                                 
δ13C δ1H                                
1 38.0  *  *  
2 27.1  31.8  30.4 2.30 1H m, 
2.49 1H m 
3 79.1 3.24 1H dd 
(4.7, 11.0) 
175.8  181.7  
4 39.0  74.9  76.2  
5 55.5  52.5  53.0  
6   23.9  21.6  
7 35.1 2.03 1H dt 
(3.1, 12.6) 
29.6  32.7  
8 38.7  45.3  43.8  
9 48.7  37.0  54.4  
10 37.5  *  40.6  
11 17.5  17.0  17.8  
12 35.8  125.3 5.251H t (3.6) 127.2 5.27 1H t (3.6) 
13 37.6  138.1  139.4  
14 158.1  42.1  42.1  
15 116.9 5.53 1H dd 
(3.2,8.2) 
27.9  29.2  
16 36.6 1.92 1H dd 
(3.0, 14.6) 
24.0  24.1  
17 37.7  47.9  49.0  
18 49.2  55.2 2.20 1H 
d(11.2)  
52.9 2.22 1H d 
(11.6) 
19 41.3  39.0  40.1  
20 28.8  38.8  38.1  
21 33.7  30.5  31.8  
22 33.1  36.6  35.7  
23 28.0 0.98 3H s * 1.28 3H s 33.7 1.27 3H s 
24 15.4 0. 80 3H s 19.7 1.26 3H s 28.3 1.25 3H s 
25 15.4 0.93 3H s 13.6 0.80 3H s 18.1 0.97 3H s 
26 29.8 1.09 3H s 16.8 1.01 3H s 17.7 1.10 3H s 
27 25.9 0.91 3H s 20.8 1.07 3H s 23.4 1.14 3H s 
28 29.9 0. 82 3H s 182.3  181.7  
29 33.3 0.95 3H s 23.3 0.95 3H 
d(6.0) 
20.6 0.91 3H d 
(6.4) 
30 21.3 0.90 3H s 21.1 0.85 3H d 
(6.4) 
23.8 0.89 3H d  
(6.4) 
NMR data of Taraxerol (Chávex et al., 2012), 4-Hydroxy-3, 4-seco-ursan-12-en-28-oic acid 3, 4 lactone 
and 3, 4-seco-Ursan-12-en-3, 28-dioic (Tu et al., 2009). 
* omitted in the reference article. 
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CHAPTER 5 
The chapter is dedicated to the results and discussions of the biological evaluation of the isolated 
compounds. This chapter reports on the cytotoxicity of the extract, fractions and compounds 
from P. pycnantha leaves via the WST 1 assay on cervical carcinoma (HeLa), colorectal 
adenocarcinoma (HT-29) breast adenocarcinoma (MCF-7) and nontumorigenic immortalized 
human cell lines (KMST-6). Cytoxicity and apoptosis were used to identify the lead compounds 
showing potent anti- cancer activity on various cell lines.  
The pro- apoptotic activity was conclusively demonstrated with specific markers of apoptosis 
nmely; the externalization of the phosphatidylserine, ROS, caspases, cell cycle and 
Topoisomerase 1 inhibition. 
5.1 BIOLOGICAL EVALUATIONS: RESULTS AND DISCUSSION  
5.1.1 Investigation of cytotoxicity of crude extract, fractions and isolated compounds 
The cytotoxicity of a compound is believed to be an indication of its apoptotic potential. 
Cytotoxicity evaluations are generally used as a preliminary screening for plants and its 
constituents to investigate any possible biological activities especially anticancer activities. 
The WST-1 cell proliferation assay is a colorimetric assay that is based on the cleavage of a 
tetrazolium salt viz., 4- [3- (4-Iodophenyl) -2- (4-nitrophenyl) -2H -5-tetrazolio] -1, 3-benzene 
disulfonate disulfonate by mitochondrial dehydrogenases to form formazan in viable cells 
(Berridge et al., 1996). The greater the number of viable, metabolically active cells, the greater 
the amount of formazan product produced following the addition of WST-1 and the 
quantification of the formazan dye produced by metabolically active cells which can be done by 
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measuring the absorbance of the dye solution with a scanning multiwell spectrophotometer 
(ELISA reader) at appropriate wavelengths. 
Cells were plated in a tissue culture in 96 well plates as described in section 3.10.1 and treated 
with crude extract, fractions and isolated compounds for 24 h at a concentration of  
0.125 – 2 mg/ml, 0.4 mg and 15.62 – 250 µg/ml for the crude extract, fractions and isolated 
compounds respectively. The cytotoxic activity against HeLa, HT-29, MCF-7 and KMST-6 cells 
as evaluated by the WST-1 assay for the crude extract of P. pycnantha leaves are presented in 
Figs. 5.1 - 5.2. From the results obtained, the % viability of the cells decreased with increase in 
dose. The IC50 values for the extract on HeLa, HT-29, MCF-7 and KMST-6 cell lines are 620, 
910, 460 and 1460 µg/ml respectively (Table 5.1). This is an indication that the plant extract is 
more sensitive and selective for the cancer cells than the KMST-6 normal cell line (IC50, 1460 
µg/ml).The reduced IC50 value of 460 µg/ml on the MCF-7 (breast cancer) cell line showed that 
the total plant extract can be used to kill breast cancer cells. The next sensitive cell line to the 
plant extract is HeLa (cervical cancer) with an IC50 value of 620 µg/ml, while the IC50 value of 
910 µg/ml obtained for HT-29 (colon cancer) cell lines showed that the killing effect of this plant 
extract is weak on the cell line. 
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Figure 5.1. The percentage viability of crude extract of Pleiocarpa pycnantha leaves on 
Hela, HT-29, MCF-7 and KMST-6 cell line. 
 
 
 
Figure 5.2. The dose response chart of percentage viability of crude extract of Pleiocarpa 
pycnantha leaves on HeLa, HT-29, MCF-7 and KMST-6 cell lines. 
 
 
 
 
 
 133 
 
Table 5.1: IC50 values for Pleiocarpa pycnantha ethanolic extract when treated for 24 h as 
determined  by WST-1. 
 
                                               IC50 µg/ml 
Cell lines                                Ethanolic extract    Selectivity Index 
HeLa                                       620                         2.4 
HT-29                                     910                         1.6 
MCF-7                                    460                         3.1 
KMST-6                               1460                           - 
The results from the findings above showed that the ethanolic extract of Pleiocarpa pycnantha 
leaves displayed cytotoxic effects on MCF-7, HeLa and HT-29 cancer cell lines. However the 
activity was low with IC50 > 100 µg/ml on all the cell lines, which made us to screen the 
individual interesting fractions for their activities.Some of the fractions demonstrated potent 
activity which gave some justification to carry out further chemical investigations of such 
fractions as described in Section 3.7 with the scheme of extraction shown in Section 3.9.1. 
The fractions were screened using a single dose of 400 µg/ml representing a near average value 
for the IC50 and the result is presented in Fig. 5.3. 
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Figure 5.3. Comparative percentage viabilities of fractions obtained from Pleiocarpa 
pycnantha leaves on HeLa, HT-29, MCF-7 and KMST-6 cell lines. 
 
Fractions P4, P5, P6, P7, P8, P9, P12 and P13 displayed cytotoxic activity on selected cell lines 
P11 was weakly cytotoxic while P1, P2, P3 and P10 were not active. Different criteria were 
used to select the fractions for further purification. The fractions; P4, P7, P9 and P12 were 
selected based on their biological activity while P11 was selected based on its interesting 
chemistry and pro-apoptotic effect on all cell lines (data not shown). Of all the fractions selected 
for further purification to isolate the active constituents; fraction P4 was outstanding in the sense 
that it killed all the cancer cell lines selectively without touching the normal cell lines. 
The percentage viability at a concentration of 400 µg/ml on the normal cell, breast cancer, colon 
cancer and cervical cancer cell lines are : 2.75, 3.70, 6.42 and 95.9% respectively. 
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This finding seemed exciting to us because many of the anticancer drugs have been reported to 
interfere and destroy the normal cells as well albeit to a lesser extent. This led us to the next 
stage viz., that of isolating active constituents from the chosen extracts which may probably 
serve as ‘leads’ in phytomedicine. 
On HeLa (cervical) cell lines as demonstrated in Fig.5.3, fractions P4, P6, P7, P8, P9 and P13 
displayed significant cytotoxicity while fractions P5 and P12 were moderatively active.  
The fraction that displayed the lowest % viability was P9 (2.42), followed by P8 (3.08), P6 
(4.09) ranking the first three, while the highest % viability fraction was P1 (84.3).  
Fractions P4, P6, P7, P8, P9 and P13 displayed outstanding % viability results on HT-29 (colon) 
cancer cell lines while P5 and P12 demonstrated average activity. The results further indicated 
that P8 (2.39) had the least % viability being the most active followed by P6 and P9 with % 
viabilities of 2.68 and 3.15 respectively. The fraction that had the highest % viability (least 
active) was P2 (100.15). 
On MCF-7 (breast cancer) cell lines, the results indicated that fractions P4, P8 and P9 displayed 
potent cytotoxicity while P6, P7 and P11 showed moderate cytotoxicity against the cell lines. 
Ranking from the 1
st
 to the 3
rd
, the best cytotoxic fraction on the cell line was P4 (2.72) followed 
by P8 (3.22%) and P9 (4.62%). The least cytotoxic fraction (least active) was P1(100.05%). 
On KMST-6 (normal) cell line, as indicated in Fig. 5.3, fraction P6 (3.62%) was very cytotoxic 
and selective for the normal cell lines while P7 (38.67%) and P8 (48.07%) were also slightly 
cytotoxic on the normal cell lines. Others except P9 (49.92%) were not selective for the normal 
cell lines. 
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A B 
C D 
Figure 5.4. Effect of compounds C1-C6 on cell viability of (A) HeLa cells (B) HT-29 
(C) MCF-7 (D) KMST-6 in a concentration dependent manner as measured by WST-1 
assay. 
 
The effects of isolated and purified compounds C1-C6 on the viability of HeLa, HT-29, MCF-7 
and KMST-6 cells are presented in Fig. 5.4 after treatment for 24 hours with concentration of 
compounds ranging from 15.62 - 250 µg/ml as determined by WST-1 assay.  
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As shown in Fig. 5.4A, compound C1 is the most cytotoxic on HeLa cell lines with an IC 50 
value of 5.06 µg/ml, followed by C2, 33.19 µg/ml. Compound C6 is fairly cytotoxic with an  
IC 50 of 80.00 µg/ml, C3 and C4 is weakly cytotoxic with IC 50 values of 130.47 and  
160.95 µg/ml respectively, while C5 is the least active with an IC50 value of >250 µg/ml, see 
Table 5.2 for IC50 values. The cytotoxicity results on HT-29 cell line (Fig. 5.4B) followed a 
similar pattern as with the HeLa cell lines. Compound C1 was the most cytotoxic on HT-29 cell 
lines with an IC50 value of 5.12µg/ml, followed by the fairly cytotoxic compounds C2 (68.30 
µg/ml) and C6 (78.9µg/ml). C3 and C4 showed weak cytotoxicity at 144.53 µg/ml and 142.19 
µg/ml respectively. C5 did not show cytotoxicity at the highest concentration used in this assay 
as the IC50 was >250 µg/ml. On MCF-7 cells (Fig.5.4C), compound C6 with an IC50 value of 
5.46 µg/ml was the most cytotoxic while C1 was the second with an IC50 value of 9.51 µg/ml 
and the third was C5 with an IC50 value of 10.99 µg/ml. 
It is noteworthy here that C5 is selective for only MCF-7 cancer cells. The selectivity index 
(SI) for C5 was > 22 for MCF-7 cells, demonstrating that the activity of this compound is highly 
selective for MCF-7 adenocarcinoma cell line. C2 (34.37 µg/ml) also displayed significant 
cytotoxicity while C3 (114.06 µg/ml) and C4 (204.30 µg/ml) are weakly cytotoxic.  
On the non-cancerous KMST-6 cell line(Fig. 5.4D), compounds C3, C4 and C5 were not 
cytotoxic on the normal cell lines with IC50 values of 160.94, 214.84 and >250 µg/ml 
respectively. C1 (50.77 µg/ml) and C2 (61.32 µg/ml) are slightly cytotoxic while C6 is highly 
cytotoxic (4.78 µg/ml) on KMST-6 cell lines. The IC50 values and the selectivity indices of all 
isolated compounds on the various cell lines are displayed in Table 5.2. 
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The use of plants and their extracts have been the basis of prevention and treatment of diseases 
from very early times in our documented history. Plant secondary metabolites and their semi-
synthetic derivatives continue to play important roles in anticancer drug therapy.  
The survey of the anticancer drug market between1981-2006 has revealed 47.1% of a total of 
155 clinically approved drugs were either unmodified natural products, semi-synthetic 
derivatives or synthesized molecules based on natural compound pharmacophores (Newman and 
Cragg, 2007). Many of the anticancer drugs today had their origins from the preliminary 
cytotoxicity screening. 
Triterpenoids exist abundantly in the plant kingdom, for example; ursolic acid (3β-hydroxy-urs-
12-en-28-oic acid) is an ursane type triterpene found in all plant parts, but mainly in the leaves 
and presenting several important biological activities which includes; anti-inflammatory, 
antiviral, antioxidant and anti-cancer properties (da Silva et al., 2008;Tu et al., 2008).  
The anti-proliferative activity of ursolic acid has been reported in a wide variety of cancer cell 
lines (Neto, 2007). Ursolic acid hydroxycinnamate esters isolated from cranberry fruit has been 
evaluated for anti-tumor activity in a 60 tumor cell line panel through the National Cancer 
Institute’s Developmental Therapeutics program (http://dtp.nci.nih.gov/about.html).  
The cis- and trans- isomers of 3-O-p-hydroxycinnamoyl ursolic acid has been shown to inhibit 
tumour growth in vitro with the cis- isomer showing slightly greater activity in most cell lines 
with GI50 values ~20 µM in MCF-7 breast, ME 180 cervical, and PC3 prostate tumor cell lines 
(Murphy et al., 2003).  
The anti-proliferative activity of hydroxycoumaroyl esters of ursolic acids was reported on  
A-549, HCT-15, MCF-7 and HT-1197 with IC50 ranging from 0.5-6.5 µg/ml from Uncaria 
rhynchophylla (Lee et al., 2000).  Many plants from Apocynaceae family have been reported for 
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anticancer activity (Bonfil et al., 2002; Okouneva et al., 2003), including this report, which 
indicated the importance of their constituents as interesting source for the discovery of new 
anticancer agents.  
 
Table 5.2: IC50 values for compounds C1-C6 and the crude extract as determined by  
WST-1 assay in µg/ml. 
 
                                                                          Cell lines 
           HeLa                      HT-29                       MCF-7                       KMST-6 
         IC50           SI           IC50           SI           IC50           SI                 IC50                                                          
C1     5.06         10.0        5.12            9.9           9.51          5.3                50.77 
C2    33.19        1.8         68.30           0.9         34.37          1.8                61.32    
C3   130.47       1.2       144.53           1.1       114.06          1.4              160.94 
C4   160.95       1.3      142.19           1.5        204.30          1.1              214.84 
C5     >250                     >250                          10.99                                >250                        
C6     80.00      0.06      78.90           0.06          5.46         0.87                  4.78 
Selectivity Index (SI) = IC50 (KMST-6)/IC50 (HeLa) or any of the cancer cell lines used. 
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5.1.2 Analysis of apoptotic effects of some representative fractions and isolated 
compounds 
To analyze the inhibitory effects of fractions and isolated compounds, we investigated apoptosis. 
Cell deaths result from either a non-specific unregulated process of necrosis or may be due to a 
defined and programmed cellular death process known as apoptosis which is regulated by 
specific cellular signaling pathways.  
We investigated whether the fractions and the isolated compounds were able to cause any 
general non-specific necrotic cell death or induce apoptosis of HeLa, HT-29, MCF-7 and KMST-
6 using Apo-percentage dye
TM
 (Biocolor Ltd). This assay stains apoptotic cells with a red dye 
and the exposure of the membrane phospholipid phosphatidylserine (PS) allows the 
unidirectional uptake of the APOpercentage 
TM
 dye (Kurokawa et al., 1999). As a consequence, 
only cells that have undergone apoptosis i.e. externalization of phosphatidylserine; will be 
labeled by the dye, while the normal and the necrotic cells remain unlabelled. 
The effect of compounds C1-C6 on HeLa cells as visualized under a Nikon inverted light 
microscope using a 20X objective and the photographs were taken using a Leica EC3 digital 
camera as displayed in Fig.5.5. The quantification of apoptosis of untreated control and 
compound C1 on HeLa cell is shown in Fig.5.6. 
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A  B 
C  D 
E  F 
G  H 
Figure5.5. Effect of compounds on HeLa cell morphology when treated for 24h A (untreated) B 
(50 µM camptothecin) C (12.5 µg/ml C1) D (12.5 µg/ml C2) E (12.5 µg/ml C3) F (12.5 µg/ml C4) 
G (12.5 µg/ml C5) H (12.5 µg/ml C6). 
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A  
B  
Figure 5.6. Flow cytometry diagram showing the quantification of apoptosis as measured 
by flow cytometer A (C1 6.25 µg/ml) B (C1 25 µg/ml)  on HeLa for 24 h. 
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A B 
C D 
Figure 5.7. The apoptotic effect of different concentrations of fractionsP4, P7 and P12 on 
(A) HeLa (B) HT-29 (C) MCF-7 (D) KMST cells in a concentration-dependent manner as 
measured using Apopercentage
TM
 assay after 24 h treatment. 
 
The effect of apoptosis induction of the fractions P4, P7 and P12 representing fractions where 
the compounds were isolated at a dose of 12.5-100 µg/ml for 24hours on HeLa, HT-29, MCF-7 
and KMST-6 cell lines as described in section 3.10.6 are presented in Figure 5.7. Camptothecin 
(50 µM) a renowned anticancer drug was used as a positive control.  
All the fractions were apoptotic at the test concentration used on all cancer cell lines. 
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Fraction P4 was apoptotic on cancer cell lines with maximum killing of ~ 60%, 40% and 82% on 
HeLa, HT-29 and MCF-7 at the highest dose of 100 µg/ml. This fraction was not selective for 
the normal cell even at the highest dose; the % apoptosis on KMST-6 was ~15% (Fig. 5.7D).  
Fraction P7 was a representative for P8 and P9 since ursolic acid was confirmed to be present in 
all 3 of these fractions. It was however shown to be non-selective as it kills both cancer and non 
cancerous cells in a similar faction. This is in agreement with cytotoxicity results. 
Fraction P7 was very active with maximum killing (~100%) at the lowest dose 12.5 µg/ml on 
HeLa, HT-29 and MCF-7 (~80%). On HT-29 cell lines(Fig. 5.7B), fraction P7 seemed to have 
reached its maximum activity level at 25µg/ml, and the increased dosage of 50 and 100 µg/ml 
did not have a further effect on the cell, and so the percentage apoptosis decreased.  
Fraction P12 was used to represent P11 and P12 since coumaroloxy ursolic acids were 
confirmed to be present in both. Though not cytotoxic on most of the cell lines, it rather 
surprisingly displayed a very good dose-response on Apopercentage
TM
 assay.  
It had a maximum killing at the highest dose of ~95%, 98% and 85% on HeLa, HT-29, and 
MCF-7 respectively. P12 was also selective for the normal cell line at this same dose with a 
maximum of ~88% killing effect contrary to the cytotoxicity result. The cytotoxicity test is 
considered as a preliminary test for screening potential apoptosis inducers; however some 
previous reserch had demonstrated that cytotoxicity may not be such a good indicator of 
apoptotic potential (Essack, 2006 Masters Dissertation, UWC; Sagar, 2007 PhD Thesis, UWC; 
Kikuchi et al., 2011). 
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A B 
C D 
Figure 5.8. Effect of apoptosis of C1-C6 on (A) HeLa (B) HT-29 (C) MCF-7 (D) KMST cell 
lines as determined by Apopercentage 
TM
 assay for 24 h. 
 
All the compounds C1-C6 were also screened for apoptosis at a dose of 3,125-50.0 µg/ml on 
HeLa, HT-29, MCF-7 and KMST-6 cell lines for 24 hours as described previously. 
The results of the induction of apoptosis of compounds C1-C6 are presented in Fig. 5.8. 
The dose-response of all the isolated compounds for their induction of apoptosis on HeLa cell 
line is presented in Fig. 5.8A. All the tested compounds displayed significant apoptotic potential 
with the exception of compound C5 with ~23% apoptosis at the highest dose 50.0 µg/ml. 
  
 
 
 
 146 
 
It should also be noted that, most of the compounds were more active than the positive control-
Camptothecin on HeLa, except C5. Ursolic acid (C1) has been previously reported to suppress 
the proliferation of a number of tumor cells, induce apoptosis Shanmugam et al., (2011) and 
inhibit tumor promotion, metastasis and angiogenesis (Kiran et al., 2008).  
The compounds C2, C3 and C4 were not cytotoxic on HeLa but were found to induce apoptotis 
on the same cell line; a similar occurrence was reported by Kikuchi et al., (2011). 
Hydroxycinnamate esters of ursolic acid from whole cranberry fruit and juice that inhibited the 
growth of several types of tumor cells in vitro, including MCF-7 breast, HT-29 colon, DU-145 
prostate, H460 lung, ME180 cervical epidermoid and K562 leukemia cell lines was reported by 
Murphy et al., (2003). 
As represented in Fig. 5.8B, compounds C1, C4 and C6 were very active on HT-29, C5 was 
moderately active while C2 and C3 were not active on HT-29 colon cancer cell lines. 
Compounds C1 and C4 were more active than Camptothecin. Compound C4 was not cytotoxic 
on HT-29 but found to be highly apoptotic. This was synonymous to the findings reported by 
Kikuchi et al., (2011). On MCF 7 cells (Fig. 5.8C), compounds C1 and C6 were very active, C5 
was moderately active while C2, C3 and C4 were partially active on MCF-7 breast cancer cell 
lines. Compounds C1 and C6 actually compare well with Camptothecin activity. In Fig.5.8D, it 
can be clearly seen that compounds C2, C3, C4 and C5 were non toxic to the normal cell line 
KMST-6. At the highest concentration, the % apoptosis had a sharp rise for C1~90% and C6 
~67% which were consistent with cytotoxicity results. 
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5.1.3 Screening isolated compounds C1-C6 for specific markers of apoptosis 
Apoptosis in mammalian cells occurs through one of two pathways viz., the cell surface death 
receptor pathway (extrinsic) or the mitochondria-initiated (intrinsic) pathway. The extrinsic 
pathway is initiated by cell surface receptor mediated activation of caspase-8 that subsequently 
transmits the death signal. Caspase 8 is an important initiator of apoptosis and the absence or 
down regulation of caspase 8 is known to cause resistance to apoptosis (Salvesen, 1999), 
whereas in the intrinsic pathway, it is marked by loss of mitochondrial integrity and activation of 
caspase-9. The loss of mitochondrial integrity, a critical event in the induction of mitochondria-
mediated intrinsic apoptosis is measured in terms of the bax/bcl ratio, cytochrome-c release and 
loss of MMP (Kroemer et al., 2007). Loss of MMP and induction of mitochondria-mediated 
apoptosis could be induced by ROS which are small biochemically reactive oxygen containing 
molecules (Simon et al., 2000).  
Further in the intrinsic pathway, activated caspase-9 induces downstream caspases (caspase-3, 6 
and 7). Caspases in turn cause cleavage of cellular proteins like, poly (ADP-ribose) polymerase 
(PARP) and activates Caspase-activated DNase (CAD) finally resulting in apoptotic cell death. 
Apoptotic cells are characterized by hall- marks such as exposure of phosphatidylserine on the 
outer leaflet of the plasma membrane (Anselmi et al., 2002; Fadok et al., 1998), 
phosphatidylserine in recognition of apoptotic cells by phagocytes and DNA fragmentation 
(Nagata, 2000). 
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5.1.3.1 Intracellular ROS measurement 
Reactive oxygen species (ROS) result in oxidation of various cell constituents including DNA, 
lipids and proteins, consequently these oxidations may cause damage to the cellular substance 
leading to cell death which is the ultimate consequence. ROS have been implicated in a number 
of diseases including various forms of non-hormone dependent cancers, atherosclerosis, ischemic 
reperfusion injury, neurodegenerative diseases, chronic inflammatory disease, such as 
rheumatoid and psoriatic arthritis, and some factors underlying the aging process itself.  
ROS might also play a role as signaling molecules and as such they may have a role in cell cycle 
progression (Boonstra, 2004). Hancock et al., (2001) also reported that ROS induce programmed 
cell death or necrosis, may suppress the expression of many genes, and possibly activate cell 
signaling cascades. Several anticancer agents, such as arsenic trioxide, doxorubicin, bleomycin, 
cisplatin, 5-Fu, and paclitaxel have been shown to induce ROS generation in cancer cells. 
To investigate whether the cytotoxic effects of isolated compounds were due to apoptosis, the 
cells were treated with 12.5 µg/ml of compounds for 4 hours and stained the nucleus with 
NucBlue
TM 
live cell staining dye for 20 mins and then with CM-H2DCFDA molecular ROS 
probe for another 30 mins, the untreated HeLa cells showed the stained nuclei to be rounded and 
homogenously stained (Fig. 5.9). The treated cancer cells showed different stained DNA nuclei 
from the control group, by presenting condensed chromatin and apoptotic bodies that are typical 
of the early and late stages of apoptosis except C5 which did not induce ROS production. 
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A    B C 
D     E F 
G    H I 
Figure 5.9. Intracellular ROS production of C1-C6 (4 h) as determined by fluorescence 
imaging on HeLa A (untreated) B (0.05% H2O2) 30min C (0.05% H2O2) 1 h D (12.5 µg/ml 
C1) E (12.5 µg/ml C2) F (12.5 µg/ml C3) G (12.5 µg/ml C4) H (12.5 µg/ml C5) I (12.5 µg/ml 
C6). 
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A 
B 
C 
Figure 5.10. Flow cytometry diagram showing the quantification of ROS  as measured by 
flow cytometer A (Untreated dot plot) B (Untreated histogram plot) (C212.5 µg/ml) on 
HeLa for 24 h. 
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A  
B  
C  
Figure 5.11. Effect of some selected compounds ROS generation on (A)HeLa (12.5 µg/ml) 
(B) HT-29(25 µg/ml)  (C) MCF-7(25 µg/ml) cell lines in a time-dependent manner. Data are 
mean ± SEM, ***P< 0.001,**P< 0.01  and *P< 0.05 compared with control. 
     *** 
    ** 
       
***
      ***  
      *** 
      ** 
     *** 
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To investigate the mechanism underlying C1-C6 induced apoptosis, we measured their ability to 
generate intracellular ROS using the CM-H2DCFDA molecular probe after 24 h of treatment as 
compared with the control (Fig. 5.10). The measurement of intracellular ROS level for C2, C3 
and C6 on HeLa cell lines showed a significant increase in ROS level after 12 and 24 h of 
treatment except C6 that showed only for 12 h as compared with the control, a similar trend was 
also observed for 50 µM Camptothecin. However, in the case of C1 and C4, there was no 
significant effect observed P>0.05 (Fig.5.11A). 
The time-dependent ROS generation at 25 µg/ml dose of tested compounds C1, C4, C5 and C6 
ROS production on HT-29 cell lines on CM-H2DCFDA molecular probe is presented in Fig. 
5.11B after a 24 h treatment. All tested compounds increased ROS production,the highest ROS 
producer on HT-29 was C6 while the least being C1 when compared to untreated control.  
The result showed a time-dependent ROS production especially at 12 h, when most of the cells 
are still active to interact with the ROS probe. The effect of 24 h treatment of C1, C4, C5 and C6 
ROS production on MCF-7 cell lines on CM-H2DCFDA molecular probe is presented in (Fig. 
5.11C). All tested compounds increased ROS production when compared to the untreated control 
with the highest ROS producer on HT-29 being C6. There was also a sharp decrease in the ROS 
production after 24 h in C5 and C6. This may be due to the fact that most of the cells would have 
died at that time. 
5.1.3.2 Caspase 3/7 and 9 measurement 
Caspases (cysteinyl-directed aspartate-specific proteases) are a family of enzymes that play a 
central role in the apoptotic process and result in the cleavage of protein substrates causing the 
disassembly of the cell. Caspase 3 and caspase 7 are “executioner caspases” that are activated 
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downstream in the apoptosis cascade by a sequence of intrinsic or extrinsic signals. Once 
activated, these enzymes cause degradation of many key cellular proteins and influence 
chromatin condensation and DNA damage during apoptosis. Activation of caspase-3/7 is thus a 
hallmark and confirmation of the apoptotic process (Boland et al., 2013). The Caspase-Glo 3/7 
Assay System contains a single reagent solution which includes a luminogenic substrate for 
caspases 3 and 7, a thermostable luciferase, and buffer to induce cell lysis. 
The presence of caspase 3 or 7 cleaves the luminogenic substrate which in turn leads to the 
release of the substrate for luciferase resulting in the production of light. The amount of 
fluorescent product generated is proportional to the amount of caspase-3/7 cleavage activity 
present in the sample (Scott, 2008).  
The activation of caspases, which are key mediators of apoptosis was analyzed upon the 
exposure of various concentrations (6.25-50 µg/ml) of C1-C6 to HeLa, HT-29 and MCF-7 cells 
for 24 hours and the caspases 3/7 and 9 were measured using a muti-well plate reader.  
The results were compared to an untreated controlwhich was set arbitrarily at 1.0. It was 
observed that some compounds showed an increased caspase activity in a concentration and 
time-dependent manner (Fig.5.12). 
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A  
B  
C  
Figure 5.12. Measurement of caspase3/7 activity at 50µg/ml.Time-dependent induction of 
selected compounds on caspase-3/7 activation in (A) HeLa (B) HT-29 (C) MCF-7cell lines. 
Data are mean±SEM, ***P< 0.001, **P< 0.01 and *P< 0.05 compared with control. 
 
 
 
 
 155 
 
The result of time-depedent caspase3/7 activity on HeLa cell line is presented in Figure 5.12A. 
Compounds C1 and C2 significantly activated caspase 3/7, P<0.001 and P<0.001 respectively 
when compared with control. Ursolic acid and derivatives have been reported to activate  
caspase 3 (Shao et al., 2011). Figure 5.12B showed the result of time – dependent caspase 3/7 
activity on HT-29 cell lines when treated with 50 µg/ml of C1, C4, C5 and C6 at various time 
intervals. Only C1 significantly increased caspase 3/7 when compared with an untreated control. 
This is in agreement with the report of Andersson et al., (2003) that ursolic acid decreased 
proliferation by induction of apoptosis accompanied by activation of caspases-3, 8 and 9 in  
HT-29 colon cells. 
The result of time – dependent caspase 3/7 activity on MCF-7 cell lines when treated with  
50 µg/ml of C1,C5 and C6 at various time intervals indicated that C1 significantly increased 
caspase 3/7 when compared with control (Fig. 5.12C). 
 
A B 
Figure 5.13. Measurement of caspase3/7 activity. Dose-dependent induction of caspase-3/7 
of selected compounds in (A) HeLa (B) MCF-7 cell lines. Data are presented as 
mean±SEM, ***P< 0.001, **P< 0.01 and *P< 0.05 compared with control. 
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Compounds C2, C3, C5 and C6 were further investigated for their dose-response on caspase3/7 
activity at different doses( 6.25-25 µg/ml) to check their dependability for 24 h (Fig.5.13).  
All compounds tested showed a significant increased caspase activity on HeLa in a concentration 
–dependent manner when compared with the control at doses 12.5 and 25 µg/ml with the 
exception of C5 (Fig.5.13A). This is an indication that cell apoptosis took place, since caspase-
3/7 activation is a hallmark and confirmation of the apoptotic process. 
Further to this, compounds C2, C3, C5 and C6 were also investigated for their dose-response on 
caspase 3/7 activity at different doses( 6.25-25 µg/ml) for 24 h on MCF-7 (Fig.5.13B). All the 
tested compounds did not show a significant increased caspase activity on MCF-7 (P>0.05) in a 
concentration –dependent manner when compared with the control with the exception of C6 
which was very significant even at 25 µg/ml (P< 0.001) . MCF-7 is deficient in caspase 3 and it 
is thus more likely that it is executioner caspase 7 that is being activated in this instance.  
MCF-7 has been characterized with caspase 3 gene mutation (Zhao et al., 2001). As described 
earlier in chapter 2, Section 2.18 that the extrinsic and intrinsic pathways for apotosis commonly 
converge at caspase 3. This is one of the reasons why the presence of caspase 3 is recognized as 
the hallmark for apoptosis and accounts for the high resistance to apoptosis inducers displayed 
by the MCF-7 cell lines. Since compound C5 is selective for MCF-7, it can be deduced that C5 
can induce an apoptotic pathway independent of caspase 3.  
Based on the findings from this research, compounds C2 and C3 are selective majorly for HeLa, 
which in turn implies that they might have both caspase 3 dependent and independent modes of 
action, similarly C1, C4 and C6 which were non selective for a specific cell line. 
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A  
B  
C  
Figure 5.14. Measurement of caspase 9 activity at 50µg/ml. Time-dependent induction of 
caspase-9 on (A) HeLa (B) HT-29 (C) MCF-7 cell lines. Data are presented as 
mean±SEM,***P< 0.001, **P< 0.01  and *P< 0.05 compared with control. 
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The occurrence of the apototic process was further confirmed by the presense of activation of 
caspase – 9 which triggers the proteolytic activation of executioner caspase3/7 and caspase 8 in a 
process in the cleavage of PARP, then subsequent DNA degragation and finally apoptotic death 
(Cecconi and Gruss, 2001; Cain et al., 2002). 
Compounds C1, C2, C3, C4 and C6 at 50 µg/ml were tested for induction of caspase 9 activity 
on HeLa cell lines after treatments at different time intervals. It was observed that only C1, C2 
and C3 significantly increased caspase activation at 12 h and 6 h of treatment as shown in Fig. 
5.14A. This may be partly due to the fact that the proteins would still be active and not denatured 
at these time points. 
The result of caspase 9 activation on HT-29 are presented in Fig 5.14B. Cells were exposed to 50 
µg/ml of C1, C4, C5 and C6 at different time points (3, 6, 12 and 24 h).  
Compound C1 significantly increased caspase activation compared with the control. At P< 0.05, 
C6 also displayed a slight increase in caspase activation within 24 h of treatment. 
Ursolic acid’s ability to induce apoptosis in many different cell types is likely to play a major 
role in its anti-proliferative activity. In HT-29 colon cells, ursolic acid has been reported to 
decrease proliferation by induction of apoptosis accompanied by activation of caspases-3, 8 and 
9 (Andersson et al., 2003).  
The result of the time dependent caspase 9 activation on MCF-7 cell lines is shown in Fig. 
5.14C. Cells were exposed to 50 µg/ml of C1,C5 and C6 at different time points (3, 6, 12 and  
24 h). The level of caspase 9 activation were compared with the untreated control arbitrarily set 
at 1.0. The result showed that only C1 showed a markedly increase in caspase 9 activation, 
although C5 showed 1.3 fold increase, but was not significant at P>0.05.  
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A  
B  
C  
Figure 5.15. Measurement of caspase 9 activity. Dose-dependent induction of caspase-9 
selected compounds in (A) HeLa (B) HT-29 (C) MCF-7 cell lines. Data are mean±SEM, 
**P< 0.01 and *P< 0.05 compared with control. 
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The investigation of different doses of C2, C3 and C6 on caspase 9 activation for 24 h showed 
that compounds C2 and C3 slightly increased caspase activity as compared to the control, but the 
differences were not that significant. The reason may be that at lower doses, C2 and C3 do not 
activate caspase while they do at higher concentration as shown in Fig. 5.14A. It could also be 
there is a time dependent dynamic at play between the 6 and 12 h intervals. Of all the three 
compounds, only C6 acivated caspase 9 at 24 h (12.5 and 25 µg/ml) P< 0.05 on HeLa (Fig 
5.15A).  
We also investigated the effect of the dose-response of compounds C5 and C6 on caspase 9 
activity on HT-29 for 24 h, in which case only compound C5 increased caspase 9 activation by 
an ~1.8 fold increase at 25 µg/ml (P< 0.01) as shown in Fig. 5.15B. The effect of dose-response 
of C2, C5 and C6 on MCF-7 cell line as shown below in Fig. 5.15C indicated there was no 
significant difference observed for all compounds when compared with the control (P>0.05) at 
doses of 6.25, 12.5 and 25 µg/ml. 
5.1.3.3 Investigation of Topoisomerase inhibition 
Topoisomerase are essential enzymes that control and modify the topological state of DNA. 
These enzymes act by sequential breakage and reunion of either one DNA strand  
(topoisomerase I) or both DNA strands (topoisomerase II) .Topoisomerase-mediated strand 
passing leads to the reduction of DNA twists, as well as the relief of supercoiling, thereby 
allowing replication, transcription, and recombinant repair to take place (Burden and Osheroff, 
1998; Pommier et al., 1998).  
Topoisomerase inhibitors are agents designed to interfere with the action of topoisomerase 
enzymes (topoisomerase I and II) which control the changes in DNA structure by catalyzing the 
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breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell 
cycle (Ting et al., 2003).  
In recent years, topoisomerases have become popular targets for cancer chemotherapy treatments 
(Rothenberg, 1997). It is thought that topoisomerase inhibitors block the ligation step of the cell 
cycle, generating single and double stranded breaks that harm the integrity of the genome and 
thus the introduction of these breaks subsequently leads to apoptosis and cell death.  
The catalytic cycle of human topoisomerases consists of several distinct steps. Compounds such 
as camptothecin and etoposide interfere with the relegation step and stabilize the enzyme-DNA 
cleavable complex. These compounds are known as topoisomerase poisons because their action 
results in an alteration of topoisomerase function leading to DNA breakage (Capranico et al., 
1997). 
To further elucidate the mechanism of action of isolated compounds, we investigated whether 
our compounds are such poisons by measuring formation of topoisomerase-induced DNA-strand 
breaks. Figure 5.16 shows as expected, that camptothecin stabilized the topoisomerase I 
cleavable complex, resulting in the generation of open-circle plasmid DNA at 150 µM.  
To our surprise, all the tested compounds inhibited topoisomerase I at different concentrations; 
viz C1 (15 µg/ml and C2, C3, C5 and C6 (40 µg/ml).  
Ursolic acid and other pentacyclic triterpenoids has been reported to inhibit topoisomerase I 
(Syrovets et al., 2000). 
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Figure 5.16. Inhibitory effects of isolated compounds on the catalytic activity of 
topoisomerase I. DNA relaxation assay showing the inhibitory effects of compounds C1, 
C2, C3, C5 and C6 on activity of topoisomerase I, control samples contained super coiled 
plasmid DNA (lane 1) and DNA incubated with 2 U of enzyme(lane 2) for 30 min at 37°C. 
One of three comparable experiments is shown. 
 
5.1.3.4. Investigation of cell cycle distribution 
Cell division cycle is a process of replicating DNA and dividing a cell in a series of coordinated 
events. At least two types of cell cycle control mechanisms are recognized; a cascade of protein 
phosphorylations that relay a cell from one stage to the next and a set of checkpoints that monitor 
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completion of critical events and delay progression to the next stage if necessary. The first type 
of control involves a highly regulated kinase family.  
Kinase activation generally requires association with a second subunit that is transiently 
expressed at the appropriate period of the cell cycle; the periodic “cyclin” subunit associates with 
its partner “cyclin-dependent kinase” (CDK) to create an active complex with unique substrate 
specificity. Regulatory phosphorylation and dephosphorylation fine-tune the activity of CDK–
cyclin complexes, ensuring well-delineated transitions between cell cycle stages (Collins et al., 
1997).  
A second type of cell cycle regulation, checkpoint control, is more supervisory and it is not an 
essential part of the cycle progression machinery.  
Cell cycle checkpoints sense flaws in critical events such as DNA replication and chromosome 
segregation .When checkpoints are activated, for example by underreplicated or damaged DNA, 
signals are relayed to the cell cycle-progression machinery. These signals cause a delay in cycle 
progression, until the danger of mutation has been averted (Collins et al., 1997).  
The cell cycle checkpoints are the pathways which regulate the completion of specific events in 
one phase of cell cycle before entering the next phase during the eukaryotic cell cycle 
progression. These checkpoints also serve as sites where cells can arrest to repair any damage, 
responding to an exogenous cellular stress signal and making use of essential growth factors, 
hormones or nutrients. If the cells fail to repair the damage during arrest at checkpoints, it could 
activate the pathways leading to apoptosis and the defects in cell cycle checkpoints have been 
reported to result in gene mutations, chromosome damage and ultimately contribute to 
tumorigenesis (Schafer, 1998). 
DNA damaging agents trigger checkpoints that produce arrest in G1 and G2 stages of the cell 
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cycle. The G1 and G2 phases of the cycle represented the “gaps” in the cell cycle that occur 
between the two obvious landmarks, DNA synthesis and mitosis. In the first gap, G1 phase, the 
cell prepares for DNA synthesis. S phase cells are synthesizing DNA and therefore have 
double DNA content. Cells can also arrest in S phase, which leads to a prolonged S phase with 
slowed DNA synthesis. The G2 phase is the second gap in the cell cycle during which the cell 
prepares for mitosis or M phase. Arrest in G1, allows repair before DNA replication, whereas 
arrest in G2, allows repair before chromosome separation in mitosis (Poot et al., 1995). 
The cells which are actively undergoing cell cycle are targeted in cancer therapy as the DNA is 
relatively exposed during cell division and hence susceptible to damage by drugs or radiation, 
gaining insight into the mechanisms and alterations by which components of the apoptotic 
machinery contribute to pathogenic processes should allow the development of more effective, 
highly specific and therefore better-tolerable therapeutic approaches. These includes; targeted 
activation of pro-apoptotic tumour suppressors or alternatively the blockade of antiapoptotic 
oncogenes in the case of cancer, whereas for the treatment of premature cell death during 
neurodegeneration the inhibition of pro-apoptotic key components such as the caspases might be 
promising (Reed, 2002). 
To determine the possible role of cell cycle arrest in compounds C1-C6, HeLa, HT-29 and  
MCF-7 cells were treated with different concentrations of the compounds.  
Cell cycle distribution was observed by flow cytometric analysis after staining of the DNA with 
propidium Iodide (PI) and the results are shown below in Fig.5.19-5.21 while the measurement 
as determined by flow cytometry was demonstrated in Fig. 5.17-5.18.  
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The result on the effect of compounds on cell cycle distribution on HeLa cells showed that at the 
concentrations used in this assay, compounds C2, C3, C5 and C6 caused a significant change in 
cell cycle phases G1 and S when compared with the control at P<0.001 (Fig.5.22).  
C1 did not show any remarkable diferrence in comparison with the control, this could be as a 
result of the low concentration. On HT-29 cells, only C2 and C3, significantly affected the cell 
cycle at the S phase P< 0.05(Fig.5.22). On MCF-7 cells, the treatment with compounds C2, C3 
and C5 resulted in a significant change (P<0.001) in the number of cells in G1 and S phases 
while there was no significant difference observed for C1 and C4 in any of the phases when 
compared with control (Fig.5.22). Ursolic acid has been reported to induce apoptosis and growth 
inhibition at the G1 phase of the cell cycle in some cancer cells (Heo et al., 2002).  
In this research we have been able to further confirm the ursolic acid ability to induce apoptosis. 
 
 
 
 
 166 
 
 Figure 5.17. Cell cycle distribution phase of untreated control on HeLa cells. 
 
 
 
 
 167 
 
 
Figure 5.18. Effect of C2 (12.5 µg/ml) on cell cycle distribution phase on HeLa cells as 
measured by flow cytometry. 
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A   B 
C                  D 
E F G 
Figure 5.19. Effect of compounds on cell cycle phases of HeLa cells at 24h (A). Untreated 
control (B). C1 (6.25 µg/ml) (C). C2 (12.5 µg/ml) (D). C3 (12.5 µg/ml) (E). C4 (12.5 µg/ml) 
(F). C5 (12.5 µg/ml) (G) C6 (6.25 µg/ml). Data are expressed as mean±SEM as determined 
by flow cytometry.  
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A B C 
D E 
F                  G 
Figure 5.20. Effect of compounds on cell cycle phases of HT-29 cells at 24 h (A). Untreated 
control (B). C1(6.25 µg/ml) (C). C2 (12.5 µg/ml) (D). C3 (12.5 µg/ml) (E). C4 (12.5 µg/ml) 
(F). C5 (12.5 µg/ml) (G) C6. (6.25 µg/ml). Data are expressed as mean±SEM as determined 
by flow cytometry.  
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A     B 
C D 
 
E F G 
Figure 5.21. Effect of compounds on cell cycle phases of MCF-7 cells at 24 h (A). Untreated 
control (B). C1 (6.25 µg/ml) (C). C2 (12.5 µg/ml) (D). C3(12.5 µg/ml) (E). C4 (12.5 µg/ml) 
(F). C5 (12.5 µg/ml) (G).  C6 (6.25 µg/ml). Data are expressed as mean±SEM as determined 
by flow cytometry. 
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Figure 5.22. Dose-response effect of compounds on cell cycle phases at 24 h (A). HeLa cells 
(B).  HT-29 cells (C).  MCF-7 cells. Data are expressed as mean±SEM ***P < 0.001, 
 **P < 0.01 and *P < 0.05 when compared with control. 
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The result on the effect of compounds on cell cycle distribution on HeLa cells further showed 
that at the concentrations used in this assay and when compared with the control; compounds C2, 
C3 caused a significant increase in the number of cells in S phase while C6 showed an increase 
in G1 phase at P<0.001 (Fig.5.22A). This implies that C2, C3 arrested the cell cycle at S phase 
while C6 arrested at G1 phase.  
On HT-29 cells, there was no significant difference between the number of cells in the control 
and the treated at G1 phase, this may be that the cells managed to repair the damaged at the first 
check point in the cell cycle. Only C2 and C3, caused a slight decrease in the number of cells at 
the S phase (Fig.5.22B). 
On MCF-7 cells, the treatment with compounds C2 and C3 resulted in increase of cells in G1 
phase and a decrease in S phase while on C5, a decrease was observed in G1 phase and an 
increase in S phase. There was no significant difference observed for C1 and C4 in any of the 
phases when compared with control (Fig.5.22C). Our results suggests that on MCF-7 cells, 
compounds C2 and C3 arrested cell cycle at the G1 phase while C5 arrested at the  
S phase.  
It has been reported that some anticancer agents cause growth inhibition by interfering with the 
process of cell cycle (Schwartz and Shah, 2005; Chakravarti et al., 2012; Shao et al., 2011). 
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CHAPTER 6 
6.0 CONCLUSION AND RECOMMENDATIONS 
To the best of our knowledge, this is the first report in the literature on the isolation of triterpenes 
and the bioactivity guided isolation of novel cytotoxic and apoptotic compounds from 
Pleiocarpa pycnantha leaves as anticancer agents. This is the first significant biological activity 
reported for the plant and the first report on isolation of ursolic acid and derivatives from 
Pleiocarpa genus. It may also be of interest to know that this is the first report on the isolation of 
seco-triterpenes from the Apocynaceae family; thus making it an important contribution to 
scientific knowledge. 
The GC/MS and the phytochemical screening results revealed the presence of triterpenes, 
saponin, glycosides, essential oils and others were mostly saturated fatty acids and methyl esters, 
the GC-MS result is not shown in the thesis. Flavonoids and alkaloids were notably absent. This 
study successfully attempted to relate specific constituents present in these plants with their 
widespread ethno medicinal uses.  
Pleiocarpa pycnantha leaves were extracted with 95% ethanol, to mimic the preparation of herbs 
and decoctions in some African countries. The fractionation of the plant material was carried out 
using standard chromatographic techniques. A total of eight (8) compounds were isolated from 
the plant, while only 5 of them, from which two were novel were characterized and their 
structures were unambiguously established by spectroscopic methods including infrared and 
ultraviolet spectroscopy, high resolution mass spectrometry, one- and two-dimensional nuclear 
magnetic resonance experiment and single X-ray crystallography.  
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Two of the remaining three isolates were inconclusive in terms of structural elucidation due to 
their very low quantity and the fact that C4 was a mixture of two compounds which we were 
unable to separate. 
The total (crude) extract and isolated compounds were tested for cytotoxicity using WST-1 assay 
on HeLa (cervical), HT-29 (colon), MCF-7 (breast) and KMST-6 (normal/non cancerous) cell 
lines. The crude extract was cytotoxic on MCF-7 (breast) and HeLa (cervical) cell lines with IC50 
value of 314.9 µg/ml and 446.2 µg/ml respectively, while it slightly affected the viability of  
HT-29 colon cancer cell line (IC50 703.0 µg/ml). The extract did not significantly affect the 
viability of the normal (KMST-6) cell line, (IC50 1904.0 µg/ml).  
Fraction P4 displayed significant cytotoxicity with % viability on breast, cervical and colon 
cancer cell lines being 2.747± 0.08, 6.423± 0.99 and 3.704± 0.83 respectively at 0.4 mg/ml while 
on normal cell line is 95.867± 1.91. The highest cytotoxicity was displayed by ursolic acid C1 
with IC50 of 5.06, 5.12 and 9.51 µg/ml on HeLa, HT-29 and MCF-7 respectively. Compounds C5 
and C6 displayed cytotoxicity on MCF-7 cell lines with IC50 values 10.99 and 5.46 µg/ml 
respectively. Compound C2 also displayed moderate cytotoxicity with IC50 of 33.20, 34.37 and 
68.34 µg/ml on HeLa, MCF-7 and HT- 29 respectively.  
The induction of apoptosis using Apo-percentage
 TM
 assay on all cell lines was tested on 
fractions P4, P7 and P12 representing fractions for isolated compounds to predict the mechanism 
of action. All tested fractions showed evidence of apoptosis with P7 highly selective for the 
normal cell line KMST-6. Fraction P4 was apoptotic on all cancer cell lines with maximum 
killing of ~ 60%, 40% and 82% on HeLa, HT-29 and MCF-7 at the highest dose of 100 µg/ml. 
This fraction was not selective for the normal cell even at the highest dose; the % apoptosis on 
KMST-6 was ~15%. Fraction P12, though not cytotoxic on most of the cell lines, displayed a 
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very good dose-response on Apopercentage
TM
 assay. It had a maximum killing at the highest 
dose of ~95%, 98% and 85% on HeLa, HT-29 and MCF-7 respectively. Fraction P12 was 
selective for the normal cell line at this same dose with maximum of ~88% killing effect, 
contrary to cytotoxicity result. 
We also tested the apoptotic potential of all isolated compounds on all the cell lines. All the 
tested compounds displayed significant apoptotic potential on HeLa with the exception of 
compound C5 with ~23% apoptosis at the highest dose 50.0 µg/ml, most of the compounds were 
more active than the positive control-Camptothecin on HeLa, except C5. On HT-29, C1, C4, C6 
were very active, C5 was moderately active while C2 and C3 were not selective for HT-29 colon 
cancer cell lines. Compounds C1 and C4 were more active than Camptothecin. C4 was not 
cytotoxic on HT-29 but found to be highly apoptotic; a similar occurrence was reported by 
Kikuchi et al., (2011). On MCF-7 cell lines, compounds C1, C6 were very active; C5 was 
moderately active while C2, C3 and C4 were partially active on MCF-7 breast cancer cell lines. 
Compounds C1 and C6 could compare well with Camptothecin activity. Finally on apoptosis 
results; C2, C3, C4 and C5 were non toxic to the normal cell line KMST-6 while at the highest 
concentration, the % apoptosis had a sharp rise for C1~90% and C6 ~67%, this was consistent 
with cytotoxicity result. Based on the results obtained above, we further screened isolated 
compounds for specific markers of apoptosis in order to understand their mechanism of action. 
All compounds were tested for their ability to induce ROS production on different cell lines, 
depending on selectivity: C2, C3 at 12.5 µg/ml caused a significant increase in ROS production 
on HeLa within 12-36 h, P<0.05 when compared with control.C1 and C6 also increased ROS 
production as shown by fluorescence imaging. There was no significant difference between C4 
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and control P>0.05 as observed in our experiments, however C5 was not tested since the 
fluorescence imaging did not indicate ROS production. 
On HT-29, compounds C1, C4, C5 and C6 were analyzed for ROS at 12 and 24 h, all 
compounds significantly increased ROS production, P<0.05  at 25 µg/ml in a time-dependent 
manner, except C1 which was only significant at 12 h. On MCF-7 cell lines; C1, C4, C5 and C6 
were selected at 25 µg/ml for 12 and 24 h, based on our results, only C5 and C6 significantly 
increased ROS production at 12 h. 
The activation of caspases which are key mediators of apoptosis was analyzed on exposure of 
compounds to the selected cell lines for this research. Caspases 3/7 and 9 activities were 
measured on time and dose-dependent basis, for a period of 3, 6, 12 and 24 h (50 µg/ml) and 
6.25-25 µg/ml respectively for 24 h. All compounds were tested for their time-response on 
caspase 9 activity on HeLa; C1 gave a maximum fold increase of ~6.2, C2 ~ 2.2 and C3~1.8 at 
12 h, 6 h and 12 h respectively. Of all the compounds tested for dose – response, only  
C6 (25 µg/ml) activated caspases 9 with~1.2 fold increase when compared to control within 24 h 
period. For the time-dependent assay on HT-29 caspase 9 activation, C1 gave a maximum fold 
increase of ~47 fold (6 h) and C6 ~ 2.4 (24 h) while in the dose-dependent results, it was 
observed that only C5 (25 µg/ml) had a significant fold increase of ~ 1.5 in 24 h. On MCF-7, 
only C1 had a significant fold increase ~18 fold within 6 h at P<0.05 when compared with 
control. 
We further confirmed the apoptotic process by investigating the executioner caspases 3/7 which 
is the hall mark of apoptosis. Based on the results of our experiment for the time-dependent 
activation of caspases 3/7 on HeLa, C1 and C2 increase significantly the caspase activity 
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with~27 and 1.8 fold at 6 h and 12 h respectively, when compared with control. On the other 
hand, for the dose-response activation of caspases 3/7 at 25 µg/ml, the maximum fold increase 
obtained for C2, C3 and C6 are ~2.0, 2.2 and 3.6 respectively. On HT-29, the time-dependent 
result showed that only C1 significantly increase caspase activity by 11.5 fold at 6 and 12 h. 
MCF-7 is deficient in caspase 3, so it most likely that it is caspase 7 that is being activated.C1 
activated caspase7 in a time-dependent manner with ~24 fold increase in 6 h, while C6 at  
25 µg/ml gave a 2fold maximum increase in 24 h. It should be noted that C1was not tested for 
dose-response caspase activity because it is a known compound. 
The result of the cell cycle analyis showed that on HeLa cells, compounds C2 and C3 arrested 
cell cycle at S phase while C6 arrested at G1 phase. On MCF-7 compounds C2 and C3 arrested 
cell cycle at G1 phase while C6 arrested at the S phase. 
To further confirm the apoptotic process, all isolated compounds except C4 were tested for 
topoisomerase I inhibition, all the compounds inhibited Topo I at different doses when compared 
with Camptothecin a well known Topoisomerase I inhibitor. This research project has thus 
further confirmed the mechanism of action of ursolic acid C1 and thus indicates the mechanism 
of action for C2-C6 on HeLa, HT-29 and MCF-7 cell lines. 
In conclusion, the phytochemical study of the ethanolic extract from Pleiocarpa pycnantha 
leaves has led to the isolation of a new taraxerane-type triterpenoid; in addition to three known 
compounds.  2, 3-seco triterpenoids are rare in nature and thus compound C5 represents the first 
example of this type to be isolated from Apocynaceae family.  
Our studies suggest that the pure isolated compounds present in Pleiocarpa pycnantha 
demonstrate cytotoxic activity against cervical, breast and colon cancer. The present study also 
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identified apoptosis as the mechanism underlying C1-C6 induced growth inhibition in HeLa, 
HT-29 and MCF-7 cell lines and that the apoptosis is mediated by cell cycle arrest, caspase 
activation, ROS production and topoisomerase inhibition.  
Although, we have not been able to get a substantial ethno botanical evidence for the use of this 
plant as anticancer agent, but the identification of ursolic acid and pleiocarpamine already 
identified as anti cancer agents triggered this research. Thus, based on our findings, we therefore 
propose that the total crude extract and components could be used in management of cervical, 
colon and breast cancer. However, these results warrant in our view, further investigations 
especially on other possible mechanisms of action and the assessment of their anti tumor 
therapeutic efficacy in vivo in experimental models. 
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